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ABSTRACT 
Chikungunya virus (CHIKV) is an arthropod-borne virus that has caused 
multiple unprecedented outbreaks in both tropical and temperate countries over the past 
five decades.  There is no commercial vaccine or antiviral drug to date, due in part to 
the lack of knowledge and understanding of the biology and pathogenesis of this virus.  
Thus, there is an increasing need for researchers to focus their research efforts in this 
area of virology.  The current study employed proteomics to investigate alterations of 
the whole cell proteome and secretome of WRL-68 cells during early CHIKV infection, 
with the main aim being to identify the key proteins modulated in response to infection.  
Two-dimensional gel electrophoresis (2-DGE) was used to compare the whole cell 
proteome and secretome profiles between mock control cells and cells infected at the 
optimised multiplicity of infection (MOI) of 5.0 at 24 hours post-infection.  Protein 
spots that were found to be differentially expressed were identified by MALDI-
TOF/TOF mass spectrometry (MS) analysis, and three selected proteins were validated 
by Western blot.  The functional association between these proteins were determined by 
STRING network analysis, and the mRNA expression level of selected proteins was 
investigated via real-time quantitative PCR.  Overall, 50 and 25 protein spots from the 
whole cell proteome and secretome samples, respectively, were found to be 
differentially expressed (fold-change > 1.3, p < 0.05) and were successfully identified.  
The mRNA expression of 15 whole cell proteins was found to correlate with the 
corresponding protein expression.  On the contrary, only one of the 15 selected proteins 
from the secretome sample showed positive correlation with its transcript expression 
level.  By combining the proteomics and bioinformatics data from STRING network 
analysis, it was deduced that CHIKV disrupt the overall host cell metabolic machinery 
and ubiquitin-proteasome pathway (UPP).  Suppression of the host immune response 
was also observed through the inhibition of immune-related protein secretion, mainly 
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cathepsin D, cathepsin L1, C3 protein and β-2 microglobulin.  Several gene expression-
related proteins were also down-regulated, including the mRNA processing factor, 
hnRNP E1, and translational factors, namely elongation factor-2, eukaryotic initiation 
factor eIF-2BA and eIF3 subunit H.  Meanwhile, up-regulation of hnRNP C1/C2 
suggests that this protein may be beneficial to CHIKV.  Cell cycle regulation via cyclin-
dependent kinase 1 (CDK1) activity may also play an important role during early 
CHIKV infection.  CDK1 was down-regulated, whereas several other proteins (such as 
SET protein) that indirectly regulate the activity of CDK1, were altered in favour of the 
inhibition of CDK1 activity.  In conclusion, CHIKV infection in the human liver cells 
induced a widespread alteration of the whole cell proteome and secretome.  
Nevertheless functional characterisations of these proteins are entailed to provide more 
insights into the actual mechanisms at play during early infection. 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ABSTRAK 
Virus chikungunya (CHIKV) adalah virus bawaan-artropoda yang telah 
mencetuskan beberapa wabak di negara-negara tropika dan iklim sederhana sejak lima 
dekad yang lalu.  Sehingga kini, tiada lagi vaksin atau ubat anti-virus komersial bagi 
merawat jangkitan ini. Ini adalah disebabkan oleh kekurangan pengetahuan dan 
pemahaman mengenai biologi dan patogenesis virus tersebut. Oleh yang demikian, 
wujud keperluan yang semakin meningkat bagi penyelidik untuk menumpukan usaha 
penyelidikan mereka dalam bidang virologi tersebut.  Kajian ini menggunakan kaedah 
proteomik untuk menyiasat perubahan proteome seluruh sel dan secretome sel-sel 
WRL-68 pada peringkat awal jangkitan CHIKV, dengan tujuan utama untuk 
mengenalpasti protein penting yang dimodulasikan sebagai tindakbalas terhadap 
jangkitan tersebut.  Elektroforesis gel dua-dimensi (2-DGE) telah digunakan untuk 
membandingkan profil-profil sel seluruh proteome dan secretome di antara sel-sel 
normal dan sel-sel yang dijangkiti CHIKV pada keadaan optimum, iaitu multiplicity of 
infection (MOI) sebanyak 5.0, selama 24 jam.  Bintik-bintik protein yang berubah 
ekspresinya telah dikenalpasti dengan mengunakan kaedah MALDI-TOF/TOF 
spektrometri jisim (MS), dan tiga protein telah dipilih untuk disahkan melalui kaedah 
Western blot.  Hubungkait antara protein-protein yang telah dikenalpasti ditentukan 
melalui analisis rangkaian STRING, dan ekspresi mRNA bagi protein terpilih disiasat 
melalui real-time quantitative PCR.   Secara keseluruhannya, 50 dan 25 bintik protein 
dari proteome seluruh sel dan sampel secretome, masing-masing, menunjukkan 
perubahan ekspresi (Gandaan perubahan > 1.3, p< 0.05), dan telah berjaya dikenalpasti.  
Ekspresi mRNA bagi 15 protein seluruh sel didapati berkorelasi dengan ekspresi 
protein.  Sebaliknya, hanya satu daripada 15 protein yang dipilih dari sampel secretome 
menunjukkan hubungan yang positif dengan tahap ekspresi transkrip.  Dengan 
menggabungkan data proteomik and bioinformatik daripada analisis rangkaian 
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STRING, boleh disimpulkan bahawa CHIKV mengganggu keseluruhan jentera 
metabolik sel perumah dan laluan ubiquitin-proteasome (UPP).  Penindasan reaksi imun 
juga diperhatikan melalui perencatan protein rembesan yang berkaitan imunisasi, 
terutamanya cathepsin D, cathepsin L1, protein C3 dan β-2 microglobulin.  Beberapa 
protein yang memainkan peranan dalam ekspresi gen juga menunjukkan penurunan 
ekspresi, termasuk faktor pemprosesan mRNA, hnRNP E1, dan faktor translasi, iaitu 
elongation factor-2, eukaryotic initiation factor eIF-2BA and eIF3 subunit H.  
Sementara itu, peningkatan ekspresi protein hnRNP C1/C2 mencadangkan bahawa 
protein ini boleh memberi manfaat kepada CHIKV.  Regulasi kitaran sel melalui cyclin-
deendent kinase 1(CDK1) juga memainkan peranan yang penting pada awal jangkitan 
CHIKV.  CDK1 menunjukkan penurunan ekspresi, manakala beberapa protein lain 
(seperti protein SET) yang mengawal regulasi aktiviti CDK1 secara tidak langsung, 
menunjukkan perubahan ekspresi yang memihak kepada perencatan aktiviti CDK1.  
Kesimpulannya, jangkitan CHIKV dalam sel-sel hati manusia menyebabkan perubahan 
proteome seluruh sel dan secretome.  Namun begitu, ciri-ciri fungsi protein-protein 
tersebut adalah penting untuk memberi maklumat yang mendalam tentang mekanisme 
sebenar yang berlaku pada awal jangkitan. 
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Previously a non-fatal and relatively benign disease, chikungunya (CHIK) has 
emerged as a potential global threat, as evidenced by sudden outbreaks of 
unprecedented magnitude over the past decade, with greater morbidity seen in each 
successive outbreak.  Since its first appearance in 1953, many countries have reported 
its re-emergence, including Malaysia, Indonesia, Thailand, India and the Réunion 
Island, with more than seven million reported cases to date.  Recent epidemiological 
documentation provided further evidence of the spread of CHIK infection to temperate 
countries such as Italy, Australia and the United States, where sporadic outbreaks have 
been reported.  Deaths attributed to complications of this disease are no longer unheard 
of, and the fatality rate is now estimated to be 1:1000 cases.  Moreover, most surviving 
patients are often incapacitated by recurring polyarthralgia that persists for years.  
Combining these factors altogether, it can be said that the epidemiological and 
socioeconomic burden brought about by this disease is a great cause for concern, and is 
beginning to garner researchers’ attention worldwide.  
 
The causative agent for this viral infection is chikungunya virus (CHIKV), an 
arbovirus belonging to the genus Alphavirus and family Togaviridae.  The genome of 
the virus comprise a small, positive sense, single-stranded RNA of approximately 11.8 
kb in length, organised as 5’ cap-nsP1-nsP2-nsP3-nsP4-(junction region)-C-E3-E2-6K-
E1-poly(A) 3’.  Transmitted by the same vectors responsible for the dissemination of 
dengue virus, namely Aedes aegypti and Aedes albopictus, CHIKV causes an acute 
illness in humans, with fever, maculopapular rash, arthralgia and myalgia being the 
hallmark symptoms.  More severe, yet unusual clinical manifestations such as 
neurological complications have also been reported, suggesting the emergence of a new 
disease.  To date, palliative treatment is the only available means to treat patients, as no 
effective antiviral drug or vaccine has yet to be developed.  Given the lack of preventive 
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or therapeutic measures along with the recurring emergence and rapid spread of 
infection, it is not surprising that CHIK is now regarded as a potential global health 
problem.  
 
Despite extensive research over the past several years, much is still unknown 
about the biology and mechanisms behind CHIKV pathogenesis.  To unravel and 
comprehend key aspects of the infection, it is important to first grasp the mechanisms 
by which the virus interacts with its human host, and how the human host responds to 
the foreign pathogen.  Different approaches have been pursued in attempts to elucidate 
virus-host interaction, one of which is through proteomic study.  Termed as ‘the large-
scale study of total proteins’, proteomics is the leading tool used to study structure, 
function, and control of biological processes and pathways via analysis of the cellular 
proteome.  This approach has been successfully employed to study host responses 
towards numerous pathogenic viruses including hepatitis C and dengue virus. 
 
Given the scarcity of knowledge on the association between CHIKV and its 
human host in general, and the promising results obtained in other studies using 
proteomic approaches as the tool of study, it is therefore of great interest to look into 
changes in global protein profiles of the host cells during CHIKV infection.  Previous 
proteomic studies have looked at the host response during the late stages of CHIKV 
infection.  The present research endeavours to look at the proteins involved during early 
stages of infection using WRL-68 cell line as the in vitro model.  To attain a more 
comprehensive overview of the proteins contributing to the observed pathogenesis, the 
whole cell proteome and secretome profiles were investigated using 2-dimensional gel 
electrophoresis (2-DGE) as the study platform, coupled with real-time quantitative 
polymerase chain reaction (real-time qPCR) analysis of transcriptional profiles of the 
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altered proteins.  In line with the general purpose of this research, several specific 
objectives were set, as stated below: 
 
i) To optimise the infection conditions (Multiplicity of infection (MOI) and time-
point) for protein sample collection for early infection study. 
ii) To generate and compare global proteome profiles of whole cell proteome and 
secretome between CHIKV-infected and mock control WRL-68 cells. 
iii) To identify and validate differentially expressed proteins via mass spectrometry 
(MS) and Western blot, respectively. 
iv) To analyse the mRNA expression of selected differentially expressed proteins.  
v) To investigate the functional roles of altered proteins and their potential relation 
to the pathogenesis of CHIKV using pathway analysis software. 
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2.1 CHIKV 
CHIKV belongs to the Alphavirus genus of the Togaviridae family.  It is a part 
of the Semliki Forest virus group of the Old World Alphavirus, also known as 
arthritogenic alphavirus, which causes polyarthritis in infected patients (Schwartz & 
Albert, 2010).  The name Chikungunya is derived from the Makonde language, meaning 
‘to walk bend over’, which is attributed to the painful arthralgia that can persist for 
months (Chevillon et al., 2008).  This arbovirus (arthropod-borne virus) has been         
re-emerging and spreading throughout Asia, Africa and parts of Europe, and is listed as 
a category C priority pathogen by the National Institute of Allergy and Infectious 
Diseases (NIAID) (Wang et al., 2008).  Category C priority pathogens are the third 
highest priority pathogens that pose a global health threat as they can be engineered for 
mass dissemination due to their ease of production and dissemination, availability and 
the potential in causing high mortality and morbidity rates (NIAID, 2012). 
 
2.1.1 CHIKV classification  
Based on phylogenetic analysis of the E1 gene sequence, CHIKV can be 
clustered into three main genotypes: West African, Asian and East/Central/South 
African (ECSA) genotype (Tsetsarkin et al., 2007).  The West African genotype was 
determined to be the ancestral cluster, appearing between 150 and 1350 years ago.  The 
ECSA genotype diverged from the ancestral genotype between 100 and 800 years ago, 
while the Asian genotype evolved from the ECSA variants approximately 50 to 430 
years ago (Powers et al., 2000).  The ECSA and West African genotypes are the 
primary clusters causing epidemics/outbreaks in Africa whereas the ECSA and Asian 
genotypes are the predominantly circulating phylogroups in Asia (Singh & Unni, 2011). 
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2.1.2 Viral structure and genome organisation  
CHIKV is small, about 50-70 nm in diameter, and has an icosahedral-like 
nucleocapsid surrounded by a lipid bilayer envelope derived from the host plasma 
membrane (Simizu et al., 1984).  The nucleocapsid contains the single-stranded, 
positive sense RNA genome which is approximately 11.8 kb in size and has two open 
reading frames (ORFs) (Singh & Unni, 2011).  The first ORF in the 5’ end encodes for 
the non-structural proteins (nsP1, 2, 3 and 4) in the form of two polyprotein precursors 
whereas the second ORF in the 3’ end encodes for the structural polyproteins (Capsid 
(C) and envelope (E) proteins; E1, E2, E3) (Pardigon, 2009), as shown in Figure 2.1.  
The 5’ end is capped with 7-methylguanosine while the 3’ is polyadenylated (Khan et 
al., 2002).  The CHIKV genome also has an untranslated junction (J) region in between 
the two ORFs and a small peptide 6K of unknown functions (Singh & Unni, 2011). 
 
The functions of alphaviral proteins are well characterised.  Non-structural 
protein 1, nsP1, is involved in RNA capping and synthesis of the negative sense viral 
RNA (Salonen et al., 2005), while nsP2 possesses RNA helicase and protease activities 
(Pastorino et al., 2008).  The macro-domain containing nsP3 is a part of the helicase 
unit whereas nsP4 is the viral RNA polymerase.  The E1 and E2 structural glycoproteins 
function in mediating virus-host cell membrane fusion and interaction with host cellular 
receptors, respectively.  E3 protein, conversely, is involved in proper folding of 
precursor E2 and its association with E1 protein (Schwartz & Albert, 2010). 
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Figure 2.1: CHIKV genome and its products (Adapted from Chevillon et al., 2007) 
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2.1.3 Transmission cycle 
CHIKV is transmitted via two cycles, the sylvatic cycle (animal-mosquito-
animal) and urban cycle (man-mosquito-man), as illustrated in Figure 2.2.  The virus is 
transmitted and maintained in the sylvatic cycle in Africa, involving forest dwelling 
Aedes species (e.g. Ae. furcifer-taylori, Ae. africanus and Ae. dalzieli), and wild 
primates (e.g. baboons and chimpanzees), squirrels, birds and rodents (Thiboutot et al., 
2010).  In Asia, CHIKV transmission occurs through the urban cycle, with the primary 
anthropophilic mosquito vectors being Ae. aegypti and Ae. albopictus (Singh & Unni, 
2011).  CHIKV maintenance outside epidemic or outbreak periods is primarily 
associated with the urban cycle and virus persistence is attributed to continuous 
introduction of CHIKV to new areas with immunologically naive population 
(Tsetsarkin et al., 2011).  Nevertheless, recent isolation of CHIKV from wild monkeys 
in Malaysia suggests the possible existence of the sylvatic cycle in Asia (Apandi et al., 
2009).    
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Figure 2.2: Transmission cycles of CHIKV (Adapted from Thiboutot et al., 2010) 
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2.1.4 Replication cycle of CHIKV 
Viral replication is initiated from the moment the virus envelope attaches to the 
cellular host receptors (Strauss & Strauss, 1994).  A study conducted by Bernard and 
colleagues in 2010 revealed that CHIKV replication in mammalian cells occurs via the 
epidermal growth factor receptor substrate 15 (Eps15)-dependent receptor mediated 
endocytosis.  During viral entry, the virus fuses with the host membrane at low 
endosomal pH, upon which the viral nucleocapsid is released into the cytoplasm 
(Bernard et al., 2010). Translation of nsP123 in the early stage of replication leads to 
formation of replication complex (RC) upon binding to free nsP4.  The full length 
minus strand is formed from the RC for further production of the positive strand RNA 
(Singh & Unni, 2011).  
 
During the late stage of replication, nsP123 is cleaved to yield mature non-
structural proteins.  Along with the host cell proteins, these proteins act as the plus 
strand replicase to produce the 26S subgenomic plus strand RNA.  This RNA encodes 
the polyprotein precursor for the structural proteins, which upon production is further 
processed in the Golgi complex and transported to the plasma membrane.  Viral RNA is 
packed into the nucleocapsid in the cytoplasm and mature virions bud out of the plasma 
membrane, the envelope proteins acquired during the budding process (Singh & Unni, 
2011).  Viral replication is rapid, each cycle completed within four hours (Edwards et 
al., 2007).  The schematic diagram in Figure 2.3 illustrates CHIKV replication in host 
cells. 
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Figure 2.3: Replication cycle of CHIKV in mammalian host cells                           
(Adapted from Singh & Unni, 2011) 
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2.2 Epidemiology of CHIKV infection 
CHIKV was first isolated from a febrile patient during a dengue outbreak in 
Newala district, Tanzania, in 1953 (Khan, et al., 2002).  Within the next five decades, 
recurring outbreaks and epidemics have been reported in Africa and Asia, the most 
recent being the epidemics and outbreaks in Congo (50,000 cases from 1999 to 2000) 
(Pastorino et al., 2004), Indonesia (5821 cases from 2001 to 2003) (Laras et al., 2005), 
India (1.4-6.5 million cases from 2006 to 2007) (Mavalankar et al., 2007) and Thailand 
(42,000 cases in 2009) (Tiawsirisup, 2011).  Increase in global travel, inadequate 
mosquito control and climatic conditions have also led to the spread of CHIKV to non-
endemic regions including Europe, Australia and the United States (Thiboutot, et al., 
2010), as depicted in Figure 2.4.  A debilitating outbreak struck the French Réunion 
Island from 2005 to 2006, infecting more than one third of its population and killing 
284 people (Renault et al., 2007).  Meanwhile, small sporadic outbreaks were reported 
Italy in 2007, with over 200 reported CHIKV infection cases (Rezza et al., 2007), and in 
Réunion Island again in 2010, with over 100 reported cases (D'Ortenzio et al., 2011). 
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Figure 2.4: Geographic distribution of CHIKV genotypes                                        
The movement and dissemination of CHIK outbreaks during 2004-2011 are depicted by 
the arrows, whereas countries with imported cases of CHIKV are denoted in triangles. 
(Adapted from Tsetsarkin et al., 2011) 
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In Malaysia, three separate outbreaks have been reported within the last             
15 years.  The first documented outbreak was in Klang district in Selangor in 1998      
(51 cases) (Lam et al., 2001), followed by a second outbreak in Perak in 2006             
(49 confirmed cases) and the latest was in Tangkak, Johor in 2008 (2964 confirmed 
cases). Clusters of infection cases have also been reported all over the Peninsular and in 
Sarawak from 2008 onwards, believed to have spread from the Johor outbreak, with 
more than 6000 confirmed cases by the end of 2009 (Chua, 2010).  From January 2010 
to July 2011, the number of reported cases have declined to 823 cases (MOH, 2010, 
2011).  In February 2012, the virus resurfaced again, causing a small sporadic outbreak 
in Kuang, Selangor, involving 22 students and lecturers from a private college (MOH, 
2012). 
 
Phylogenetic analysis of the E1 glycoprotein sequence derived from CHIKV 
isolated during the three outbreaks revealed that strains from the Asian genotype were 
responsible for the Klang and the early 2006 Perak outbreaks.  However, CHIKV 
isolated from patients during the late 2006 Perak and the 2008 to 2009 Johor outbreaks 
were of the ECSA genotype (Noridah et al., 2007).  The ECSA clustered strains 
responsible for the late 2006 Perak outbreak were imported from India, as contact 
tracing identified the patient who was the source of the virus to be from the Indian 
continent, whereas strains accountable for the Johor outbreak were believed to be 
introduced independently (Lim, 2010). 
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2.3 Clinical manifestation 
The incubation period for CHIKV is short, requiring only two to six days, with 
symptoms showing on day four onwards (Ziegler et al., 2008).  CHIKV infection is 
mostly symptomatic, with asymptomatic infection reported in only 3-25% of patients 
(Chia et al., 2010).  Upon infection, CHIK tends to present itself in two phases.  The 
first phase or the acute phase is heralded by sudden onset of high fever, maculopapular 
rash and arthralgia (Figure 2.5).  The chronic phase occurs after infection is resolved, 
whereby more than 95% of patients are incapacitated by the disabling polyarthralgia, 
often from months to years (Thiboutot, et al., 2010).  Recurrent arthralgia and myalgia 
are typical long-term symptoms experienced by patients (Ozden et al., 2007). 
 
Atypical clinical presentations associated with CHIK infection have been 
observed in the recent outbreaks, including neurological complications such as 
encephalitis, myelopathy and myopathy (Chandak et al., 2009), encephalopathy- and 
myelitis-associated central nervous system (CNS) infections (Arpino et al., 2009), acute 
nephritis (Solanki et al., 2007) and severe acute hepatitis (Garnier et al., 2006).  These 
severe complications were found to occur more prevalently in patients above 65 years 
of age and those with underlying medical conditions such as diabetes, alcoholic liver 
disease and ischemic heart disease (Chia, et al., 2010).   
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Figure 2.5: Typical symptoms experienced by patients (A: Maculopapular rash 
and B: Arthralgia) 
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Death is not a common characteristic of CHIK infection and has not been 
attributed directly to the virus infection, although mortalities associated with atypical 
complications caused indirectly by the infection have been reported in the recent 
Réunion Island outbreak (Economopoulou et al., 2009).  In Malaysia, the first death was 
reported in 2010, whereby the patient suffered from severe systemic infection involving 
the liver, leading to eventual circulatory collapse (Chua, 2010).  The risk of death due to 
atypical complications is higher among neonates, the elderly and adults with pre-
existing conditions due to their weakened immune system (Schwartz & Albert, 2010).   
 
Mother-to-child-transmission of CHIKV was first reported in the Réunion Island 
outbreak.  Ramful and colleagues discovered that vertical transmission rate is higher 
when delivery occurs during the viraemic period, with the risk of infection increasing to 
50%.  Foetuses were also susceptible to CHIKV infection during perinatal period.  
Transmission during birth was found to occur irrespective of the delivery method, and is 
postulated to take place transplacentally.  Infected neonates displayed symptoms four 
days after birth, and while most suffered from typical infection which resolved within 
two weeks, some developed complications such as hemorrhagic syndromes, seizures 
and encephalopathy (Ramful et al., 2007).  
 
 Association between blood group and susceptibility to CHIKV infection was 
recently investigated.  Rhesus positive individuals, particularly those with O positive 
blood group were more vulnerable to CHIKV infection than their Rhesus negative 
counterparts (Lokireddy et al., 2009).  In a separate study, similar findings were 
obtained, although most infected Rhesus positive individuals were of the AB and A 
blood type (Kumar et al., 2010).  The role of blood group antigens in CHIKV disease 
development however, requires further investigation. 
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2.4 Prevention and treatment 
There are currently no commercially licensed vaccines or antiviral therapies 
available to combat this infectious disease.  Therefore, palliative treatment is 
administered to patients to relieve their symptoms.  Analgesics, antipyretics and anti-
inflammatory agents are given to treat the classic CHIK symptoms; fever and arthralgia.  
These pharmacological agents include paracetamol, non-steroidal anti-inflammatory 
drugs (NSAIDS) such as ibuprofen and indomethacin, as well as corticosteroids.  Due to 
reports of possible haemorrhagic manifestations of the infection, aspirins are not 
prescribed to patients (Powers & Logue, 2007; Tesh, 1982).  In cases where a patient’s 
arthritis is unresolved or refractory to NSAIDs, administration of 250 mg of chloroquine 
was proven to be helpful (Brighton, 1984).  Mild exercise is recommended to improve 
stiffness and morning arthralgia (Chhabra et al., 2008), whereas bed rest and fluids 
promote faster recuperation (Cavrini et al., 2009).  
 
Due to the lack of cure, prevention remains the best weapon against CHIKV 
infection.  Controlling mosquito vector breeding remains a challenge albeit being the 
most effective measure in reducing the spread of CHIKV, due in part to the ubiquitous 
nature of the Aedes mosquito species and the ability of CHIKV to adapt to different 
species through genetic evolution.  Current control measures rely heavily in reducing 
the number of artificial water-filled container habitats that support mosquito breeding 
(Singh & Unni, 2011).  Personal protection from mosquito bites via fogging, wearing 
long-sleeve clothes and the use of repellents and insecticides are also practiced to 
minimise exposure to infected mosquitoes (Her et al., 2009).  Epidemiological and 
vector surveillance should be intensified for early detection of new cases and 
monitoring of vector population and infestation, allowing effective and proper control 
measures to be implemented (Cavrini, et al., 2009; Chhabra, et al., 2008). 
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2.5 Current status of CHIKV research  
In light of the aggressive outbreak in India and the French Réunion Island, 
researchers from various expertise and research fields are united in a multidisciplinary 
effort to understand the biology of CHIKV and its interaction with the human host and 
mosquito vector.  Recent research highlights include findings pertaining virus tropism in 
human host cells, CHIKV genetic evolution, CHIKV-host immune interaction and 
development of vaccine and antiviral treatment. 
 
2.5.1 CHIKV cellular and tissue tropism 
In vitro studies in the 1960s to 1980s revealed CHIKV to be highly pathogenic 
in a wide array of non-human cell lines, including Vero monkey kidney cells, BHK21 
hamster kidney cells, chick embryo cells and L292 mouse fibroblast-like cells (Hahon 
& Zimmerman, 1970; White et al., 1972).  Sourisseau and colleagues recently studied 
CHIKV tropism in a panel of human primary and non-primary cell lines to determine 
CHIKV tropism in human.  Using four clinical strains from the Réunion Island 
outbreak, CHIKV was found to induce rapid apoptosis in most adherent human cell 
lines (ThBMEC bone marrow endothelial cells, MRC5 primary lung fibroblasts, BEAS-
2B bronchial epithelial cells, HeLa cervical carcinoma cells, 293T kidney epithelial 
cells and Hs 789.Sk primary skin fibroblasts), but was refractory in monocytoid (THP-1 
and U937 cells) and lymphoid (Jurkat cells) cell lines, lymphocytes (Primary CD4+ T 
cells), monocytes (Primary CD14+ cells) and monocytes-derived dendritic cells.         
The absence of infection was associated with poor binding of CHIKV to target cells.  
The observed findings are likely caused by the lack of receptors required for viral 
attachment to the cell surface, indicating that the unknown receptor is not ubiquitously 
found in all cell types (Sourisseau et al., 2007).  
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In vivo study in neonates and type I interferon (IFN) deficient adult mice by 
Couderc and colleagues revealed that CHIKV primarily targets muscle, joint and skin 
fibroblast, as well as the liver, spleen and brain (Figure 2.6).  Liver was found to be the 
main target organ for viral replication during early infection, as indicated by high viral 
titer within the first two days of infection.  In fact, liver was determined to be the only 
organ infected during early infection, suggesting that this organ may serve as a reservoir 
for rapid viral replication before dissemination to other target organs.  CNS infection 
was also observed in severe cases of infection, gaining access through the choroid 
plexuses. Their findings suggest that the classical symptoms of CHIK closely reflect 
CHIKV tissue tropism in contrast to other acute viral infections in which symptoms 
predominantly reflect the systemic immune response (Couderc et al., 2008).   
 
Immunohistological study of muscle biopsies from two patients exhibiting 
myositic syndrome during the acute and recurrent phases of CHIK found CHIKV 
exclusively inside the skeletal muscle progenitor cells (satellite cells), and not in muscle 
fibers.  CHIKV persistence in the progenitor cells was demonstrated by detection of 
viral antigen in biopsied muscle specimens from a patient who developed the infection           
three months back and was suffering from recurrent myalgia.  This suggests that these 
cells may serve as small reservoirs for the virus and virus-encoded components, 
plausibly accounting for the recurrent myalgia observed in many patients.  Further in 
vitro study to determine CHIKV ability to replicate in the satellite cells showed that this 
arbovirus was selective towards undifferentiated satellite cells as differentiated myotube 
cultures were refractory (Ozden, et al., 2007).  Regardless, further studies are required 
to elucidate the role of viral persistence and selectivity towards satellite cells and its 
relation to the observed clinical symptoms. 
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Figure 2.6: Dissemination of CHIKV in vertebrates  
CHIKV transmission occurs immediately after the patient is bitten by CHIKV-infected 
mosquito. CHIKV replicates in the skin fibroblasts prior to dissemination to the target 
organs. The target cells are indicated for each tissue (Adapted from Pardigon, 2009) 
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2.5.2 CHIKV genetic mutation and evolution  
Like most RNA viruses, the mutation rate of CHIKV genome is high, given the 
lack of proof-reading ability of the virus RNA polymerase (Elena & Sanjuan, 2005). 
Moreover, a single mutation can change the vector specificity, causing potential 
epidemics or outbreaks.  Hence, studying the microevolution of the viral genome can 
provide important evidence to comprehend the atypical magnitude and virulence of 
previous outbreaks and to predict future outbreaks. 
 
Genetic adaptation of CHIKV to new mosquito vectors is a probable factor 
facilitating recent CHIKV emergence (Weaver & Reisen, 2010).  The most notable and 
widely studied mutation is the alanine to valine substitution at position 226 of the E1 
glycoprotein (E1-A226V), in a region involved in fusion of viral particles with host 
endosomal membrane for viral entry.  This mutation increased CHIKV adaptability in 
Ae. albopictus, the primary circulating vector in Europe that caused massive outbreaks 
in Indian Ocean Islands, mainly the Réunion Island (Cavrini, et al., 2009).  Strains 
carrying this mutation was subsequently identified in later outbreaks in India (Cherian 
et al., 2009), Madagascar (Vazeille et al., 2007) and Italy (Bordi et al., 2008) in 2007, 
and the re-emerging outbreak in Réunion Island in 2010 (D'Ortenzio, et al., 2011).  
  
The relationship between the A226V mutation and virus adaptability in            
Ae. albopictus has been linked to the abrogation of cholesterol dependence of the virus 
for propagation in Ae. albopictus, which are cholesterol auxotrophs (Schuffenecker et 
al., 2006).  This adaptive mutation had no effect on CHIKV dissemination in the 
primary vector, Ae. aegypti, and only slightly increased its transmission in suckling 
mice model (Tsetsarkin, et al., 2007).  In contrast to the hypothesis that the A226V 
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mutation is responsible for the increase in symptom severity in patients, CHIKV 
carrying this mutation was recently determined to be more susceptible towards the 
innate immune response in non-human primate cells through antiviral action of IFN-α, 
although its replication kinetics are unaffected (Bordi et al., 2011).  Additional studies 
are required to explore the interplay between this point mutation and the innate defence 
system in human and its relation to disease severity. 
 
The rapid genomic evolution of CHIKV also allows phylogenetic studies to 
distinguish different strains of the virus which is helpful in understanding its 
evolutionary potential and the geographic distribution and dissemination during 
outbreaks (Zheng et al., 2010).  Phylogenetic clustering of CHIKV strains from several 
outbreaks delineated the virus into three genotypes, while paraphyletic grouping of the 
African strains validated that CHIKV originated in Africa and subsequently 
disseminated to Asia (Powers, et al., 2000).  Strains and isolates from a particular 
outbreak have also been reported to show little genetic variation, forming a 
monophyletic clade.  For instance, strains obtained from an outbreak in the Republic of 
Congo were found to be closely related to strains from previous outbreaks in Central 
Africa, indicating a strong phylogeographic structuring of CHIKV species (Powers & 
Logue, 2007).  
 
2.5.3 CHIKV-host immune interaction 
The study of CHIKV immune interaction with its human counterpart plays a 
vital role in understanding the pathophysiology of CHIKV.  Chikungunya fever 
(CHIKF) has been attributed to cytokines such as interleukins (IL-1β, IL-6) and tumour 
necrosis factor-alpha (TNF-α), which are known pyretics.  These inflammatory 
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cytokines are also postulated to be involved in the recurring arthralgia experienced by 
CHIKF patients, as they cause rheumatoid arthritis-like inflammation and tissue 
destruction, which are common symptoms of other alphavirus infections (Kam et al., 
2009).  Type I IFNs (IFNα/β) have been associated with CHIK infection.  A study on 
type I IFN-impaired mice revealed that severity of the infection depended on the level 
of IFN impairment, as mice with partially and totally abrogated IFN pathway contracted 
the mild and severe forms of the infection respectively, while healthy adult wild type 
mice were found to be resistant (Couderc, et al., 2008).  In vitro study by Sourisseau et 
al. also demonstrated that both type I and type II (IFN-γ) IFNs limited CHIKV, 
decreasing virus-induced cytopathic effect (CPE) (Sourisseau, et al., 2007).  
 
Recent ex vivo multiplex study involving 50 cytokines, chemokines and growth 
factor plasma has shed some light on the association between CHIKV infection and the 
human immune response.  Kinetic studies on these inflammatory mediators revealed 
that CHIKV infection educed strong innate responses involving the production of high 
levels of antiviral IFN-α.  This is followed by activation of the adaptive immune 
response, as characterised by high levels of IL-4, IL-10 and IFN-γ, and the production 
of CD8+ T cells during early acute phase.  Engagement of the CD4+ T cells mediated 
response and the elevated levels of anti-inflammatory proteins IL-1 receptor antagonist 
(IL1rα) and IL-2 receptor alpha (IL2RA), as well as pro-inflammatory proteins such as 
IL-6, IL-8, regulated on activation, normal T cell expressed and secreted (RANTES), 
migration inhibitory factor (MIF) and macrophage inflammatory protein-1β (MIP-1β), 
were observed during the late phase of acute infection.  Interestingly, evidence also 
suggested that CHIKV induced CD95-mediated apoptosis of CD4+ T cells in the first 
two days of symptoms, as determined by the increased expression of CD95+ in CD4+ T 
cells (Wauquier et al., 2011). 
26 
 
2.5.4 Vaccine and antiviral development 
Development of potential CHIKV vaccine candidates dates back to 1967, where 
a group of researchers created the formalin-inactivated whole virus vaccine based on the 
African CHIK 168 strain.  Potency test on this first generation vaccine however, 
generated controversial results (Harrison et al., 1967).  In the late 1980s, the second 
generation vaccine was developed through repeated passaging of CHIKV strain 15561 
in MRC5 cells, producing attenuated vaccine TSI-GSD-218 which showed promising 
results in the phase I and II clinical trials (Edelman et al., 2000; Levitt et al., 1986).  
 
Other alternative vaccine approaches currently being pursued are the chimeric, 
DNA and adenovirus vaccines.  Both the chimeric alphavirus vaccine, which is based 
on recombination of CHIKV structural gene and alphaviruses such as eastern equine 
encephalitis virus as the backbone, and the DNA vaccine, provided immunity in mice 
(Mallilankaraman et al., 2011; Wang, et al., 2008).  The recombinant CHIKV 
glycoprotein-encoded adenovirus vaccine, on the other hand, successfully protected 
mice against viraemia and also arthritis with a single immunisation (Wang et al., 2011). 
 
Weak base compounds such as chloroquine have been used traditionally to 
impair infectivity of alphaviruses (Her, et al., 2009).  Although chloroquine was shown 
to reduce CHIKV growth in vitro, it failed the Phase III clinical trial (Sourisseau, et al., 
2007).  Another study on four compounds (ribavirin, IFN-α, glycyrrhizin and                
6-azauridine) previously shown to elicit antiviral activities against flaviviruses, 
exhibited potent inhibition towards CHIKV in vitro.  Moreover, combination of 
ribavirin and IFN-α showed synergistic effect, and warrants further investigation as a 
potential antiviral drug (Briolant et al., 2004; Crance et al., 2003).  
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2.6 Proteomics 
The importance of studying proteins came to light following the advancement of 
genomic sequencing when researchers realised that having complete genome sequences 
is insufficient to elucidate biological function of cells as proteins are the active agents in 
cells (Pandey & Mann, 2000).  Proteins play vital roles in living organisms, as they are 
the major components of the metabolic and regulatory pathways of cells, and cells rely 
on those pathways for survival (Tyagi et al., 2010).  Changes in their composition or 
expression, however minute, may lead to the onset of pathological diseases (Bodzon-
Kulakowska et al., 2007).  Moreover, almost all drugs are directed against proteins. 
Ergo, the study of proteins directly contributes to drug development and pathway 
studies (Pandey & Mann, 2000).  
 
Proteomics is defined as the study of total proteins, termed as ‘proteome’ by 
Marc Wilkins in 1994, expressed in a particular cell line, tissue or organism (Dove, 
1999; Lee & Lee, 2004).  The study of proteome consists of three main approaches, 
namely expression proteomics, structural/cell-map proteomics and functional 
proteomics.  Expression proteomics, also known as differential expression proteomics, 
refer to the study of global changes in protein expression levels whereas structural 
proteomics involve determining the structure of protein complexes or specific proteins 
present in cellular organelles in attempts to identify all proteins within a complex or 
organelle, determine their subcellular location and characterise all protein-protein 
interactions.  Meanwhile, functional proteomics serve to study the function of proteins 
to obtain important information such as protein signalling, disease pathogenesis and 
protein-drug interactions (Graves & Haystead, 2002).  In general, proteomics provide a 
powerful set of tools aimed to characterise thousands of proteins within cells, tissues, 
and organisms (Issaq & Veenstra, 2008). 
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2.6.1 Tools of proteomics 
Identification and characterisation of proteins were made possible by the 
development and integration of three imperative tools: i) Mass spectrometry (MS), ii) 
Analytical protein separation technology and iii) Bioinformatics tools (Liebler, 2002).  
The invention of MS is perhaps the most significant breakthrough in proteomics, as it 
extends analysis far beyond the mere display of proteins.  MS is an analytic tool used to 
identify proteins, where the associated instrument (a mass spectrometer) measures the 
masses of molecules converted into ions via the mass-to-charge (݉/ݖ) ratio (Sellers & 
Miecznikowski, 2010).  Development of mass spectrometry replaces the conventional 
Edman degradation method of identifying proteins, enabling high-throughput protein 
identification (Pandey & Mann, 2000). 
 
Analytical separation techniques function to resolve complex protein mixtures 
into individual components, as well as allowing comparison of protein levels between 
two or more samples (Liebler, 2002).  The main separation techniques used today are 
the conventional 2-DGE and gel-free based approaches such as multidimensional liquid 
chromatography (LC) (Monteoliva & Albar, 2004).  Bioinformatics tools such as 
databases for protein identification, 2-D gels, as well as protein and genome-sequence 
databases, for example Swiss-Prot and the National Center for Biotechnology 
Information (NCBI), play essential roles in interpreting the massive amounts of data and 
expression information generated through proteomics analyses (Vihinen, 2001). 
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2.6.2 2-DGE 
Introduced by O’Farrell in 1975, 2-DGE involves separating proteins based on 
two independent parameters; i) Isoelectric point (pI) in the first dimension via 
isoelectric focusing (IEF) and ii) Molecular mass (Mr) in the second dimension by 
sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) (Beranova-
Giorgianni, 2003).  The resulting separations allow a complex protein mixture to be 
resolved into their respective protein represented as a single spot on the SDS-PAGE gel 
(Monteoliva & Albar, 2004).  2-DGE has been instrumental in changing the paradigm 
and boosting the development of proteomics in the 80’s and early 90’s with the advent 
of MS (Rabilloud et al., 2010).  Although it is no longer the exclusive separation tool 
given the introduction of alternate methods such as online liquid chromatography-mass 
spectrometry (LC-MS), 2-DGE remains a mainstay in differential expression 
proteomics (Shen et al., 2008). 
 
2.6.2.1. Sample preparation 
The classical 2-DGE workflow is illustrated in Figure 2.7.  Sample preparation 
is a crucial step prior to 2-DGE, which requires meticulous selection of methods with 
proper optimisation to ensure superior results.  There is no universal preparation 
method, as each choice depends largely on the type of sample at hand, which can be as 
simple and homogenous as cell culture to heterogenous and complex samples like 
tissue, blood, serum or plasma samples.  Regardless, the general steps involved in 
preparing samples for 2-DGE serve the same objectives, first to extract the protein by 
lysing the cells, followed by removal of contaminants and protein solubilisation, and 
finally quantification of protein concentration (Canas et al., 2007). 
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Figure 2.7: Schematic diagram of the conventional 2-DGE workflow 
The 2-DGE workflow can be summarised into 5 main steps as follows; i) Protein 
extraction and processing of biological sample, ii) IEF separation according to the pI 
value, iii) SDS-PAGE separation according to the Mr, iv) Quantitative analysis of the 
gel image to determine protein spots of interest, v) In-gel digestion of gel plugs and 
extraction of the resulting peptides for MS identification and characterisation (Adapted 
and modified from Rabilloud and Leong, 2011). 
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Cellular disruption or homogenisation is the initial preparation step to extract 
proteins from cells, tissues or organs from various organisms.  Depending on the 
complexity of the sample, homogenisation can be performed either by using the 
mechanical (eg. rotor-stator or open blade mills), ultrasonic (eg. sonication), pressure, 
freeze-thaw (eg. dry ice method), osmotic or detergent lysis method, or a combination 
of two or more of the aforementioned methods (Bodzon-Kulakowska, et al., 2007).  
After cell disruption and prior to solubilisation, interfering compounds such as salts, 
polysaccharides, nucleic acids and lipids must be removed as they interfere with the first 
dimension run and can cause vertical or horizontal streaking on 2-D gels (Canas, et al., 
2007).  Dialysis, ultrafiltration, protein precipitation (eg. acetone precipitation) and 
solid-phase extraction are commonly used methods to efficiently clean up samples from 
these contaminants (Bodzon-Kulakowska, et al., 2007).   Alternatively, several kits such 
as 2D clean up kit from GE Healthcare have been developed to effectively remove 
contaminants while minimising protein loss (Wells & Weil, 2003). 
 
 Proteins are held by multiple bonds; hydrogen bond, ionic bond, disulphide 
bridges and hydrophobic interactions, which confer their native conformation and allow 
quaternary structures to be formed between polypeptides.  Successful solubilisation of a 
complex protein mixture requires disruption of all bonds.  General solubilising solution 
contains a concoction of chaotropes to break hydrogen bonds and hydrophobic 
interactions (eg. urea and thiourea), reducing agents to reduce disulphide bonds (eg. 
dithiothreitol (DTT)), neutral or zwitterionic detergents to disrupt hydrophobic 
interactions (eg. 3-[(3-cholamidopropyl) dimethyl-ammonio]-1-propanesulfonate 
(CHAPS) and Triton-X), and buffer salts to prevent protein-protein interactions (eg. tris 
buffer) (Canas, et al., 2007).  Protease inhibitors are also added to prevent proteolysis 
by endogenous proteases liberated upon cell lysis (Bodzon-Kulakowska, et al., 2007). 
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 To ensure reproducibility of the gels, it is crucial to load equivalent amount of 
protein for each gel.  Several techniques and kits have been established to accurately 
quantitate protein concentration, the most common being Bradford protein assay, 
bicinchoninic acid (BCA) assay and 2D Quant kit from GE Healthcare.  Nonetheless, 
the choice of quantification protocol relies on the compatibility of the solubilising 
buffer with the selected method.  High concentrations of chaotropes and detergents may 
cause interference, leading to deviation from linear response, hence, a method with 
higher tolerance towards these interference should be selected (Canas, et al., 2007). 
 
2.6.2.2. IEF 
Prior to running IEF, the samples are rehydrated in immobilised pH gradient 
(IPG) drystrips to allow adsorption of proteins into the gel.  Three techniques have been 
ascertained for effectual rehydration, the most common being rehydration loading 
(passive and active rehydration).  The cup loading method is used for extreme pH and 
small volume of sample, while paper bridge rehydration is applied when rehydration 
loading is not feasible (Westermeiner & Naven, 2002).  Proteins are then focused to 
their respective pI, which is the pH value of the protein at which the net charge is zero.  
A wide range of pH gradient drystrips are currently available, ranging from wide 
gradient (eg. pH 4-7, 3-10 and 3-12) to narrow gradient or zoom-in gels (eg. pH 5-6) 
(Gorg et al., 2000).  Low voltage (100 V) is used to initiate run to remove salts and 
allow ampholytes to reach their final position, as these interfering substances generate 
strong Joule heating if high field strength is applied immediately.  This is followed by 
gradual increase of the field strength (500 V, 1000 V) to a final voltage of 8000 V 
(Gorg, et al., 2000; Rabilloud & Lelong, 2011). 
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2.6.2.3. SDS-PAGE 
 Proteins separated in the isoelectric focusing are further equilibrated with SDS 
to confer the proteins a net negative charge, rendering them mobile in the second 
dimension.  SDS-PAGE is then performed, first at low voltage (50 V) to allow the SDS 
front to re-solubilise the proteins while sweeping across the IPG strip, followed by high 
voltage (500 V) (Rabilloud & Lelong, 2011).  Proteins are subsequently visualised by 
staining the gels with dyes such as Coomassie brilliant blue (CBB), silver stain and 
fluorescent stain (Patel et al., 2005).  Silver staining is the most commonly used 
method, due to its high detectability and sensitivity (detects up to ng).  Despite its low 
sensitivity and narrow linear dynamic range, CBB is still widely used given the 
incompatibility of the silver staining protocol with MS unless modified (Monteoliva & 
Albar, 2004; Yan et al., 2000).  Gel images are then scanned and converted to digital 
data using a scanner and analysed with image analysis software tools such as 
ImageMaster™ (GE Healthcare), Progenesis SameSpots (Nonlinear Dynamics) and 
PDQuest™ (Bio-Rad Laboratories) (Sellers & Miecznikowski, 2010).  
 
2.6.3 MS 
Protein spots of interest are picked or excised from the gel and digested with 
sequence-specific proteases such as trypsin, which cleaves after lysine and arginine 
residues, into smaller peptides.  The rationale for analysing peptides rather than proteins 
is that peptides can be eluted from the gel and analysed more easily than proteins. 
Furthermore, a subset of peptides from a protein provides sufficient data for 
identification, whereas analysis based on the molecular weight of proteins may result in 
ambiguous identification (Pandey & Mann, 2000).  Digested peptides are then 
introduced into the mass spectrometer. 
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The two important modules in a mass spectrometer are the ion source and mass 
analyser.  The ion source functions to ionise the charged and polar molecules to gas-
phase ions, a pre-requisite prior to mass analysis, while the mass analyser separates and 
measures the ݉/ݖ ratio of each ion, presenting the data in the form of a mass spectrum 
(Yates, 1998).  To date, the two key ion sources for proteins and peptides analysis are 
matrix-assisted laser desorption/ionisation (MALDI) and electrospray ionisation (ESI)), 
both of which are soft ionisation techniques suitable for analysis of femtomole 
quantities of non-volatile and thermally labile analytes (Watson & Sparkman, 2007). 
Common mass analysers include time-of-flight (TOF), triple quadrupole and 
quadrupole ion trap analysers (Chen, 2008).  
 
MS protein identification can be performed in two ways, i) ‘peptide-mass 
mapping’ which generates the ‘peptide mass fingerprint’ (PMF) of the studied protein, 
and ii) tandem MS (MS/MS).  In peptide-mass mapping, different masses of the 
digested peptides of a particular protein are used to generate the peptide mass profile 
which is then compared with theoretical peptide libraries from existing databases to 
determine the protein identity (Barrett et al., 2005).  Tandem MS is a two-step 
procedure involving peptide-mass fingerprinting in the first step, and fragmentation of 
individual peptides in the second step to gain amino acid sequence information of each 
peptide fragment.  Although more complex and less scalable than mass fingerprinting, 
tandem MS provides more specific sequence information which can be used to search 
both protein and nucleotide databases for unambiguous identification of proteins 
(Pandey & Mann, 2000).  
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2.6.3.1. Proteomic data analysis 
Bioinformatics serve as an vital tool for analysis and interpretation of the mass 
spectra generated during MS analysis, without which protein identification and 
characterisation is virtually implausible.  Each protein spot generates a unique digestion 
fingerprint that is searched against sequence databases for matching fingerprints to 
accurately identify the protein of interest.  Various internet-based MS programs are 
available for interpretation of MS data, and can be grouped based on methods of 
analysis, such as peptide mass fingerprinting (Mascot, PeptIdent, MassSearch), protein 
molecular weight and sequence tags (PeptideSearch, PeptideMass) and peptide 
sequence tags (MS-Tag, MS-Seq).  ExPASy (http://www.expasy.ch) is a bioinformatics 
resource portal operated by the Swiss Institute of Bioinformatics (SIB), providing a 
large selection of protein identification tools (Vihinen, 2001).  
 
Online protein and complete genome-sequence databases such as expressed 
sequence tag (EST) and NCBI databases collectively provide a complete catalogue of 
proteins and genes expressed in organisms.  This allows protein identification even with 
limited sequence information or raw mass spectral data by matching them with a 
database entry (Liebler, 2002).  These databases also provide a platform for cross-
species protein identification of organisms with incomplete databases against others 
with fully sequenced genomes (Barrett, et al., 2005).  Databases for 2-D reference maps 
are available as well to link identified spots to the images of the gels.  The World-
2DPAGE List houses an index of 2D databases such as SWISS-2DPAGE, to aid in spot 
selection and data analysis (Hoogland et al., 2008). 
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2.6.4 Viral proteomics: Evaluation of virus-host interaction 
Proteomic technologies have been widely employed in the discovery of novel 
drug targets, early disease biomarkers and in the elucidation of biopathomechanisms, 
especially in cancer research (Garbis et al., 2005).  In virology studies, proteomic 
approaches are extensively applied to study protein composition of virions, the structure 
and interactions of viral proteins, and the effects of viral infection on cellular proteome 
(Maxwell & Frappier, 2007).  Both the gel-based and non-gel based approaches have 
been successfully used to study host responses towards a wide range of pathogenic 
viruses including dengue virus (Pattanakitsakul et al., 2007), West Nile virus (Pastorino 
et al., 2009), and hepatitis C virus infection (Jacobs et al., 2005). 
 
Despite extensive research on CHIKV and its interaction with the host and 
vector, little attention has been dedicated to proteomic study on this subject. 
Tchankouo-Nguetcheu and colleagues were the first to study protein modulation in 
midguts of Ae. aegypti mosquito vector in response to CHIKV by means of 2-DGE. 
Initial findings suggest alteration of proteins involved in cell protection and metabolic 
pathways subverted by the virus to favour their survival, replication and transmission in 
the vector (Tchankouo-Nguetcheu et al., 2010).  Another proteomic study was 
conducted by Dhanwani and colleagues in 2011, on the effect of virus infection in new-
born mice tissues.  Proteins related to stress, inflammation, apoptosis and metabolic 
pathways involved in nitrogen, iron and energy metabolism were found to be modulated 
upon infection (Dhanwani et al., 2011).  Meanwhile, proteomic analysis of CHIKV 
infection in microglial cells show down-regulation of the host cell antiviral responses as 
a possible target for host transcriptional shutoff (Abere et al., 2012).  Taken together, 
these studies provide plausible hypotheses as well as new insights in deciphering the 
mechanism involved in the pathogenesis of CHIK infection. 
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3.1 Cell culture and maintenance 
 
3.1.1 Cell lines 
The cell lines used in this research were WRL-68 human embryonic liver cell 
line, African green monkey kidney (Vero) cell line and C6/36 Aedes albopictus 
mosquito cell line. All cell lines were purchased from American Type Culture 
Collection (ATCC) and maintained at a low passage number. 
 
3.1.2 Virus stock 
CHIKV, clinical isolate CHIK06/08, of the ECSA genotype was obtained from 
Sungai Buloh General Health Laboratory, Selangor. 
  
3.1.3 Cell culture media and solutions 
 
i) Media for mammalian cell culture 
 
A) 10× Dulbecco’s Modified Eagle Medium (DMEM) stock 
DMEM powder (Sigma-Aldrich®, USA)           2 packets 
Sodium hydrogen carbonate (MERCK, Germany)                  6.00g 
4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)                   9.56 g 
(Promega, USA)         
De-ionised water (ddH2O)                              Top up to 200.0 ml 
 
The solution was stirred for 1 hour, filtered with 0.22 µM polyethersulfone (PES) filter 
(Nalgene®, USA) and stored at 4 °C. 
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B) 1× DMEM growth medium (Supplemented with 10% foetal bovine serum 
(FBS)) 
10× DMEM stock                 10.0 ml      
FBS (GIBCO®, USA)                 10.0 ml 
Sterile ddH2O                  80.0 ml 
 
C) 1× DMEM maintenance medium (Supplemented with 2% FBS) 
10× DMEM stock                 10.0 ml 
FBS                                           2.0 ml 
Sterile ddH2O                  88.0 ml 
 
D) 1× DMEM serum-free medium 
10× DMEM stock                 10.0 ml 
Sterile ddH2O                  90.0 ml 
 
ii) Media for C6/36 insect cell culture 
 
A) 2× Leibovitz’s L-15 medium stock 
L-15 powder (Sigma-Aldrich®, USA)              1 bottle 
ddH2O           Top up to 500.0 ml 
 
The solution was stirred for 1 hour, filtered with 0.22 µM PES filter and stored at 4 °C. 
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B) 1× L-15 growth medium (Supplemented with 10% FBS) 
2× L-15 stock                  50.0 ml 
FBS                   10.0 ml 
Tryptose phosphate broth (TPB) (Sigma-Aldrich®, USA)                                       10.0 ml 
ddH2O                             38.0 ml 
 
C) 1× L-15 maintenance medium (Supplemented with 2% FBS) 
2× L-15 stock                             50.0 ml 
FBS                     2.0 ml 
TPB                                       10.0 ml 
ddH2O                   38.0 ml 
  
iii) Cryopreserving medium 
FBS                     9.0 ml 
100% dimethyl sulfoxide (DMSO) (Sigma-Aldrich®, USA)                                    1.0 ml 
 
Cryopreserving medium was prepared fresh before use and kept in the dark. 
 
iv) Phosphate buffered saline (PBS) 
PBS (Sigma-Aldrich®, USA)                                 1 bottle 
ddH2O                          1 L 
 
PBS solution was autoclaved and stored at room temperature (25 °C). 
 
v) Trypsin/0.25% ethylenediaminetetraacetic acid (EDTA) (GIBCO®, USA) 
 
*NOTE: All media were prepared under sterile conditions and stored at 4°C. 
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3.1.4 Cell culture and maintenance procedures 
 
3.1.4.1 Cultivation of cell lines 
Both WRL-68 and Vero mammalian cell lines were grown in DMEM growth 
medium at 37 °C in a humidified incubator with 5% carbon dioxide (CO2). C6/36 
mosquito cell line on the other hand was propagated in L-15 growth medium at 28 °C 
without 5% CO2.  
 
All cell lines were maintained in 25 cm2 culture flask (NUNC™, USA) and         
sub-cultivated upon reaching 80% confluency.  Briefly, spent medium was discarded 
and the adherent cells were washed twice with PBS and trypsinised in 1 ml 
trypsin/0.25% EDTA for 2 to 5 minutes at 37 °C.  Cells were detached by gently 
tapping the flask.  An equivalent amount of medium was added to stop trypsin activity.  
The cells were transferred to a 15 ml centrifuge tube and centrifuged at 250 × g for 5 
minutes.  The resulting cell pellet was resuspended in 1 ml of DMEM growth medium 
for mammalian cell lines and L-15 growth medium for C6/36 cell line.  The cells were 
sub-cultivated at a ratio of 1:6 and 1:4 for mammalian and insect cell lines respectively 
with medium renewal of every two days. 
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3.1.4.2 Cryopreservation and thawing 
All three cell lines were preserved in cryopreserving medium containing 10% 
DMSO and stored in liquid nitrogen.  Briefly, confluent cells were trypsinised and 
centrifuged at 250 × g for 5 minutes.  The supernatant was discarded and the cells were 
resuspended in 4 ml of cryopreserving medium and stored in 1.0 ml-aliquot in 1.5 ml 
cryovials (NUNC™, USA).  The cells were incubated at 4°C for 30 minutes, -20°C for 
4 hours and -80°C overnight prior to being transferred to liquid nitrogen for long term 
storage. 
 
Cells were revived by rapid thawing at 37°C for 2 minutes followed by 
immediate transfer to a new 25 cm2 culture flask containing fresh DMEM growth 
medium.  The cells were incubated for 4 hours at 37 °C for mammalian cells and 28 °C 
for insect cells.  Spent medium was then discarded and replaced with fresh medium to 
remove toxic DMSO and unattached cells.  The cells were further incubated under their 
respective conditions and subjected to normal cell passaging upon reaching confluency.  
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3.2 CHIKV stock production 
CHIKV was propagated twice in C6/36 cell line.  Briefly, C6/36 cells were 
grown to 80% confluency in 25 cm2 culture flask and infected with 100 µl of CHIKV 
stock for 2 hours at 28°C with gentle shaking at every 15 minutes interval.  Viral 
inoculum was removed following incubation and infected cells were further incubated 
for 6 days in L-15 maintenance medium at 28 °C.  Uninfected cells were cultured in 
parallel under the same conditions but without virus infection. 
 
After 6 days incubation, the uninfected and CHIKV-infected cells were frozen at 
-80 °C and subsequently thawed at room temperature to lyse the cells for the release of 
virus particles.  This process was repeated thrice for complete cell lysis.  Lysed cells 
were transferred to a 2.5 ml microcentrifuge tubes in 2.0 ml-aliquots and spun at          
1,000 × g for 5 minutes to remove cellular debris.  The supernatant was harvested and 
stored in 1.0 ml-aliquot at -80 °C. 
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3.3 Cell counting and seeding 
 
3.3.1 Chemicals and reagents  
 
i) Trypan blue solution 0.4% (Sigma-Aldrich®, USA) 
 
3.3.2 Procedure 
Confluent cells were trypsinised and centrifuged at 250 ×g for 5 minutes.           
The supernatant was discarded and the cells were resuspended in 1 ml of DMEM 
growth medium.  Ten µl of cells were mixed with 90 µl of trypan blue and 10 µl of the 
mixed cell suspension was loaded on one side of the haemocytometer chamber.  Cells 
within the four side quadrants were viewed at 100× magnification and counted with a 
cell counter.  The number of cells per ml of medium was calculated according to the 
formula below: 
Number of cells/ml=
Total number of cells in 4 quadrants
4
×  10 (Dilution factor) × 104 
 
The cells were seeded at the appropriate density and incubated overnight at           
37 °C in DMEM growth medium. 
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3.4 CHIKV titration: Plaque assay 
 
3.4.1 Chemicals and reagents  
 
i) 5% low melting point agarose 
Type VII low melting point agarose (Sigma-Aldrich®, USA)               2.5 g 
ddH2O                   50.0 ml 
 
Solution was heated to dissolve the agarose powder and autoclaved.  
 
ii) 0.5% agarose overlay 
5% low melting point agarose                 5.0 ml 
ddH2O                   50.0 ml 
 
Agarose overlay was prepared under sterile conditions and kept warm in 37 °C 
waterbath. 
 
iii) Trichloroacetic acid (TCA)  
TCA (MERCK, Germany)                  20.0 g 
ddH2O                 100.0 ml 
 
iv) Crystal violet solution (Sigma-Aldrich®, USA) 
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3.4.2 Virus dilution 
 Ten-fold serial dilutions (10-1 to 10-8) of the virus stock were prepared.  Briefly, 
900 µl of serum-free DMEM medium was added to eight microcentrifuge tubes 
(labelled 10-1 to 10-8).  One hundred µl of virus stock was added to the first tube and 
mixed well by inverting the tube repeatedly.  Serial dilution was then performed by 
transferring 100 µl to the subsequent dilution and repeating the procedure.   
 
3.4.3 Virus infection 
 Cells were seeded at a density of 5.0 × 105 cells per well in 6-well culture dish 
(NUNC™, USA) overnight at 37 °C.  Prior to infection, DMEM growth medium was 
discarded and following that 200 µl of each virus dilution were added to the various 
well in duplicates.  Supernatant of uninfected C6/36 cells were added to the negative 
control wells (mock control cells).  Cells were incubated for 2 hours at 37 °C with 
gentle shaking every 15 minutes to prevent the cell sheets from drying.  Viral inoculum 
was removed following incubation and 2 ml of 0.5% agarose overlay diluted in DMEM 
maintenance medium was added to each well.  The agarose overlay was left to solidify 
at room temperature for 15 minutes. The cells were further incubated for 30 hours at      
37 °C. 
 
3.4.4 Plaque staining and counting 
Cell sheets were fixed onto the plate by adding 2 ml of 20% TCA to each well 
with 5 minutes incubation.  TCA solution was then removed and the agarose overlay 
was gently flicked off the plate.  Cell sheets were rinsed with distilled water to remove 
residual TCA and agarose.  Two ml of crystal violet solution was added to each well 
with 30 minutes incubation to stain the cells.  Crystal violet was then rinsed off and 
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visible plaques were counted.  The dilution that gives a plaque number of between         
20 and 100 was used to determine the virus stock concentration.  Virus stock 
concentration (pfu/ml) was counted using the formula below: 
 
Plaque forming unit (pfu)/ml=
Number of plaques
Dilution factor × Inoculum volume
 
 
 
3.5 Determination of multiplicity of infection (MOI) 
 Virus titre (pfu/ml) was used to determine the MOI, defined as the average 
number of virus particles infecting a cell in a population subjected to infection.  The 
MOI is calculated based on the formula below: 
 
MOI= Virus titre (pfu/ml) × Inoculum volume (ml)
Total number of seeded cells 
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3.6 Optimisation of infection condition  
 
3.6.1 Confirmation of infection by indirect immunofluorescence assay (IIFA) 
 
3.6.1.1 Chemicals and reagents  
 
i) 3.7% formaldehyde in PBS 
37% formaldehyde (MERCK, Germany)             100.0 µl  
PBS                             900.0 µl 
 
ii) 0.15 M glycine in PBS 
Glycine (MERCK, Germany)                56.30 g 
PBS                   50.0 ml 
 
iii) 0.1% Triton X-100 in PBS 
Triton X-100 (AppliChem, Sweden)                           50.0 µl 
PBS                 49.95 ml 
 
iv) 0.2% gelatin in PBS 
Gelatin (Sigma-Aldrich®, USA)                   0.2 g 
PBS                   50.0 ml 
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v) Anti-CHIK E2 monoclonal antibody (mAb) 3E4 
Anti-CHIK E2 mAb 3E4 (82 µg/ml), a kind gift from Dr. Phillippe Després of Pasteur 
Institute, France, was diluted in PBS/0.2% gelatin at a ratio of 1:1000. 
 
vi) Goat anti-mouse IgG secondary antibody (Novus Biologicals, USA) 
The secondary antibody was diluted in PBS/0.2% gelatin at a ratio of 1:100. 
 
vii) Fluoromount (Sigma-Aldrich®, USA)  
  
3.6.1.2 Procedure 
WRL-68 cells were seeded at a density of 1.5 × 105 cells per well in 24-well 
culture dish (NUNC™, USA) overnight at 37 °C.  Spent medium was discarded and 
cells were washed twice with PBS to remove traces of FBS.  Cells were infected in 
serum-free DMEM medium at the MOI of 0.5, 1.0, 5.0 and 10.0 for 2 hours at 37 °C 
with gentle shaking every 15 minutes.  Viral inoculum was removed after incubation 
and cells were further incubated for 24 and 48 hours in 500 µl DMEM maintenance 
medium.  
 
The medium was removed following incubation at the desired time-point and 
cells were rinsed with PBS and fixed with 300 µl of 3.7% formaldehyde in PBS for         
20 minutes at room temperature.  Cells were then washed with PBS and further 
incubated with 300 µl of 0.15 M glycine in PBS for 10 minutes to quench excess 
formaldehyde.  The cells were washed again with PBS and permeabilised with 300 µl of 
0.1% Triton X-100 in PBS for 5 minutes.  Permeabilised cells were washed thoroughly 
and incubated with 150 µl of anti-CHIK E2 mAb 3E4 for 40 minutes at 37 °C. 
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Thereafter, the cells were washed extensively to remove unbound antibodies and 
incubated with 150 µl of goat anti-mouse IgG secondary antibody conjugated with 
fluorescein isothiocyanate (FITC) for 30 minutes at 37 °C in the dark.  Cells were then 
rinsed with PBS and two drops of fluoromount were added to each well to reduce 
fluorochrome quenching during analysis.  The cells were observed under an inverted 
microscope (Nikon Eclipse Ti-5, Japan) and fluorescence pictures were acquired using 
NIS-Elements imaging software (Nikon, Japan).  
 
3.6.2 Quantitative analysis of cell infection via flow cytometry 
 
3.6.2.1 Chemicals and reagents  
 
i) 3.7% formaldehyde in PBS 
 
ii) Staining buffer (0.1% Sodium azide, 1.0% FBS)    
Sodium azide (w/v)                20.0 mg 
FBS                  200.0 µl 
PBS                   20.0 ml 
 
iii) Anti-CHIK E2 mAb 3E4 
Anti-CHIK E2 mAb 3E4 (82 µg/ml) was diluted in staining buffer at a ratio of 1:250. 
 
iv) Goat anti-mouse IgG secondary antibody  
The secondary antibody was diluted in staining buffer at a ratio of 1:100. 
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3.6.2.2 Procedure 
WRL-68 cells were seeded at a density of 2.0 × 106 cells per 25 cm2 culture flask 
(NUNC™, USA) overnight at 37 °C.  The cells were infected with CHIKV at various 
MOI (MOI 0.5, 1.0, 5.0 and 10.0) in 1 ml DMEM serum-free medium for 2 hours at     
37 °C with gentle shaking at every 15 minutes interval.  Viral inoculum was removed 
after incubation and the cells were further incubated in 5 ml DMEM maintenance 
medium for 24 and 48 hours.  Cells were harvested after incubation at their designated 
time-points and washed twice with PBS.  Thereafter, 1.5 × 106 cells per sample were 
counted and fixed with 150 µl of 3.7% formaldehyde in PBS for 30 minutes.  
Permeabilised cells were pelleted at 6,000 × g for 3 minutes, washed twice with staining 
buffer and incubated with 50 µl of anti-CHIK E2 mAb antibody 3E4 for 90 minutes at  
37 °C.  After extensive washing with staining buffer, the cells were further incubated 
with 200 µl of FITC-conjugated secondary antibody for 60 minutes at 37 °C. 
Thereafter, the cells were washed thoroughly with staining buffer and resuspended in 
500 µl PBS.   
 
The cells were sorted using BD FACSCanto II flow cytometer (BD Bioscience, 
USA) and analysed with BD FACSDiva software (BD Bioscience, USA).  Unstained 
control was used to adjust the forward scatter (FSC) and side scatter (SSC) voltages 
whereas cells stained with secondary antibody only was used to adjust the FITC 
voltage.  Ten thousand events (representing 1.0 × 104 cells) were recorded for each 
sample and a dot plot was generated, using mock control sample to set the quadrant.  
Results were presented as percentage infection (%) ± standard deviation (SD) for three 
independent experiments. 
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3.6.3 Quantitative analysis of cell death by Annexin V (AV)/propidium iodide 
(PI) co-labelling 
 
3.6.3.1 Kits and reagents  
 
i) FITC AV apoptosis detection kit I (BD Pharmigen™, USA) 
Components: 
10× Annexin binding buffer                50.0 ml  
FITC AV                    0.5 ml        
PI staining solution                    2.0 ml 
 
1× Annexin binding buffer was prepared by diluting 1 ml of 10× Annexin binding 
buffer in 9 ml PBS. 
 
3.6.3.2 Procedure 
Percentage of cell death was determined using FITC AV Apoptotic Detection 
Kit according to the manufacturer’s protocol.  Briefly, cells were seeded at the 
appropriate density in 25 cm2 culture flask and infected at different MOI (MOI 0.5, 1.0, 
5.0, 10.0) and time-points (24 and 48 hours).  Following infection, the cells were 
harvested and washed twice with PBS.  One million cells were counted for each sample 
and resuspended in 1 ml of 1× Annexin binding buffer.  One hundred µl (equivalent to 
1.0 × 105 cells) of the solution was transferred to a 5 ml round bottom test tube (BD 
Bioscience, USA).  Five µl of AV and PI was added to each tube with 15 minutes 
incubation in the dark at room temperature.  Four hundred µl of 1× Annexin binding 
buffer was then added to each tube and samples were analysed by flow cytometry 
within 1 hour. 
 53 
 
Prior to analysing the samples, compensation controls were performed to detect 
and rectify spillover of the emission of one fluorochrome (FITC-AV or PI) into the 
detector designated to collect the emission of another fluorochrome (PI or FITC-AV). 
Three controls were used for the setup: i) unstained control; ii) cells stained with AV 
only; and iii) cells stained with PI only.  Auto compensation was performed by 
adjusting the SSC, FSC, FITC-AV and PI voltages using unstained control, while 
manual compensation was performed thereafter for fine tuning.  Ten thousand events 
(representing 1.0 × 104cells) were recorded for each sample and the dot plot was 
generated.  Results were presented as percentage of cell death (%) ± SD for three 
independent experiments. 
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3.7 Optimisation of the condition for secretome sample preparation 
 
3.7.1 Kits and reagents 
 
i) CellTiter 96® Aqueous One Solution Cell Proliferation assay (MTS) 
(Promega, USA) 
Components: 
CellTiter 96® Aqueous One Solution Cell Proliferation reagent           50.0 ml  
 
ii) CytoTox-Glo™ Cytotoxicity assay (Promega, USA) 
Components: 
AAF-Glo™ substrate                 10.0 ml  
Assay buffer                    5.0 ml 
Digitonin                0.175 ml 
 
CytoTox-Glo™ Cytotoxicity assay reagent was prepared by mixing one bottle of AAF-
Glo™ substrate with a bottle of assay buffer.  Lysis reagent was prepared by adding      
13 µl of digitonin to 2.75 ml of assay buffer. 
 
3.7.2 MTS cell proliferation assay 
For secretome study, the effect of serum deprivation on WRL-68 cell 
proliferation was determined using MTS cell viability assay.  Briefly, cells were seeded 
at a density of 1.0 × 104 cells/well in 96-well dish overnight, followed by extensive 
washing with serum-free DMEM medium and incubation in either DMEM growth 
medium or serum-free DMEM medium at the selected time-point in triplicates.  Twenty 
µl of CellTiter 96® Aqueous One Solution Cell Proliferation reagent was then added to 
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the cells, followed by 4 hours incubation at 37°C.  The absorbance was read at 490 nm 
and cell viability graph was plotted based on the data from three independent 
experiments.  All data were presented as mean ± SD. 
 
3.7.3 Dead-cell protease release assay 
Quantification of cellular disruption was determined using CytoTox-Glo™ 
Cytotoxicity assay according to the manufacturer’s protocol.  WRL-68 cells were 
seeded at a density of 1.0 × 104 cells/well in 96-well dish overnight, followed by 
extensive washing with serum-free DMEM medium and incubation in either DMEM 
growth medium or serum-free DMEM medium at the optimised time-point to determine 
the effect of serum deprivation on cell membrane integrity.  The effect of CHIKV-
infection at the optimised MOI on WRL-68 cellular disruption was evaluated 
concomitantly by infecting the cells for 2 hours with CHIKV, followed by extensive 
washing with serum-free DMEM medium and further incubation at the desired time-
point.  
 
 After incubation, 50 µl of lysis reagent was added to the positive control wells 
for 1 minute to completely lyse the cells.  Fifty µl CytoTox-Glo™ Cytotoxicity assay 
reagent was subsequently added to all wells, followed by 15 minutes incubation. 
Luminescence was measured using GloMax® 20/20 luminometer (Promega, USA) and 
the luminescence signals were quantified as relative luminescence unit (RLU).  The 
relative percentage of cell lysis was calculated based on the maximum cellular 
disruption obtained from cells treated with lysis reagent.  All data were presented as 
mean ± SD. 
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3.8 WRL-68 cell infection for 2-DGE 
 
3.8.1 Infection protocol of WRL-68 cells for whole cell proteome study 
WRL-68 cells were seeded at a density of 4.5 × 106 cells in 75 cm2 culture flasks 
overnight at 37°C.  Cells were infected with CHIKV in serum-free DMEM medium at 
the optimised MOI and incubated for 2 hours at 37 °C with gentle shaking at every      
15 minutes interval.  Viral inoculum was then removed and the cells were further 
incubated at the optimised time-point in DMEM maintenance medium.  Mock control 
cells were cultured in parallel as control.  
 
3.8.2 Infection protocol of WRL-68 cells for secretome study 
WRL-68 cells were seeded at a density of 4.5 × 106 cells in 75 cm2 culture flasks 
overnight at 37 °C.  Cells were infected with CHIKV in serum-free DMEM medium at 
the optimised MOI and incubated for 2 hours at 37 °C with gentle shaking at every        
15 minutes interval.  Viral inoculum was then removed and the cells were washed 
extensively with serum-free medium to remove traces of FBS from the virus 
supernatant.  Infected cells were further incubated at the optimised time-point in serum-
free DMEM medium.  Mock control cells were cultured in parallel as control. 
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3.9 Protein sample processing 
 
3.9.1 Protein extraction 
 
3.9.1.1 Chemicals and reagents 
 
i) Lysis buffer stock solution (7 M Urea, 2 M Thiourea, 4% CHAPS,             
2% IPG buffer, 40 mM DTT) 
Urea (GE Healthcare, Uppsala, Sweden)                10.5 g 
Thiourea (Invitrogen, USA)         3.8 g 
CHAPS (Invitrogen, USA)                    1.0 g 
DTT (Gold Biotechnology®, USA)               0.154 g 
IPG buffer pH 3-10 (GE Healthcare, Uppsala, Sweden)           500.0 µl 
ddH2O               Top up to 25.0 ml 
 
Lysis buffer was stored in 1.0 ml-aliquots at -20°C. Ten µl of nuclease mix                     
(GE Healthcare, Uppsala, Sweden) and protease cocktail inhibitor (GE Healthcare, 
Uppsala, Sweden) were added to the aliquots fresh before use. 
 
ii) Rehydration buffer stock solution (7 M Urea, 2 M Thiourea, 2% CHAPS, 
0.5% IPG buffer) 
Urea                     10.5 g 
Thiourea           3.8 g 
CHAPS            0.5 g 
IPG buffer pH 3-10                 125.0 µl 
1% bromophenol blue stock solution                50.0 µl 
ddH2O                          Top up to 25.0 ml 
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Rehydration buffer stock solution was stored in 0.6 ml-aliquots at -20°C.  10.8 µl of 1M 
DTT were added to the aliquots fresh before use.  Bromophenol blue was omitted from 
the stock used to re-dissolve proteins after clean-up. 
 
iii) 1 M DTT stock solution 
DTT              0.1542 mg 
ddH2O                                1.0 ml 
 
DTT stock solution was stored in 25µL-aliquots at -20°C. 
 
iv) Bromophenol blue stock solution (1% Bromophenol blue, 50 mM Tris 
base) 
Bromophenol blue (GE Healthcare, Uppsala, Sweden)         100.0 mg 
Tris base (MERCK, Germany)               60.0 mg 
ddH2O                              10.0 ml 
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3.9.1.2 Extraction procedure for whole cell proteins 
Mock control and CHIKV-infected cells were trypsinised and the cell 
suspensions were centrifuged at 3,000 × g for 5 minutes.  Supernatants were discarded 
and the cell pellets were washed with PBS and centrifuged again.  Cell pellets were 
harvested and 200 µl of lysis buffer was added to lyse the cells.  The samples were 
incubated on ice for 30 minutes with brief vortexing at every 15 minutes interval.  
Extracted protein was then centrifuged at 17,000 × g to remove cellular debris and 
stored at -80 °C. 
 
3.9.1.3 Extraction procedure for secretome 
The supernatant of and CHIKV-infected WRL-68 cells were collected in 50 ml 
centrifuge tubes and centrifuged at 3,000 × g for 5 minutes to remove dead cells and 
cellular debris.  The supernatants were filtered through 0.22 µm syringe filters 
(Sartorius Stedim Biotech, Germany) and further concentrated using Vivaspin® 20 
centrifugal concentrator with a 3,000 kDa molecular weight cut-off membrane 
(Sartorius Stedim Biotech, Germany) and stored at -80 °C. 
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3.9.2 Protein clean-up and quantification 
 
3.9.2.1 Kits and reagents 
 
i) 2-D Clean-Up kit (GE Heathcare, Uppsala, Sweden) 
Components: 
Precipitant                15.00 ml 
Co-precipitant                17.00 ml 
Wash buffer                50.00 ml 
Wash additive                  0.25 ml 
 
ii) Quick Start Bradford Protein assay kit I (Bio-Rad, USA) 
Bradford dye reagent         1.0 L 
Bovine serum albumin (BSA) (2.0 mg/ml)         5 × 1.0 ml 
 
3.9.2.2 Protein clean-up: 2-D Clean-Up kit 
Protein samples were cleaned up using 2-D Clean-Up kit according to the 
manufacturer’s protocol.  Briefly, 300 µl of precipitant was added to 100 µl of samples 
with 15 minutes incubation on ice, followed by the addition of equal volume of           
co-precipitant.  The samples were vortexed and centrifuged at full speed (17,000 × g) 
for 5 minutes at 4 °C.  The supernatants were decanted and 40 µl of co-precipitant was 
added to each pellet with 5 minutes incubation prior to centrifugation at full speed for 5 
minutes.  A cocktail of 10 µl Milli-Q, 5 µl wash additive and 1 ml wash buffer wash 
then added to the samples with vortexing to disperse the protein pellets.  The pellets 
were incubated at -20 °C for 30 minutes with vigorous vortexing every 10 minutes and 
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centrifuged at full speed for 5 minutes.  The pellets were then re-dissolved in 100 µl 
rehydration buffer without bromophenol blue. 
 
3.9.2.3 Protein estimation: Bradford assay 
The concentrations of whole cell proteins and secretome were estimated using 
Bradford Protein assay kit I, with BSA as the protein standard.  BSA stock (2 mg/ml) 
was first diluted to 1 mg/ml in ddH2O.  200 µl of Bradford dye reagent was pipetted into 
each well of the 96-well dish.  The BSA stock (1 mg/ml) was added to the wells in 
triplicates to produce a range of amounts from 1 µg to 5 µg.  One µl of each protein 
sample was added to the wells in triplicates.  The mixture was equilibrated for                
5 minutes at room temperature and the absorbance was read at 595 nm.  The protein 
concentration for each sample was calculated from the BSA standard curve generated 
using Microsoft Excel. 
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3.10 First dimensional electrophoresis: Isoelectric focusing (IEF) 
 
3.10.1 Chemicals and reagents  
 
i) Rehydration buffer stock solution (7 M Urea, 2 M Thiourea, 2% CHAPS, 
0.5% IPG Buffer) 
Rehydration buffer containing 1% bromophenol blue was prepared according to the 
recipe described in section 3.9.1.1. 
 
ii) Drystrip cover fluid (GE Healthcare, Uppsala, Sweden) 
 
3.10.2 Passive rehydration  
Prior to running the first dimension, the protein samples were rehydrated for     
16 hours to allow proteins to absorb into the gel.  Briefly, 40 µg (for analytical gels) or 
80 µg (for preparative gels for MS analysis) of proteins were mixed with rehydration 
buffer (with bromophenol blue) to a final volume of 250 µl per drystrip and loaded onto 
the Immobiline® DryStrip reswelling tray (GE Healthcare, Uppsala, Sweden). 
Immobiline™ drystrip pH 3-10 linear, 13 cm gels (GE Healthcare, Uppsala, Sweden) 
were gently slid into the sample solution with the gel side facing down to avoid trapping 
bubbles and overlaid with 2 ml of drystrip cover fluid to prevent the drystrips from 
drying out. 
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3.10.3 IEF 
Following 16 hours incubation, the rehydrated drystrips were transferred onto 
the ceramic strip holder and placed on the IPGphor electrode platform.  Damped paper 
wicks (GE Healthcare, Uppsala, Sweden) were placed on both ends of the strips and 
platinum wire electrodes were placed on top of the paper wicks.  Six ml of drystrip 
cover fluid was added onto the drystrips and focusing was performed at 20 °C using the 
protocols tabulated in Tables 3.1 (for whole cell proteins) and 3.2 (for secretome).  The 
drystrips were stored individually in screw-capped glass tubes in -80 °C after focusing. 
 
Table 3.1: IEF protocol for whole cell proteome samples 
Steps Voltage (V) Voltage-hour (Vhr) Approx. time 
Step-and-hold 500 550 1h 15min 
Gradient 1000 1000 1h 
Gradient 8000 12000 3h 
Step-and-hold 8000 11000 1 h 20 min 
Total: 24550 6 h 35 min 
 
Table 3.2: IEF protocol for secretome samples 
Steps Voltage (V) Voltage-hour (Vhr) Approx. time 
Step-and-hold 500 600 1 h 30 min 
Gradient 1000 1000 1 h 
Gradient 8000 12000 3h 
Step-and-hold 8000 16000 2 h 
Total: 30000 7 h 30 min 
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3.11 Second dimensional electrophoresis: SDS-PAGE 
 
3.11.1 Chemicals and reagents 
 
i) SDS equilibration buffer solution (6 M Urea, 75 mM Tris-HCl pH 8.8, 
29.3% Glycerol, 2% SDS, 0.002% Bromophenol blue) 
Urea                      72.1 g 
Tris-HCl, pH 8.8                  10.0 ml 
87% glycerol (w/w) (MERCK, Germany)              69.0 ml 
SDS (GE Healthcare, Uppsala, Sweden)       4.0 g 
1% bromophenol blue stock solution              400.0 µl 
ddH2O           Top up to 200.0 ml 
 
ii) 10× Laemmli SDS electrophoresis buffer 
Tris base                    30.3 g 
Glycine (MERCK, Germany)                144.1 g 
SDS                     10.0 g  
ddH2O                            Top up to 1.0 L 
 
iii) 1× Laemmli SDS electrophoresis buffer 
10× Laemmli SDS electrophoresis buffer            100.0 ml 
ddH2O                 Top up to 1.0 L 
 
iv) 10% SDS solution 
SDS            5.0 g  
ddH2O             Top up to 50.0 ml 
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v) 30% T, 2.6% C monomer stock solution 
Acrylamide (GE Healthcare, Uppsala, Sweden)             150.0 g  
N,N’-methylenebisacrylamide (GE Healthcare, Uppsala, Sweden)    4.0 g 
ddH2O                      Top up to 500.0 ml 
 
The solution was filtered through 0.45 µM PES filter and stored at 4°C. 
 
vi) 4× Resolving gel buffer solution (1.5 M Tris-HCl, pH 8.8) 
Tris base                   181.7 g  
ddH2O           Top up to 500.0 ml 
 
The pH of the solution was adjusted to 8.8, and the solution was stored at 4°C. 
 
vii) 10% ammonium persulfate (APS) solution 
APS (MERCK, Germany)                    0.1 g  
ddH2O                                           1.0 ml 
 
APS solution was prepared fresh before use. 
 
v) Agarose sealing solution 
1× Laemmli SDS electrophoresis buffer            100.0 ml 
Agarose (Invitrogen, USA)         0.5 g 
1% bromophenol blue stock solution                                    200.0 µl 
 
vi) DTT 
 
vii) Iodoacetaminde (IAA) (MERCK, Germany) 
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3.11.2 Polyacrylamide gel casting 
The gel caster was set up and 12.5% polyacrylamide gel solution was prepared 
following the recipe in Table 3.3.  The solution was mixed well and pipetted into the gel 
casting chamber until the height of 1 cm below the top of the glass plates.  Isopropanol 
(MERCK, Germany) was overlaid on top of each gel to remove bubbles and the gels 
were left to polymerize for 1 hour prior to being stored at 4 °C overnight. 
 
 Table 3.3: Recipe for casting two 12.5% polyacrylamide gels 
Solutions Amount (ml) 
ddH2O 15.80 
4× Resolving buffer  12.50 
Monomer solution  20.85 
10% SDS 0.60 
10% APS 0.25 
Tetramethylethylenediamine (TEMED) (MERCK, Germany) 0.0167 
 
 
 
 
 
 
 
 
 67 
 
3.11.3 Drystrip equilibration  
Equilibration was performed on focused drystrips in two steps.  The drystrips 
were first reduced in equilibration buffer containing 1% DTT for 15 minutes.             
The equilibration buffer was discarded and the drystrips were further alkylated in 
equilibration buffer containing 2.5% IAA for another 15 minutes.  The equilibration 
buffer was decanted and the equilibrated strips were rinsed with 1× Laemlli 
electrophoresis running buffer to remove residual DTT and IAA. 
 
3.11.4 SDS-PAGE  
Equilibrated strips were gently laid on top of the polymerized gels with the 
plastic backing pushed against the back plate.  The strips were sealed into place with 
agarose sealing gel which was previously melted in the microwave and left to cool 
down to 60 °C.  The sealing gel was left to solidify for 2 minutes and second 
dimensional separation was performed using SE600 Ruby™ vertical electrophoresis 
unit (GE Healthcare, Uppsala, Sweden) in two steps as tabulated in Table 3.4. 
 
 Table 3.4: SDS-PAGE running protocol 
Voltage (V) Current (mA/gel) Time (min) 
50 40 30 
500 40 165 
Total run time: 195 
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3.11.5 Silver staining 
 
3.11.5.1 Silver staining solutions (For 2 gels) 
 
i) Fixing solution 
Absolute ethanol (Hmbg, Germany)             200.0 ml 
Acetic acid (MERCK, Germany)               50.0 ml 
Distilled water (dH2O )(Analytical gels)/ddH2O(Preparative gels)         250.0 ml 
 
ii) Sensitising solution 
Absolute ethanol               150.0 ml 
Sodium acetate (MERCK, Germany)                 34.0 g 
Sodium thiosulfate (MERCK, Germany)       1.0 g 
25% glutaraldehyde (Calbiochem®, USA)*                2.5 ml 
dH2O (Analytical gels)/ddH2O (Preparative gels)         Top up to 500.0 ml 
 
* Glutaraldehyde was omitted when staining preparative gels. 
 
iii) Silver nitrate solution 
Silver nitrate (MERCK, Germany)                 1.25 g 
37% formaldehyde*                   0.2 ml 
dH2O (Analytical gels)/ddH2O (Preparative gels)                   Top up to 500.0 ml 
 
* 37% Formaldehyde was omitted when staining preparative gels. 
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iv) Developing solution 
Sodium carbonate anhydrous (Amresco, USA)               12.5 g 
37% formaldehyde                   0.2 ml 
dH2O (Analytical gels)/ddH2O (Preparative gels)                                Top up to 500.0 ml 
 
v) Stopping solution 
EDTA disodium salt (Calbiochem®, USA)                  7.3 g 
dH2O (Analytical gels)/ddH2O (Preparative gels)                    Top up to 500.0 ml 
 
vi) Preserving solution 
Absolute ethanol               150.0 ml 
87% glycerol                  23.0 ml 
dH2O (Analytical gels)/ddH2O (Preparative gels)                                Top up to 500.0 ml 
 
3.11.5.2 Procedure 
The gels were fixed overnight in fixing solution with constant shaking at room 
temperature.  Fixing solution was poured off the next day and the gels were sensitised 
with sensitising solution for 30 minutes, followed by washing with distilled (for 
analytical gels) or de-ionised water (for preparative gels) thrice, 15 minutes each wash. 
The gels were subsequently stained with silver nitrate solution for 20 minutes and 
washed twice with distilled or de-ionised water for 2 minutes.  The spots were 
developed in developing solution for 2 to 4 minutes and the reaction was stopped with 
stopping solution for 10 minutes.  Developing and stopping solution were washed off 
with distilled or de-ionised thrice, 10 minutes each wash.  Gels were stored in 
preserving solution at 4 °C or scanned directly with ImageScanner™ III (GE 
Healthcare, Uppsala, Sweden). 
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3.11.6 Differential image analysis 
Scanned images were analysed using ImageMaster™ 2D Platinum v7.0 software 
(Amersham Biosciences, Sweden).  A total of ten gels (Five gels from five individual 
flasks for each group) were used for analysis of both whole cell proteins and secretome. 
The parameters used for spot detection were (i) minimal area: 5.0; (ii) smooth factor: 
3.0; and (iii) saliency: 200.0.  Quantitative comparison was performed based on 
normalised percentage spot volume, which is the ratio between each spot and the sum of 
all spot intensities in the gel, calculated by the software.  Manual matching was then 
performed to eliminate artefacts and rectify incorrectly matched spots. 
 
For statistical analysis, significance of the differential expression was 
determined by analysis of variance (ANOVA) and Student’s t-tests. All data were 
presented as mean ± SD.  Protein spots having p-value <0.05 and a fold-change of at 
least 1.3 were deemed statistically significant.  
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3.12 MS analysis 
 
3.12.1 Chemicals and reagents 
 
i) 100 mM ammonium bicarbonate 
Ammonium bicarbonate (MERCK, Germany)             1.582 g 
ddH2O                 200.0 ml 
 
ii) 50% acentonitrile (ACN) 
100% ACN (MERCK, Germany)               50.0 ml 
ddH2O                   50.0 ml 
 
iii) 10 mM DTT in 100 mM ammonium bicarbonate 
DTT                 0.0154 g 
100 mM ammonium bicarbonate               10.0 ml 
 
iv) 55 mM iodoacetamide in 100 mM ammonium bicarbonate 
IAA                          0.10175 g 
100 mM ammonium bicarbonate               10.0 ml 
 
v) 50 mM ammonium bicarbonate in 50% ACN 
100% ACN                  10.0 ml 
100 mM Ammonium bicarbonate               10.0 ml 
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vi) 50 mM sodium thiosulphate 
Sodium thiosulphate               0.0791 g 
ddH2O                   10.0 ml 
 
vii) Destaining solution (15 mM Potassium ferricyanate in 50 mM Sodium 
thiosulphate) 
Potassium ferricyanate (MERCK, Germany)            0.0494 g 
50 mM sodium thiosulphate                10.0 ml 
 
viii) 1000 ng/µl trypsin in 50 mM acetic acid (Stock) 
Trypsin powder (Promega, USA)               1 bottle 
Glacial acetic acid                     2.8 µl 
ddH2O                  100.0 µl 
 
ix) 10 ng/µl trypsin in 50 mM ammonium bicarbonate 
1000 ng/µl trypsin stock                    1.0 µl 
100 mM ammonium bicarbonate                 99.0µl 
 
x) 0.1% formic acid 
Formic acid (MERCK, Germany)       1.0 µl 
ddH2O                     1.0 ml 
 
xi) 0.1% formic acid in 50% ACN 
Formic acid                     1.0 µl 
100% ACN                 500.0 µl 
ddH2O                 499.0 ml 
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xii) Buffer A (2% ACN, 0.1% Trifluoroacetic Acid (TFA)) 
TFA                   100.0 µl 
100% ACN                    2.0 ml 
ddH2O                   97.9 ml 
 
xiii) Buffer B (98% ACN, 0.1% TFA) 
TFA                   100.0 µl 
100% ACN                  98.0 ml 
ddH2O                     1.9 ml 
 
xiv) α-Cyano-4-Hydroxycinnamic Acid (CHCA) matrix 
CHCA matrix (Sigma-Aldrich®, USA)                10.0 mg 
Buffer A                 400.0 µl 
Buffer B                 600.0 µl 
 
3.12.2 In-gel trypsin digestion/peptide extraction 
Significantly expressed spots were picked from five gels and pooled together in 
a microcentrifuge tube and stored at -20 °C in de-ionised water. Samples ready to be 
digested were thawed and the water was removed. Gel pieces were washed with 150 µl 
of 100 mM ammonium bicarbonate for 15 minutes with constant shaking.  The gel 
plugs were destained with 150 µl of destaining solution twice, 10 minutes each wash, 
and reduced at 60 °C for 30 minutes with 150 µl of 10 mM DTT in 100 mM ammonium 
bicarbonate. The gel plugs were cooled to room temperature for 5 minutes, spun down 
for 1 minute at 1,000 × g and subsequently alkylated with 150 µl of 55 mM IAA in      
100 mM ammonium bicarbonate in the dark for 20 minutes. Washing was performed 
thrice with 500 µl of 50 mM ammonium bicarbonate in 50% ACN, 20 minutes each 
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wash with shaking, followed by dehydration of the gel pieces with 50 µl of 100% ACN 
for 15 minutes with shaking. The gel plugs were dried in a HetoVac VR-1 vacuum 
concentrator (Birkercd, Denmark) at medium speed for 20 minutes and proteins were 
digested for 16 hours with 25 µl of 10 ng/µl MS grade trypsin in 50 mM ammonium 
bicarbonate at 37 °C. 
 
Digested peptides spun at 1,000 ×g for 1 minute to spin down the contents, 
followed by first extraction with 50 µl of 50% ACN for 15 minutes with constant 
shaking. The extracted peptides were transferred to a new microcentrifuge tube and a 
second extraction was performed with 50 µl of 100% ACN for another 15 minutes with 
shaking. Both extractions were pooled into the same tube and dehydrated with HetoVac 
VR-1 vacuum concentrator for 1 to 2 hours. Dried peptides were stored at -20°C. 
 
3.12.3 Desalting with ZipTip® 
Dried peptides were dissolved in 10 µl of 0.1% formic acid. Ten µl of wetting 
solution (50% ACN) was aspirated into a ZipTip®C18 micropipette tip (Millipore, 
USA) to wet the C18 column and discarded onto tissue. This was repeated twice, 
followed by equilibration of the ZipTip® C18 column with 10 µl of equilibration 
solution (0.1% formic acid) thrice. The sample was aspirated and pipetted up and down 
repeatedly 10 times and discarded onto the tissue. Ten µl of washing solution (0.1% 
formic acid) was aspirated and discarded thrice and 2 µl of elution solution (50% ACN 
in 0.1% formic acid) was pipetted up and down repeatedly 5 times to elute the peptides. 
Equivalent amount of CHCA matrix solution was added to the eluted peptides and 0.7 
µl of the solution was spotted onto the MALDI stainless-steel plate in duplicates. 
Another 0.7 µl of peptides was subsequently spotted after the spots have dried. 
 75 
 
3.12.4 MALDI-TOF/TOF analysis 
The peptide mass spectra and MS/MS spectra for each protein spot were 
obtained on a MALDI-TOF/TOF mass spectrometer (ABI 4800 Plus, Applied 
Biosystems™, USA) in the positive ion reflector mode.  The MS and MS/MS data were 
searched using internal MASCOT (Matrix Science, UK) against Swiss-Prot database 
information, whereby seven parameters were set for searching; i) trypsin enzyme; ii) 
one missed cleavage; iii) variable modifications of carbamidomethyl and oxidation of 
methionine; iv) peptide charge of 1+; v) monoisotropic mass values; vi) peptide mass 
tolerance of ± 50 ppm and; vii) fragment mss tolerance of ± 0.1 Da.   
 
3.12.5 Bioinformatics 
Identified proteins were searched against UniProt (Swiss-Prot/TrEMBL) 
Knowledgebase to determine their main biological functions in the cell.  Protein-protein 
interactions were predicted using Search Tool for the Retrieval of Interacting 
Genes/Proteins (STRING) database v9.0 (www.string-db.org/). 
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3.13 Western blot 
 
3.13.1 Chemicals and reagents 
 
i) RIPA buffer (25mMTris pH 7.6, 150 mM Sodium chloride (NaCl), 1.0% 
Triton-X, 1.0% Sodium deoxycholate, 0.1% SDS) 
Tris base                    0.03 g         
NaCl                   0.088 g 
Triton-X                    0.1 ml 
Sodium deoxycholate          0.1 g 
SDS                     0.01 g 
ddH2O             Top up to 10.0 ml 
 
The pH of the solution was adjusted to 7.6, and the solution was stored at -20 °C. 
 
ii) Bicinchoninic Acid (BCA) Protein assay kit (Pierce, USA) 
BCA reagent A               500.0 ml 
BCA reagent B                 25.0 ml 
BSA (2.0 mg/ml)           10 x 1.0 ml 
 
iii) Stacking gel buffer (0.5 M Tris-HCl, pH 6.8) 
Tris base                   18.17 g  
ddH2O             Top up to 50.0 ml 
 
The pH of the solution was adjusted to 8.8, and the solution was stored at 4°C. 
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iv) 5× Sample buffer (10.0% SDS, 10 mM DTT, 20% Glycerol,                         
0.2 M Tris-HCl pH 6.8, 0.05% Bromophenol blue) 
SDS            5.0 g 
DTT                   0.078 g 
87% glycerol                11.49 ml 
0.5 M Tris-HCl, pH 6.8                           20.0 ml 
0.05% bromophenol blue                0.025 g 
ddH2O             Top up to 50.0 ml 
 
v) 1× Tris-buffered saline with 0.05% Tween-20 (TBST) 
Tris base           2.4 g 
NaCl            8.8 g 
Tween-20                    0.5 ml 
ddH2O                 Top up to 1.0 L 
 
The pH of the solution was adjusted to 7.6, and the solution was stored at 4°C. 
 
vi) 1× Laemmli SDS electrophoresis buffer  
Refer to Section 3.11.1 for the recipe. 
 
vii) 10×Towbin buffer (without methanol) 
Tris base                    30.3 g  
Glycine                  144.4 g 
ddH2O                 Top up to 1.0 L 
 
The 10× Towbin buffer was diluted to 1× buffer before use. 
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viii) Blocking buffer (5% Non-fat dry milk) 
Blotting grade blocker non-fat dry milk (Bio-Rad, USA)     1.0 g 
TBST buffer                  20.0 ml 
 
ix) Mouse mAbs specific to β-actin (ACTB), glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH), cyclin dependent kinase 1 (CDK1),pyruvate 
dehydrogenase E1 (PDHA1) and GTP-binding nuclear protein ran (RAN) 
All primary antibodies were diluted in TBST buffer at a ratio of 1:500. 
 
x) Goat anti-mouse IgG secondary antibody conjugated to horseradish 
peroxidase (HRP) 
The secondary antibody was diluted in TBST buffer at a ratio of 1:2,500. 
 
xi) 2-D Clean-Up kit  
 
xii) PageRulerPrestained protein ladder  (Fermentas, Lithuania)  
 
xiii) TMB Stabilised Substrate for HRP (Promega, USA) 
 
xiv) Methanol, absolute (MERCK, Germany) 
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3.13.2 Protein extraction and quantification 
The whole cell protein samples for mock control and CHIKV-infected WRL-68 
cells were extracted following the protocol described in section 3.9.1.2, but lysis buffer 
was replaced with 600 µl of RIPA buffer per flask.  Extracted protein samples were 
quantified using BCA protein assay kit, following manufacturer’s protocol.  Briefly, a 
series of BSA standards of eight different concentrations (2.0 mg/ml, 1.5 mg/ml,         
1.0 mg/ml, 0.75 mg/ml, 0.50 mg/ml 0.25 mg/ml and 0.125 mg/ml) were prepared.  BCA 
working reagent was prepared by mixing 50 parts of BCA reagent A with 1 part of BCA 
reagent B.  Two-hundred µl of BCA working reagent was pipetted into each well of the 
96-well dish.  Ten µl of each BSA concentration and sample was added to each well in 
triplicate.  The mixture was equilibrated for 30 minutes at 37 °C and the absorbance was 
read at 570 nm. The protein concentration for each sample was calculated from the BSA 
standard curve generated using Microsoft Excel. 
 
The secretome of mock control and CHIKV-infected cells were processed 
according to the protocols described in sections 3.9.1.2 (Protein sample processing), 
3.9.2.2 (Protein clean-up) and 3.9.2.3 (Protein estimation).  
 
3.13.3 1-D Western blot 
 
3.13.3.1 Gel casting 
Proteins were resolved on 12% polyacrylamide gels that were cast fresh before 
use.  Briefly, the resolving gel solution (see Table 3.5 for recipe) was prepared and 
pipette into the gel casting chamber until the height of 1 cm below the top of the glass 
plates.  Isopropanol was overlaid on top of each gel to remove bubbles and the gels 
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were left to polymerize at room temperature.  The isopropanol layer was subsequently 
removed and the polymerized gel was rinsed with ddH2O.  Thereafter, the stacking gel 
solution (see Table 3.6 for recipe) was prepared and pipetted on top of the resolving gel.  
An 8-well comb was inserted into the gel sandwich to form the wells.  The stacking gel 
layer was left to solidify at room temperature. 
 
3.13.3.2 SDS-PAGE 
Twenty µg of whole cell proteins for each sample was mixed with 5× sample 
buffer at a ratio of 4 volume of protein sample to 1 volume of 5× sample buffer. The 
protein mixture was denatured at 95 °C for 5 minutes, and loaded into each lane.  Seven 
µl of PageRuler Prestained protein ladder was loaded into the last lane on both ends of 
the gel. Proteins were resolved using the dual vertical mini-gel electrophoresis system 
(C.B.S. Scientific, USA), at a constant voltage of 100 V.  Three biological replicates for 
each group (mock control and CHIKV-infected) were resolved on the same gel.   
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  Table 3.5: Recipe for casting the resolving gel solution (12% polyacrylamide gel) 
Solutions Amount (ml) 
ddH2O 3.1 
Stacking gel buffer  1.25 
Monomer solution  0.67 
10% SDS 0.05 
10% APS 0.025 
TEMED 0.005 
 
Table 3.6: Recipe for casting the stacking gel solution (4% polyacrylamide gel) 
Solutions Amount (ml) 
ddH2O 10.2  
4× Resolving buffer  7.5 
Monomer solution  12.0 
10% SDS 0.30 
10% APS 0.15 
TEMED 0.02 
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3.13.3.3 Protein transfer 
 Prior to protein transfer, the polyvinylidene fluoride (PVDF) membrane was 
soaked in absolute methanol for 2 minutes to activate the membrane, followed by 
simultaneous equilibration with electrophoresed gel in Towbin buffer for at least 5 
minutes.  The membrane and gel were positioned side by side, sandwiched in between 
two pre-wet filter papers and sponges, and clamped tightly to ensure no air bubbles have 
formed between the gel and membrane.  The sandwich was submerged in Towbin buffer 
and protein transfer was performed using the EBU-200 mini-electrophoresis blotting 
system (C.B.S. Scientific, USA) at a constant current of 100 mA, with a maximum 
voltage of 80 V for 1 hour 30 minutes at 4 °C.  After transfer, the membrane was 
blocked overnight in blocking buffer containing 5% non-fat dry milk at 4°C.  
 
3.13.3.4 Antibody staining 
 After overnight blocking, the membrane was washed thrice with TBST buffer, 
10 minutes per wash.  The membrane was probed with two antibodies, the endogenous 
control (either ACTB or GAPDH), and the target protein (CDK1 or PDHA1), without 
stripping, by making a straight cut from one end of the protein marker to another, thus 
separating the target protein from the endogenous control.  The cut membranes were 
incubated separately with the respective mouse mAb for 1 hour 30 minutes at room 
temperature.  The membranes were rinsed thrice with TBST buffer, 5 minutes each 
rinse, and subsequently incubated with HRP-conjugated goat anti-mouse IgG secondary 
antibody for 1 hour at room temperature.  Thereafter, the membranes were rinsed again 
with TBST buffer and stained with TMB stabilised substrate for HRP for until the 
intended bands develop.  The membrane was rinsed with water and stored dry at room 
temperature, protected from light. 
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3.13.3.5 Image analysis 
The blot was scanned using ImageScanner™ III in reflective mode, and 
densitometric quantification was performed using ImageJ v1.45 
(http://rsb.info.nih.gov/ij). The mean relative density for each target band was 
normalised against ACTB or GAPDH and the significance of the expression changes 
was determined by using Student’s t-test.  
 
3.13.4 2-D Western blot 
 
3.13.4.1 2-DGE 
2-DGE was performed to resolve secretome sample prior to protein transfer.  
Sixty µg of secretome sample was rehydrate in Immobiline™ drystrip pH 3-10 linear, 7 
cm gels (GE Healthcare, Uppsala, Sweden), as previously described in section 3.10.2.  
IEF was performed following the protocol in Table 3.7. 
 
Table 3.7: IEF protocol for secretome samples 
Steps Voltage (V) Voltage-hour (Vhr) Approx. time 
Step-and -hold 200 200 1 h 15 min 
Gradient 500 500 1 h 
Gradient 1000 1000 2 h 
Step-and -hold 4000 17000 4 h 
Total: 18700 8 h 15 min 
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 Following IEF, the focused strip was equilibrated according to the protocol 
described in section 3.11.3, and resolved on 12.5% polyacrylamide gel (which was cast 
following the recipe in Table 3.3) at a constant voltage of 100 V.  
 
3.13.4.2 Protein transfer, staining and image analysis 
The blotting sandwich was assembled according to section 3.13.3.2.  Protein 
transfer was carried out at a constant current of 80 mA, with a constant voltage of 80 V, 
for 1 hour at 4 °C.  After transfer, the membrane was blocked overnight in blocking 
buffer containing 5% non-fat dry milk at 4°C.  Protein staining was carried out 
according to the detailed protocol in section 3.13.3.3, without cutting the membrane as 
the membrane was stained with the target protein only.  The membrane was scanned 
using the ImageScanner™ III in reflective mode. 
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3.14 Real-time qPCR 
 
3.14.1 Chemicals, reagents and kits 
 
i) RNeasy Mini kit (Qiagen, USA) 
Components: 
Buffer RLT                  45.0 ml 
Buffer RW1                  45.0 ml 
Buffer RPE                  55.0 ml 
RNase-free water                 10.0 ml 
RNeasy mini spin columns             50 pieces 
Collection tube (1.5 ml)             50 pieces 
 
ii) RNase-free DNase set (Qiagen, USA) 
Components: 
DNase I, RNase-free            1,500 Kunitz unit 
Buffer RDD                    2.0 ml 
RNase-free water                   1.5 ml 
 
DNase I incubation mix was prepared before use by adding 10 µl of DNase I to 70 µl of 
buffer RDD. 
 
iii) Preparation of 1% agarose gel 
Agarose powder (Invitrogen, USA)                   0.5 g 
1× Tris/Borate/EDTA (TBE) buffer (Promega, USA)            50.0 ml 
Ethidium bromide (EtBr)        1.0 µl 
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The mixture was heated to dissolve the agarose powder.  The agarose gel solution was 
cooled down to 60 °C prior to addition of 1 µl EtBr.  The gel was cast and allowed to 
polymerize for 1 hour. 
 
iv) High Capacity RNA-to-cDNA kit (Applied Biosystems™, USA)    
2× RT buffer                    1.0 ml 
20× Enzyme mix                100.0 µl 
 
v) Fast SYBR® Green Master Mix (Applied Biosystems™, USA)2 × 5 ml 
 
vi) QIAshredder mini spin column (Qiagen, USA) 
 
vii) 6× RNA loading dye (Fermentas, Lithuania) 
 
3.14.2 RNA extraction 
Total RNA from mock control and CHIKV-infected C6/36 cells was extracted 
using Qiagen RNeasy Mini kit according to the manufacturer’s protocol.  All 
centrifugation steps were performed at full speed.  C6/36 cell pellet was lysed in 350 µl 
of buffer RLT and centrifuged in a QIAshredder mini spin column for 2 minutes.  An 
equal volume of 70% ethanol (HMBG, Germany) was mixed with the flow-through and 
transferred to an RNeasy spin column placed in a 2 ml collection tube and further 
centrifuged for 15 seconds.  The flow-through was discarded and 350 µl of buffer RW1 
was added to the spin column which was then centrifuged for another 15 seconds.  The 
flow-through was discarded and 80 µl of DNase I incubation mix was added to the spin 
column, followed by 15 minutes incubation at room temperature.  The column was 
subsequently spun for 15 seconds and the flow-through was discarded.  Another 350 µl 
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of buffer RPE was added to the spin column followed by 15 seconds centrifugation.  
The flow-through was discarded and 500 µl of buffer RPE was added and the spin 
column was centrifuged for 2 minutes.  The flow-through was discarded and the spin 
column was centrifuged again for 1 minute with the column cap opened to remove 
residual ethanol and buffer. The spin column was transferred to a new 1.5 ml centrifuge 
tube. Fifty µl of RNase-free water was pipetted directly onto the RNeasy membrane and 
the spin column was centrifuged for 1 minute to elute the RNA.  
 
3.14.3 RNA quantitation 
RNA quantitation and quality determination was performed using GeneQuant™ 
1300 spectrophotometer (GE Healthcare, Uppsala, Sweden).  Purified RNA was diluted 
40 times in RNase-free water to a final volume of 80 µl and pipetted into a quartz 
cuvette.  The absorbance was read using the spectrophotometer which was previously 
blanked with 80 µl of RNase-free water.  Pure RNA would give an A260/280 
absorbance reading between 1.8 and 2.0 and an A230/260 reading above 2.0.  
 
3.14.4 Determination of RNA integrity 
RNA integrity was determined via agarose gel electrophoresis.  One µg of RNA 
sample was diluted with nuclease-free water to a final volume of 5 µl.  Diluted RNA 
was mixed well with 1 µl of 6× RNA loading dye and pipetted into the wells of the 1% 
agarose gel.  Electrophoresis was performed at 100V and 100 mA for 45 minutes.  Gel 
image was visualised by Bio-Rad Quantity One software. 
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3.14.5 Conversion of RNA to cDNA 
Conversion of total RNA to cDNA was performed using High Capacity RNA-
to-cDNA kit (Applied Biosystems™, USA) following the manufacturer’s protocol.        
One µg of RNA sample was converted per 20 µl reaction following the recipe in Table 
3.8.  RT reaction mix was aliquot to 0.2 ml PCR tubes. The tubes were briefly 
centrifuged to spin down the contents and eliminate air bubbles.  Reverse transcription 
was performed using a PCR thermal cycler (PTC-100® Programmable Thermal 
Controller) in 3 steps.  RNA to cDNA conversion was first performed at 37 °C for 60 
minutes, followed by 5 minutes run at 95 °C to stop the reaction and the product was 
cooled to 4 °C.  Converted cDNA was stored at -80 °C until qPCR was performed. 
 
Table 3.8: Volume of components required per reaction 
Components Amount (µl) 
2X RT buffer 10.0 
20X Enzyme mix 1.0 
RNA sample  Up to 9.0 
Nuclease-free water Top up to 20.0 
Total per Reaction: 20.0 
 
 
 
 
 
 
 
 
 
 
 89 
 
3.14.6 Primer amplification efficiency test 
All primers were designed using Primer3 Input (Version 0.4.0) online software 
at http://frodo.wi.mit.edu/primer3/ and purchased from 1st Base Laboratories, Malaysia.  
Primer specificity was also confirmed using Basic Local Alignment Search Tool 
(BLAST) prior to purchase.  Each primer pair was then subjected to an efficiency test to 
determine their amplification efficiency and specificity to the gene product.  Five-fold 
dilutions of the cDNA product were performed to give a range of amounts from 25 ng 
to 0.04ng.  Both the forward and reverse primers were diluted 100 times.  Two µl of 
each cDNA product dilution was mixed with 4 µl each of the forward and reverse 
primers and 10 µl of Fast SYBR® Green Master Mix to a final volume of 20 µl in a 
MicroAmp® optical 8-cap strips (Applied Biosystems™, USA). The strips were spun 
briefly to spin down the content and real-time PCR was performed using the 
StepOnePlus™ Real-Time PCR System (Applied Biosystems™, USA), following 
manufacturer’s protocol as shown in Table 3.9.  All dilutions were assayed in 
triplicates.  The amplification plot was generated and the slope of the curve was 
determined to calculate the efficiency of the primer whereas primer specificity was 
evaluated by determining the number of peaks in the dissociation curve. 
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Table 3.9: Real-time qPCR protocol 
Steps Number of 
cycles 
Temperature 
(°C) 
Duration  
i)   cDNA synthesis 1 60 30 min 
ii)  Pre-denaturation 1 94 2 min 
iii) cDNAamplification 40   
  - Denaturation  94 15 sec 
  - Annealing   55-65 30 sec 
 - Elongation  72 1 min 
iv) Final extension 1 72 10 min 
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3.14.7 Quantitation of mRNA expression 
For each reaction, 2 µl containing 1ng of template cDNAwas mixed with 4 µl 
each of the 100X diluted forward and reverse primers, and 10 µl of Fast SYBR® Green 
Master Mix.Non-template control (NTC) was prepared by substituting 2 µl of template 
cDNA with de-ionised water.  Real-time PCR quantitation was performed using 
StepOnePlus™ Real-Time PCR System and all reactions were analysed in triplicates 
using StepOnePlus™ software v2.1 (Applied Biosystems™, USA). The expression 
level for each gene was normalised against the expression of the internal control,         
ACTB, and fold-change of CHIKV-infected sample relative to the mock control was 
calculated based on the delta-delta Ct (ddCt) algorithm, 2(-ΔΔCt).  Significance of 
expression was determined statistically using Student’s t-test where significance was 
defined as p< 0.05.  
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CHAPTER 4 
RESULTS 
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4.1 Determination of virus titer by plaque assay 
Following propagation, the titer of each virus stock was determined via plaque 
assay method using Vero cells. CHIKV was found to be highly infectious in Vero cells, 
with visible plaques forming shortly after 24 hours post-infection.  The earliest 
incubation time-point to obtain clear and distinct plaques was determined to be 30 hours 
post-infection (Figure 4.1).  To minimise error, each dilution was performed in 
duplicate and the dilution producing a range of 20 to 100 plaques was chosen to 
determine the virus titer.  Based on plaque titration, CHIKV stock titer was found to be 
between 2.0x 108 and 5.0 x 108 pfu/ml. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1 Plaque titration of CHIKV in Vero cells at different dilutions 
CHIKV stock was subjected to 10-fold serial dilution to a total of 8 dilutions (Panels B: 
10-1 dilution, C: 10-2 dilution, D: 10-3 dilution, E: 10-4 dilution, F: 10-5 dilution, G: 10-6 
dilution, H: 10-7 dilution, I: 10-8 dilution), each plated in duplicate.  Mock control Vero 
cells (Panel A) served as negative control.  The 10-6 dilution (boxed in red) was selected 
to calculate the titer of the virus using the formula mentioned in section 3.4.4.  The virus 
titer for this batch was determined to be 2.5 x 108 pfu/ml. 
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4.2 Optimisation of infection condition for early host response study 
Optimisation of the MOI and time-point for early infection study was performed 
by using four approaches; 
i) Morphological analysis 
ii) IIFA  
iii) Flow cytometric quantification of infected cells  
iv) AV/PI staining to quantify cell death 
 
4.2.1 Morphological changes of WRL-68 cells upon CHIKV infection 
WRL-68 cells were infected at four different MOIs, ranging from low (MOI of 
0.5 and1.0) to high (MOI of 5.0 and 10.0) MOI, and incubated for 24 and 48 hours. The 
effect of CHIKV infection on the morphology of the cells was observed under inverted 
microscope at 100× magnification.  At 24 hours post infection, morphology of WRL-68 
cells infected at the MOI of 0.5, 1.0 and 5.0 was indistinguishable from mock control 
cells while slight CPE was apparent at the MOI of 10.0.  However, marked CPE was 
observed at 48 hours post-infection, as characterised by cell shrinkage, rounding and 
detachment.  CPE was also found to be more profound with increasing MOI, indicating 
that cytopathogenicity was time- and MOI-dependent (Figure 4.2). 
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Figure 4.2: Morphological changes of WRL-68 cells infected with CHIKV 
WRL-68 cells were infected with CHIKV at four different MOI (Panels II: MOI = 
0.5, III: MOI = 1.0, IV: MOI = 5.0, V: MOI = 10.0) and incubated for 24 (Panel A) 
and 48 hours (Panel B).  Mock control cells (Panel I) served as negative control.  At 
24 hours post-infection, cells infected with CHIKV at the MOI of 0.5, 1.0 and 5.0 
exhibited no apparent morphological changes while slight CPE could be seen at the 
MOI of 10.0.  However, CPE was observed in CHIKV-infected cells at all four MOIs 
at 48 hours post-infection, and was more profound at the MOI of 5.0 and 10.0.  All 
images were captured at 100× magnification. 
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4.2.2 Confirmation of CHIKV infection in WRL-68 cells via IIFA 
Infection of CHIKV in WRL-68 cells was confirmed by indirect 
immunostaining of cells with anti-CHIK mAb 3E4 specific to the viral E2 structural 
protein, as shown in Figure 4.3.  CHIKV was found to be highly infectious in WRL-68 
cells, as viral antigens were detected in the cells at the lowest MOI (MOI of 0.5) at 24 
hours post-infection.  Fluorescence intensity, however, was found to be higher at the 
MOI of 5.0 and 10.0 as compared to lower MOI (MOI of 0.5 and 1.0).  At 48 hours 
post-infection, intense cytoplasmic staining was observed in all infected cells regardless 
of the MOI used.  Conversely, no fluorescence signals were detected in mock control 
cells at either time-point, indicating no infection. 
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Figure 4.3: Confirmation of CHIKV infection through anti-CHIK mAb 3E4 
immunostaining 
Fluorescence detection of CHIKV antigen was performed on WRL-68 cells infected 
at four different MOI (Panels II: MOI = 0.5, III: MOI = 1.0, IV: MOI = 5.0, V: MOI 
= 10.0) and incubated for 24 (Panel A) and 48 hours (Panel B).  Mock control cells 
(Panel I) served as negative control.  Fluorescence intensity of WRL-68 cells infected 
at low MOI (MOI of 0.5 and 1.0) were lower than that of cells infected at high MOI 
(MOI of 5.0 and 10.0) at 24 hours post-infection.  At 48 hours post-infection 
however, fluorescence intensity of infected cells appeared similar, irrespective of the 
MOI used.  Cells were visualised under Nikon Eclipse Ti-5 fluorescence inverted 
microscope and images were captured at 100× magnification. 
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4.2.3 Quantitative analysis of infection via flow cytometry 
 IIFA per se does not provide sufficient proof for accurate selection of the 
optimal MOI and infection time-point due to the lack of quantitative data.  Therefore, 
the number of infected cells (presented as percentage of infection) was further 
quantified by flow cytometry.  Infected cells were distinguished from uninfected cells 
based on the relative fluorescence intensity, measured in terms of signal area (FITC-A).  
The quadrants were defined in such a way that the uninfected population, having 
minimal or no fluorescence emission (low FITC-A value), appears in the third quadrant 
(Q3), whereas infected population emits a high fluorescence signal (high FITC-A value) 
and thus appears in Q4.  The dot plots from one of the triplicates are depicted in Figure 
4.4.  
 
 Figure 4.5 shows the mean percentage of infected cells from three independent 
experiments.  The percentage of infected cells was found to be greater with increasing 
MOI and incubation period.  At 24 hours post-infection, both the MOI of 5.0 and 10.0 
showed similarly high percentage of infection at 74.77% ± 9.83 and 75.53% ± 7.43, 
respectively, while a lower percentage of infection was recorded for the MOI of 0.5 
(35.53% ± 3.38) and 1.0 (56.57% ± 6.81).  There was a significant increase in the 
percentage of infected cells at 48 hours post-infection, with more than 70% infection 
recorded for cells infected at the MOI of 0.5 (74.75% ± 9.30) and 1.0 (80.50% ± 12.63), 
and more than 90% of cells infected at the MOI of 5.0 (92.43% ± 4.01) and 10.0 
(93.10% ± 0.10).  Conversely, mock control cells showed no infection at both time-
points. 
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Figure 4.4: Representative flow cytometric dot plots of mock control and 
CHIKV-infected WRL-68 cells at different MOI at 24 and 48 hours post-
infection 
The percentage of infected cells was determined by calculating the number of infected 
cells (Q4)/total number of cells (Q3+Q4) × 100%.  The percentage of infected cells 
was determined for CHIKV-infected cells at four different MOI (Panels II: MOI = 
0.5, III: MOI = 1.0, IV: MOI = 5.0 and V: MOI = 10.0) at 24 (Panel A) and 48 hours 
(Panel B) post-infection.  Mock control cells served as negative control (Panel I).  The 
uninfected population is gated in Q3 whereas infected population is gated in Q4.  A 
shift in the population from Q3 to Q4 could be observed when the MOI was increased 
and when the incubation time was longer, indicating an increase in the number of 
infected cells. 
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Figure 4.5: Mean percentage of infection of WRL-68 cells infected at different 
MOI at 24 and 48 hours post-infection 
The percentage of infection was determined to increase in a MOI and time-dependent 
manner.  At 24 hours, infection was highest at the MOI of 5.0 (74.77% ± 9.83) and 10.0 
(75.53% ± 7.43).  At 48 hours post-infection, infection at all four MOI resulted in more 
than 70% infection.  Percentage of infection in mock control cells remained zero at both 
time-points, indicating no infection.  Data presented are representative of three 
independent experiments and the error bars represent standard deviation. 
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4.2.4 Quantitative analysis of cell death via AV/PI co-labelling 
 Measurement of cell death was performed by flow cytometric quantification of 
CHIKV-infected cells co-labelled with AV and PI, which stains apoptotic and necrotic 
cells, respectively.  Viable cells would not take up any dye (AV-/PI-) and will appear in 
Q3 of the dot plot, as illustrated in Figure 4.6.  Cells undergoing early apoptosis will be 
stained with AV only (AV+/PI-), thus appearing as a population in Q4. Meanwhile, late 
apoptotic cells gated in Q2 are positively stained with both AV and PI (AV+/PI+), 
whereas Q1 population represents dead or necrotic cells stained with PI only (AV-/PI+). 
 
To avoid the effects of apoptosis and necrosis in cellular proteome alteration, 
cell death was defined as cells undergoing both early and late apoptosis, as well as 
necrosis.  Hence, cell populations in Q1, Q2 and Q4were considered as dead cells in 
determining cell death percentage.  Based on the graph shown in Figure 4.7, cell death 
was observed even for mock control (14.33% ± 3.72 and 17.63% ± 8.15 at 24 and 48 
hours respectively).  At 24 hours post-infection, cells infected at all four MOI showed 
slightly higher cell death percentage than mock control cells.  Cell viability was 
considerably lower after 48 hours post-infection, with over 50% cell death regardless of 
the MOI used.  Conversely, percentage of cell death for mock control cells at 48 hours 
incubation remained similar to that of 24 hours. 
 
Based on the results, the MOI of 5.0 and 24 hours incubation was selected as the 
optimal condition for early infection study.  A high percentage of infection (74.77%) 
was achieved under this condition, while the percentage of cell death (25.90%), albeit 
higher than mock control cells (14.33%), was similar to infection at other MOI at 24 
hours incubation.  Furthermore, infection under this condition did not induce any CPE.  
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Figure 4.6: Representative AV/PI flow cytometric dot plots of mock and CHIKV-
infected WRL-68 cells at different MOI at 24 and 48 hours post-infection 
The percentage of infected cells was determined by calculating the number dead cells 
(Q1+Q2+Q4)/Total number of cells (Q1+Q2+Q3+Q4) × 100%.  The percentage of cell 
death was determined for WRL-68 cells infected at four different MOI (Panels II:       
MOI = 0.5, III: MOI = 1.0, IV: MOI = 5.0 and V: MOI = 10.0) at 24 (Panel A) and 48 
hours (Panel B) post-infection.  Mock control cells served as negative control (Panel I).  
Live cells are gated in Q3 (Red dots), while cells undergoing early and late apoptosis 
are gated in Q4 (Blue dots) and Q2 (Green dots), respectively.  Necrotic cells are 
represented by the red dots in Q1.  The percentage of cell death was observed to 
increase in a MOI and time-dependent manner. 
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Figure 4.7: Mean percentage of cell death (%) of WRL-68 cells infected at 
different MOI at 24 and 48 hours post-infection 
The percentage of cell death was found to increase in a MOI and time-dependent 
manner.  At 24 hours post-infection, cell death was below 30% for all the MOI used, 
and 14.33% for mock control cells.  A significant increase in percentage of cell death by 
at least 2.5-fold was observed in cells infected at all four MOI, at 48 hours post-
infection.  Cell death for mock control cells, however, remained similar to that of         
24 hours.  Data presented are representative of three independent experiments and the 
error bars represent standard deviation. 
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4.3 Optimisation of sample harvesting for analysis of the secretome  
 For the purpose of analysing the secretome, the effects of serum deprivation and 
CHIKV infection (at the optimised condition) on cell integrity and viability were 
evaluated using two assays:  
i) MTS cell proliferation assay 
ii) Dead-cell protease assay 
 
4.3.1 Effect of serum deprivation on cell viability  
MTS was used to investigate the viability of serum-starved WRL-68 cells at the 
chosen time-point, which was 24 hours.  Figure 4.8 shows the relative viability between 
cells grown in normal DMEM medium (10% FBS) and serum-free medium.  No 
significant difference in cell viability was observed between the two conditions. 
 
4.3.2 Effect of serum deprivation and CHIKV infection on cell membrane 
integrity 
 Figure 4.9 depicts the relative percentage of cell lysis between uninfected     
WRL-68 cells incubated in DMEM growth medium, serum-free medium and CHIKV-
infected cells (MOI of 5.0) incubated in serum-free medium for 24 hours.  Cells lysed 
with digitonin were used as the positive control, normalised to 100%.  A low percentage 
of cellular disruption (7.64% ± 0.29) was observed in cells cultured in growth medium.  
Only a slight increase in the percentage of lysed cells was detected in serum-free 
cultured cells (9.11% ± 0.46) and CHIKV-infected cells (9.08% ± 0.42), as compared to 
cells incubated in growth medium.  
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Figure 4.8: Relative cell viability of WRL-68 cells grown in DMEM growth 
medium (10% FBS) and serum-free medium for 24 hours  
Cell viability of WRL-68 cells grown in DMEM growth medium was normalised to 
100%, and the relative viability of serum-starved cells was determined.  At 24 hours 
incubation, the absence of serum did not significantly reduce cell viability as percentage 
viability was above 98%.  Data presented are representative of three independent 
experiments and the error bars represent standard deviation. 
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Figure 4.9: Relative percentage of cell lysis between WRL-68 cells incubated in 
DMEM growth medium, serum-free medium and CHIKV-infected cells incubated 
in serum-free medium for 24 hours 
Percentage of cell lysis for digitonin-lysed cells (positive control) was normalised to 
100%.  The absence of serum in the culture medium was found to have no significant 
effect on cellular disruption.  Similarly, WRL-68 cells infected with CHIKV at the MOI 
of 5.0 showed similar percentage as the mock control cells.  Data presented are 
representative of three independent experiments and the error bars represent standard 
deviation. 
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4.4 Comparative proteomic study 
 WRL-68 cells were infected with CHIKV at the MOI of 5.0 at 24 hours post-
infection.  After infection, the cells were lysed to obtain whole cell proteome or cell 
lysate while the medium was harvested for the secretome.  2-DGE was employed to 
resolve and compare the whole cell proteome and secretome of mock control and 
CHIKV-infected cells to identify the proteins and potential pathways involved during 
early CHIKV infection.  Differentially modulated protein spots were further identified 
with MALDI-TOF/TOF MS analysis and the expression of three proteins was validated 
using Western blot.  The obtained results are presented in the sections that follow. 
 
4.4.1 Differential protein expression of CHIKV-infected WRL-68 whole cell 
proteome and secretome 
Forty µg of proteins was first separated based on the isoelectric point (pI) on a 
13 cm, pH3-10 linear Immobiline™ DryStrip, followed by a second separation on the 
basis of the molecular weight (Mr) on a 12.5% SDS-PAGE gel.  The resulting gel was 
silver stained and analysed with ImageMaster™ gel analysis software.  Figures 4.10 and 
4.12 show the representative whole cell proteome and secretome gels of mock control 
WRL-68 cells, respectively.  The expanded views show the spot number of 
differentially expressed proteins between mock control and CHIKV-infected whole cell 
proteome (Figures 4.11A and 4.11B) and secretome (Figure 4.13A and 4.13B).Five 
biological replicates (from five individual flasks) were used for analysis for each group 
(mock control and CHIKV-infected).  
 
The gel analysis software detected and matched approximately 1,700 and 1,300 
spots for whole cell proteome and secretome samples, respectively.  Quantitative 
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analysis of normalised spot volume revealed 53 differentially expressed protein spots 
for the whole cell proteome sample, and 34 spots with significant modulation for the 
secretome sample.  All proteins were differentially expressed by at least 1.3-fold and 
were statistically significant (p<0.05), as determined by ANOVA and Student’s t-test.   
 
Overall, majority of the protein spots were found to be down-regulated in both 
studies (44 and 25 spots for the whole cell proteome and secretome samples, 
respectively).  Only nine spots were up-regulated in both samples.  For the whole cell 
proteome sample, most protein spots had a fold difference lower than 2.0, and only one 
spot (UL8) showed a 3.1 fold increase upon infection.  The secretome sample, on the 
other hand, showed higher overall fold-change, with 24 spots having at least a 2.0 fold 
difference.  These protein spots were further subjected to MALDI-TOF/TOF MS for 
identification.  
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Figure 4.10: Representative proteome map of WRL-68 whole cell proteome 
Forty µg of mock control and CHIKV-infected WRL-68 whole cell proteome were 
resolved on 13 cm linear Immobiline™ DryStrip of pH 3-10 in the first dimension 
and 12.5% SDS-PAGE gel in the second dimension.  The silver stained gels were 
analysed using ImageMaster™ gel analysis software.  A total of 53 protein spots 
were determined to be differentially expressed, nine of which were up-regulated 
(circled orange) whereas 44 were down-regulated (circled blue).  Boxed areas (I, II, 
III, IV and V) show the locations of the expanded views illustrated in Figure 4.11. 
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Figure 4.11: Expanded views showing the location of differentially expressed 
spots on the mock control and CHIKV-infected WRL-68 whole cell proteome 
gels  
Expanded view of five sections (I, II, III, IV and V) showing differentially expressed 
proteins in mock control (A) and CHIKV-infected (B) 2-D gels.  UL1 to UL9 refer to 
up-regulated protein spots, whereas DL10 to DL53 refer to down-regulated protein 
spots.  Five biological replicates per group (n=5) were used for analysis. 
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Figure 4.12: Representative proteome map of WRL-68 secretome 
Forty µg of mock control and CHIKV-infected WRL-68 secretome were resolved on 
13 cm linear Immobiline™ DryStrip of pH 3-10 in the first dimension and 12.5% 
SDS-PAGE gel in the second dimension.  The silver stained gels were analysed 
using ImageMaster™ gel analysis software.  A total of 34 protein spots were 
determined to be differentially expressed, nine of which were up-regulated        
(circled orange) whereas 25 were down-regulated (circled blue).  Boxed areas (I, II, 
III and IV) show the location of the expanded images illustrated in Figure 4.13. 
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Figure 4.13: Expanded views showing the location of differentially expressed 
spots on the mock control and CHIKV-infected WRL-68 secretome gels 
Expanded view of five sections (I, II, III and IV) showing differentially expressed 
proteins between mock control (A) and CHIKV-infected (B) 2-D gels.  US1 to US9 
refer to up-regulated protein spots, whereas DS10 to DS34 refer to down-regulated 
protein spots.  Five biological replicates per group (n=5) were used for analysis. 
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4.4.2 MS identification of differentially expressed proteins 
The 87 differentially expressed protein spots from the whole cell proteome and 
secretome samples were excised from five preparative gels each and pooled together. 
The proteins were digested with MS grade trypsin and subjected to MALDI-TOF/TOF 
MS analysis.  The MS/MS spectra were then queried against Mascot’s databases of 
known sequences and the top 10 protein hits were ranked based on their MOWSE score.  
Protein identification was considered successful if the MOWSE score was greater than 
the significant threshold of the Mascot algorithm, and if the protein was the top match.  
In addition to MOWSE score, the percentage sequence coverage, pI and molecular mass 
values of the identified protein were taken into consideration in determining the 
confidence level of identification. 
 
Fifty spots (94.3% identified) from the whole cell proteome sample and 25 spots 
(73.5% identified) from the secretome sample were successfully identified, as listed in 
Tables 4.1 and 4.2.  These proteins were functionally categorised based on the 
information obtained from Uniprot (SWISS-PROT/TrEMBL) Knowledgebase.  A total 
of 12 spots (Spots UL9, DL17 and DL53 from the whole cell proteome sample and 
spots US3, US4, US5, US6, DS11, DS12, DS13, DS14 and DS23 from the secretome 
sample) failed to be identified.  In addition, several spots were identified as the same 
protein.  For instance, spots DL39, DL40 and DL41 were identified as guanine 
nucleotide-binding protein (GNB2L1), while spots DS26 and DS27 were identified as 
tissue inhibitor of matrix metalloproteinase 2 (TIMP2).  Hence, the 50 and 25 
successfully identified spots corresponded to identification of 45 and 20 proteins, 
respectively. 
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Of the 45 identified proteins from the whole cell proteome sample, eight 
exhibited an increase in spot intensity upon CHIKV infection. These proteins include 
PDHA1 (UL8), chromobox protein homolog 3 (CBX3) (UL7), heterogeneous nuclear 
ribonucleoprotein C1/C2 (hnRNP C1/C2) (UL4), protein SET (SET) (UL1), 
cytokeratin-7 (KRT7) (UL5), cytokeratin-17 (KRT17) (UL6), nucleophosmin (NPM1) 
(UL2), and reticulocalbin-1 (RCN1) (UL3).  The other 37 proteins showed reduced spot 
intensity, including proteins involved in metabolism, protein translation, protein 
ubiquitination, as well as protein transport and trafficking. 
 
Conversely, for the secretome fraction, five of the identified proteins showed an 
increase in spot intensity whereas 15 proteins exhibited a decrease in spot intensity.  
Three of the up-regulated proteins are transport proteins, namely glutamate receptor 
subunit 3A precursor (GRIN3A) (US1), Ran-specific GTPase-activating protein 
(RANBP1) (US8) and GTP-binding nuclear protein Ran (RAN) (US9), whereas the 
other two up-regulated proteins are moesin (MSN) (US2) and aldose reductase 
(AKR1B1) (US7).  Percentage spot volume for proteins involved in the immune and 
defence response, cell adhesion, protein repair and metalloproteinase inhibition, were all 
found to be significantly reduced during early CHIKV infection, as shown in Table 4.2. 
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Spot 
no. Protein ID 
MOWSE 
Score/ 
Coverage 
(%)  
Theoretical pI/ Mr 
(Experimental      
pI/ Mr) 
Mock-control      
(Mean ± SD) 
CHIKV-
infected    
(Mean ± SD) 
Fold-change        
(p-value) 
Peptides 
matched 
 RNA/DNA/protein synthesis 
Transcription 
      
UL7 Chromobox protein homolog 3 88 (27) 5.23/20.8 (4.6/17.3) 0.0360 ± 0.007 0.0501 ± 0.009 1.39 (0.022) 5 
DL33 Pirin 
 
107 (33) 6.42/32.1 (6.8/30.2) 0.0198 ± 0.002 0.0126 ± 0.011 -1.57 (0.005) 15 
 Translation       
DL12
DL13 
Elongation factor 2  
Elongation factor 2 
497 (37) 
338 (20) 
6.42/95.3 (6.7/75.0) 
6.42/95.3 (6.8/75.0) 
0.1986 ± 0.017 
0.1261 ± 0.023 
0.1470 ± 0.045 
0.0774 ± 0.030 
-1.35 (0.043) 
-1.63 (0.022) 
46 
17 
DL29 Eukaryotic translation initiation factor 
3 subunit H 
174 (11) 6.09/39.9 (6.3/36.9) 0.0702 ± 0.015 0.0444 ± 0.015 -1.58 (0.028) 4 
DL43 Translation initiation factor eIF-2B 
subunit alpha 
 
94 (34) 6.90/33.7 (6.8/25.4) 0.0375 ± 0.007 0.0243 ± 0.004 -1.54 (0.008) 11 
 mRNA processing       
UL4 Heterogeneous nuclear 
ribonucleoproteins C1/C2  
278 (27) 4.95/33.7 (4.4/37.1) 0.0292 ± 0.018 0.0905 ± 0.022 3.10 (0.0028) 21 
DL25 La ribonucleoprotein 101 (23) 6.68/46.8 (6.5/43.1) 0.0886 ± 0.022 0.0128 ± 0.053 -1.67 (0.015) 16 
Table 4.1: List of differentially expressed proteins in the whole cell proteome sample identified by MALDI-TOF/TOF MS 
All identified proteins have significant MOWSE scores (p < 0.05) of at least 55 and are categorised according to their respective biological 
functions in the cells.  
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DL30 Poly(rC)-binding protein1  
 
Metabolism 
Carbohydrate metabolism 
116 (29) 6.66/37.5 (6.4/37.0) 0.0698 ± 0.009 0.0492 ± 0.016 -1.42 (0.039) 17 
 
UL8 Pyruvate dehydrogenase E1 126 (19) 8.35/43.3 (6.8/39.1) 0.0395 ± 0.019 0.0773 ± 0.023 1.96 (0.024) 14 
DL11 Phosphoglucomutase 2 197 (26) 6.28/68.2 (6.2/63.9) 0.0269 ± 0.007 0.0118 ± 0.003 -2.29 (0.004) 16 
DL14 Gamma-enolase 215 (36) 4.91/47.2 (4.2/42.8) 0.0873 ± 0.011 0.0592 ± 0.010 -1.47 (0.003) 17 
DL26 Alpha-enolase 113 (28) 7.01/47.1 (6.7/42.8) 0.2530 ± 0.020 0.1909 ± 0.026 -1.32 (0.003) 18 
DL28 Isocitrate dehydrogenase (NADP)  176 (24) 6.53/46.6 (6.7/39.1) 0.1428 ± 0.032 0.0910 ± 0.019 -1.57 (0.015) 16 
DL35 Glucosamine-6-phosphate isomerase 95 (27) 6.42/32.7 (6.9/26.1) 0.0652 ± 0.014 0.0455 ± 0.008 -1.43 (0.027) 16 
DL44 Phosphoglycerate mutase 1 347 (44) 6.28/68.2 (6.2/23.1) 0.0450 ± 0.004 0.0327 ± 0.008 -1.37 (0.019) 14 
DL47 Triosephosphateisomerase 141 (55) 6.45/26.7 (6.5/21.6) 0.1147 ± 0.013 0.0778 ± 0.008 -1.81 (0.000) 15 
DL48 Triosephosphateisomerase 129 (33) 6.45/26.7 (6.7/21.6) 0.0416 ± 0.010 0.0230 ± 0.003 -1.47 (0.005) 9 
        
 Nucleotide metabolism       
DL20 Inosine triphosphate pyrophosphatase 97 (27) 5.50/21.4 (6.8/19.8) 0.0391 ± 0.003 0.0296 ± 0.005 -1.32 (0.012) 6 
DL21 Adenine phosphoribosyltransferase 239 (57) 5.78/19.6 (7.0/18.2) 0.0214 ± 0.005 0.0141 ± 0.003 -1.52 (0.035) 12 
DL22 Nicotinamide 
phosphoribosyltransferase 
164 (15) 6.69/55.5 (7.2/48.2) 0.0527 ± 0.008 0.0365 ± 0.006 -1.44 (0.010) 14 
DL27 Adenylosuccinate synthetase isozyme 2 486 (46) 6.13/50.0 (6.3/40.9) 0.0503 ± 0.016 0.0223 ± 0.012 -2.25 (0.014) 28 
DL34 Ribose-phosphate pyrophosphokinase I 104 (38) 6.51/34.8 (7.0/28.3) 0.0668 ± 0.007 0.0504 ± 0.002 -1.33 (0.001) 14 
DL49 S-methyl-5-thioadenosine 
phosphorylase 
303 (53) 6.75/31.2 (7.0/24.5) 0.0261 ± 0.004 0.0182 ± 0.005 -1.44 (0.039) 25 
 
 
Table 4.1: Continue 
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 Lipid metabolism       
DL15 Hydroxymethylglutaryl-CoA synthase , 
cytoplasmic 
62 (17) 5.22/57.3 (3.8/49.3) 0.0655 ± 0.014 0.0405 ± 0.003 -1.62 (0.005) 14 
DL32 Aldo-ketoreductase family 1        
member C2 
250 (40) 7.13/36.7 (7.4/33.1) 0.0873 ± 0.016 0.0541 ± 0.017 -1.62 (0.015) 15 
DL46 Isopentyl-diphosphate Delta-isomerase 
1 (IPP isomerase) 
129 (14) 5.93/26.3 (6.1/22.1) 0.0643 ± 0.007 0.0395 ± 0.007 -1.63 (0.001) 4 
        
 Amino acid metabolism       
DL31 Phosphoserine aminotransferase  81 (14) 7.56/40.4 (7.8/38.0) 0.0956 ± 0.026 0.0553 ± 0.015 -1.73 (0.018) 10 
        
 Detoxification       
DL36 S-formylglutathione hydrolase              68 (31) 6.54/31.4 (6.7/26.1) 0.1085 ± 0.011 0.0737 ± 0.015 -1.47 (0.004) 14 
 Cell cycle and apoptosis       
UL1 Protein SET  303 (38) 4.23/33.5 (3.0/39.1) 0.0953 ± 0.025 0.1363 ± 0.017 1.43 (0.017) 20 
DL39 
DL40 
DL41 
Guanine nucleotide-binding protein  
Guanine nucleotide-binding protein 
Guanine nucleotide-binding protein 
64 (18) 
400 (58) 
606 (67) 
7.60/35.1 (7.2/25.5) 
7.60/35.1 (7.7/25.8) 
7.60/35.1 (7.8/25.8) 
0.0417 ± 0.007 
0.1428 ± 0.048 
0.1226 ± 0.011 
0.0162 ± 0.003 
0.0758 ± 0.036 
0.0871 ± 0.018 
-2.58 (0.002) 
-1.88 (0.038) 
-1.40 (0.006) 
8 
24 
30 
DL42 Cell division control protein 2 homolog 
(Cyclin dependent kinase 1) 
335 (58) 8.37/34.0 (8.8/25.4) 0.0426 ± 0.011 0.0240 ± 0.005 -1.77 (0.010) 28 
 Cell structure       
UL5 Keratin, type I cytoskeletal 17  760 (47) 4.97/48.1 (4.3/42.8) 0.1510 ± 0.017 0.2054 ± 0.024 1.36 (0.004) 40 
UL6 Keratin, type II cytoskeletal 7  751 (52) 5.50/51.4 (5.0/47.9) 0.2186 ± 0.019 0.3065 ± 0.055 1.40 (0.010) 36 
DL37 Actin-related protein 2/3 complex 
subunit 2 (p34-ARC) 
192 (42) 6.84/34.3 (7.2/25.9) 0.1003 ± 0.013 0.0710 ± 0.011 -1.41 (0.007) 20 
Table 4.1: Continue 
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 Transport and trafficking       
DL16 Copine-1 147 (4) 5.52/59.0 (5.2/60.0) 0.0436 ± 0.015 0.0249 ± 0.003 -1.75 (0.030) 3 
DL23 
DL24 
Rab GDP dissociation inhibitor beta  
Rab GDP dissociation inhibitor beta 
441 (42) 
132 (34) 
6.11/50.6 (6.1/42.8) 
6.11/50.6 (6.2/43.1) 
0.0894 ± 0.015 
0.0575 ± 0.013 
0.0382 ± 0.022 
0.0381 ± 0.010 
-2.34 (0.003) 
-1.51 (0.036) 
25 
16 
DL38 Electron transfer flavoprotein subunit 
alpha 
129 (22) 8.62/35.1 (7.3/25.7) 0.0639 ± 0.013 0.0450 ± 0.012 -1.42 (0.047) 8 
DL51 Fatty-acid binding protein, epidermal 100 (52) 6.60/15.2 (6.0/9.1) 0.0389 ± 0.008 0.0268 ± 0.002 -1.46 (0.012) 12 
 Protein ubiquitination and 
degradation 
      
DL19 Ubiquitin-conjugating enzyme E2 215 (39) 5.33/22.4 (5.7/20.9) 0.0420 ± 0002 0.0290 ± 0.003 -1.45 (0.001) 16 
DL45 Proteasome subunit alpha type-6 215 (50) 6.34/27.4 (6.3/22.7) 0.0964 ± 0.012 0.0635 ± 0.017 -1.52 (0.008) 21 
 Immune response       
DL52 Peptidyl-prolylcis-trans isomerase A  
(Cyclophilin A) 
158 (41) 7.68/18.0 (6.8/10.7) 0.0543 ± 0.003 0.0399 ± 0.006 -1.36 (0.003) 22 
 Chaperone       
UL2 Nucleophosmin (B23) 100 (22) 4.64/32.6 (3.7/33.1) 0.0307 ± 0.006 0.0426 ± 0.005 1.38 (0.011) 8 
 Binding        
UL3 Reticulocalbin-1 precursor 299 (30) 4.86/38.9 (3.8/38.5) 0.0226 ± 0.002 0.0319 ± 0.004 1.41 (0.004) 17 
 Signalling       
DL50 Thioredoxin-like protein 5 103 (22) 5.40/13.9 (4.7/8.0) 0.0366 ± 0.003 0.0268 ± 0.006 -1.37 (0.020) 4 
 Miscellaneous        
DL10 Spartin 80 (7) 5.66/72.8 (5.3/73.4) 0.0256 ± 0.007 0.0154 ± 0.005 -1.67 (0.035) 5 
DL18 Spermidine synthase 228 (23) 5.30/33.8 (4.7/28.6) 0.0390 ± 0.007 0.0290 ± 0.006 -1.35 (0.036) 12 
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Spot 
no. Protein ID 
MOWSE 
Score/ 
Coverage 
(%)  
Theoretical pI/ Mr 
(Experimental      
pI/ Mr) 
Mock-control 
(Mean ± SD) 
CHIKV-
infected    
(Mean ± SD) 
Fold-change 
(p-value) 
Peptides 
matched 
 Immune and defence response       
DS10 Cathepsin D 395 (38) 6.10/44.5 (6.1/48.2) 0.1655 ± 0.028 0.0610 ± 0.031 -2.72 (0.001) 23 
DS16 Cathepsin L1 109 (5) 5.31/37.5 (6.5/39.8) 0.1904 ± 0.048 0.1072 ± 0.027 -1.78 (0.010) 2 
DS17 Cathepsin L1 109 (5) 5.31/37.5 (6.6/39.8) 0.3237 ± 0.067 0.1280 ± 0.051 -2.53 (0.001) 2 
DS19 Complement C3 precursor 224 (10) 6.02/187.0 (7.4/73.0) 0.0786 ± 0.033 0.0245 ± 0.011 -3.21 (0.009) 28 
DS33 β-2 microglobulin 68 (8) 6.06/13.7 (6.8/7.3) 0.9748 ± 0.157 0.5797 ± 0.125 -1.68 (0.002) 1 
DS34 Cystatin-3 179 (47) 9.00/15.8 (8.5/9.5) 0.1393 ± 0.025 0.0512 ± 0.013 -2.72 (0.000) 14 
 Transport proteins       
US1 Glutamate receptor subunit 3A 
precursor 
44 (11) 7.81/125.5 (6.0/42.2) 0.0308 ± 0.013 
 
0.0941 ± 0.046 
 
 3.05 (0.014) 
 
18 
US8 Ran-specific GTPase-activating 
protein 
102 (19) 5.19/23.3 (5.3/23.0) 0.0243 ± 0.003 0.0438 ± 0.012  1.80 (0.011) 9 
US9 GTP-binding nuclear protein Ran 227 (51) 7.01/24.4 (7.7/22.1) 0.0594 ± 0.010 0.2185 ± 0.036  3.68 (0.000) 19 
DS18 Vesicular integral-membrane protein 
VIP36 precursor 
473 (44) 6.46/40.2 (5.5/33.7) 0.0307± 0.018 0.0136 ± 0.003 -2.25 (0.050) 23 
DS22 Tubulointerstitial nephritis antigen-like 
precursor 
85 (16) 6.54/52.4 (7.0/55.4) 0.0475± 0.009 0.0170 ± 0.010 -2.79 (0.001) 11 
Table 4.2: List of differentially expressed proteins in the secretome sample identified by MALDI-TOF/TOF MS 
All identified proteins have significant MOWSE scores (p < 0.05) of at least 55 and are categorised according to their respective biological 
functions in the cells.  
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 Cell adhesion       
DS15 Collagen alpha-1(V) chain precursor 199 (9) 4.94/183.4 (4.2/34.8) 0.1119 ± 0.036 0.0356 ± 0.013 -3.14 (0.002) 25 
DS32 Cadherin-2 precursor 405 (11) 4.64/99.7 (5.9/10.4) 0.2778 ± 0.060 0.0935 ±0.042 -2.97 (0.001) 18 
 Metalloproteinases inhibitor       
DL26 
DL27 
Tissue inhibitor of metalloproteinases 2 
Tissue inhibitor of metalloproteinases 2 
282 (35) 
360 (39) 
7.45/24.4 (6.7/21.3) 
7.45/24.4 (7.0/21.3) 
0.2858 ± 0.105 
0.7474 ± 0.105 
0.1357 ± 0.059 
0.4013 ± 0.140 
-2.11 (0.024) 
-1.86 (0.002) 
15 
20 
DL28 Tissue inhibitor of metalloproteinases 1  498 (67) 8.46/23.2 (7.4/23.7) 0.2818 ± 0.079 0.0817 ± 0.033 -3.45 (0.001) 18 
 Carbohydrate and lipid metabolism       
US7 Aldose reductase 212 (45) 6.51/35.8 (7.1/34.5) 0.1718 ± 0.051 0.3167 ± 0.050 1.84 (0.002) 28 
DS20 
DS21
DS30 
DS31 
Kexin type 9 precursor 
Kexin type 9 precursor 
Kexin type 9 precursor 
Kexin type 9 precursor 
288 (9) 
67 (6) 
428 (34) 
460 (19) 
6.09/74.3 (6.8/66.9) 
6.09/74.3 (7.0/66.5) 
6.09/74.3 (5.3/16.2) 
6.09/74.3 (4.9/13.1) 
0.2072 ± 0.046 
0.0336 ± 0.015 
0.1723 ± 0.045 
0.1423 ± 0.008 
0.0482 ± 0.020 
N/A 
0.0493 ± 0.027 
0.0599 ± 0.013 
-4.30 (0.001) 
N/A (0.001) 
-3.50 (0.002) 
-2.41 (0.001) 
11 
6 
29 
22 
 Protein repair       
DS29 Protein-L-isoaspartate O-
methyltransferase 
98 (35) 6.70/24.6 (7.3/22.3) 0.0238 ± 0.005 0.0104 ± 0.002 -2.29 (0.002) 12 
 Regulation of MAPK cascade       
DL25 Renin receptor precursor(ATPase H(+)-
transporting lysosomal accessory 
protein 2) 
104 (380) 5.76/39.0 (5.6/22.7) 0.1632 ± 0.064 0.0370 ± 0.015 -4.42 (0.003) 18 
 Miscellaneous        
US2 Moesin 86 (22) 6.08/67.8 (6.9/74.5) 0.0829 ± 0.025 0.1272 ± 0.022 1.53 (0.021) 22 
DS24 Plasminogen activator inhibitor 1 
precursor 
88 (23) 6.68/45.0 (7.9/42.1) 0.0294 ± 0.010 0.0120 ± 0.005 -2.46 (0.009) 14 
Table 4.2: Continue 
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4.4.3 Functional classification and sub-cellular location distribution of altered 
proteins 
Figures 4.14A and 4.14B show functional distribution of identified proteins 
from the whole cell proteome and secretome samples, respectively. Whole cell proteins 
were clustered into 10 main groups whereas proteins from the secretome sample were 
categorised into seven functional classes, based on the information obtained from 
UniProt (SWISS-PROT/TrEMBL) Knowledgebase.  Early CHIKV infection had major 
impact on the expression changes of metabolic enzymes, which constituted 42.22% of 
the total altered whole cell proteins, followed by proteins involved in 
DNA/RNA/protein synthesis (17.78%).  On the contrary, a major proportion of 
differentially modulated proteins from the secretome sample were involved in transport 
as well as in immune and defence response (25.00% for both). 
 
The percentage breakdown of the sub-cellular protein distribution is shown in 
Figures 4.15A and 4.15Bfor the whole cell proteome and secretome samples, 
respectively.  More than half of the whole cell proteins were found in the cytoplasm 
(56.90%).  Nevertheless, proteins located in the nucleus (17.24%), cell membrane 
(8.62%), mitochondrion (5.17%), cytoskeleton/intermediate filament (5.17%), 
endoplasmic reticulum (ER) (3.45%) and peroxisome (3.45%), were also differentially 
expressed upon CHIKV infection.  Conversely, only 50.00% of proteins identified in 
the secretome fraction were secreted proteins, while other modulated proteins, albeit 
detected in the culture medium, were intracellular proteins located primarily in the 
cellular membrane (15.38%), lysosome (11.54%), cytoplasm (11.54%), nucleus (7.69%) 
and ER (3.85%). 
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Figure 4.14: Functional classification of differentially expressed proteins from 
the whole cell proteome (A) and secretome (B) samples. 
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Figure 4.15: Sub-cellular distribution of differentially expressed proteins from 
the whole cell proteome (A) and secretome (B) samples. 
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4.4.4 Protein network analysis 
 Prediction of protein-protein interactions was performed using STRING 
database v9.0 to illustrate the connections between differentially expressed proteins.  
Proteins were linked based on seven criteria; neighbourhood, gene fusion, co-
occurrence, co-expression, experimental evidences, existing databases and textmining.  
Medium stringency (STRING score = 0.4) was used to analyse the network.  Proteins 
were represented as nodes and their functional links were defined by solid lines.  The 
thickness of the lines signifies the level of confidence of the reported association.  
Twenty additional interacting proteins were also added to the interaction map to provide 
a more comprehensive overview of the biological processes affected during CHIKV 
infection. The protein names and gene symbols used in the networks are listed in 
Appendices A1 (Whole cell proteome) and A2 (Secretome). 
 
STRING network analysis of altered whole cell proteins revealed 37 interlinked 
proteins (Figure 4.16A), while 17 of the 20 proteins from the secretome sample were 
connected by at least one criterion (Figure 4.16B).  Gene ontology (GO) enrichment 
analysis of biological process was further evaluated using STRING database to identify 
significant biological processes associated with the network. False discovery rate (FDR) 
correction was the default statistical method used to determine the significance of each 
process.  Eight and five processes were found to be significant in the predicted whole 
cell proteome and secretome networks, respectively, as shown in Table 4.3.  Analysis of 
the whole cell proteome network revealed involvement of energy production, cell cycle 
regulation, gene expression, mRNA metabolism, protein metabolism and modification, 
DNA replication and ubiquitin-protein ligase activity.  Signal transduction, cellular 
component and extracellular matrix (ECM) organisation, regulation of cytokine 
stimulus and immune response were shown to be involved in the secretome network. 
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Figure 4.16: Whole cell proteome (A) and secretome (B) networks showing 
functional linkages between identified proteins 
STRING interaction maps were generated using default settings (Medium confidence of 
0.4 and 7 criteria for linkage: neighbourhood, gene fusion, co-occurrence, co-
expression, experimental evidences, existing databases and textmining).  Twenty 
additional interplay proteins were also added to each network.   
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Table 4.3: GO enrichment analysis of biological processes involved in the whole 
cell proteome and secretome networks 
The significance of the GO biological processes was determined by FDR analysis            
(p< 0.05). 
GO Biological process p-value 
Whole cell proteome network 
Regulation of ubiquitin-protein ligase activity 
 
4.34 x 10-14 
Gene expression 1.14 x 10-6 
mRNA metabolic process 8.06 x 10-6 
Protein modification 1.75 x 10-5 
Regulation of cell cycle 1.63 x 10-5 
Protein metabolic process 1.02 x 10-5 
Generation of energy and precursor metabolite 1.35 x 10-2 
DNA replication 4.98 x 10-2 
Secretome network 
Regulation of cellular component organisation 
 
7.03 x 10-3 
Response to cytokine stimulus 1.11 x 10-2 
Regulation of signal transduction 1.24 x 10-2 
ECM organisation 1.70 x 10-2 
Regulation of immune process 3.53 x 10-2 
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4.4.5 Protein validation by Western blot analysis 
 One-dimensional (1-D) Western blot was applied to validate the expression of 
two selected whole cell proteins, CDK1 (Figure 4.17A) and PDHA1 (Figure 4.17B), 
which were normalised against the endogenous controls, ACTB and GAPDH, 
respectively.  Densitometric analysis revealed down-regulation of CDK1 and up-
regulation of PDHA1 by 1.42 and 1.72 folds, respectively (Figures 4.17C and 4.17D), 
confirming the directions of the fold changes.  The fold-differences obtained for both 
proteins were also comparable to that of the fold differences determined by 2-DGE 
analysis, which showed down-regulation by 1.77 for CDK1 and up-regulation by 1.96 
for PDHA1.  
 
Conversely, 2-D Western blot was used to validate the position of RAN, which 
was identified to be up-regulated in the secretome sample.  Although the protein 
expression level cannot be accurately determined, 2-D Western blot analysis allows 
confirmation of protein location on the gel based on molecular weight and pI/pH values.  
Figure 4.17E shows the position and spot intensity of RAN protein in mock control (I) 
and CHIKV-infected (II) 2-Dimmunoblots.  The location of RAN on both immunoblots 
was similar to that of 2-DGE gel (Figure 4.12), confirming the identity of the protein 
spot.  RAN protein exhibited a molecular weight of slightly below 26 kDa (Theoretical 
value: 24,408 kDa) and apI/pH of around 7 to 8 (Theoretical value: 7.01).  Furthermore, 
comparison between the immunoblots also showed a similar increase in spot intensity 
upon CHIKV infection, as was observed with 2-DGE analysis. 
 
 
 
136 
 
 
 
 
 
 
Figure 4.17: Western blot validation of CDK1, PDHA1 and RAN proteins 
Down-regulation of CDK1 (A) and up-regulation of PDHA1 (B) was validated by 1-D 
Western blot.  Densitometric analysis of the mean relative intensity (n=3) for each 
target protein showed a 0.70 (or 1.42 fold decrease) and 1.72 fold differences for CDK1 
(C) and PDHA1 (D), respectively.  The band intensities of CDK1 and PDHA1 were 
normalized against ACTB and GAPDH, respectively. Error bars indicate standard 
deviation of three biological replicates.  Student’s t-test was employed to determine the 
significance of the fold-differences, where * indicates p-value<0.05.  Panel E shows the 
position of RAN protein spot in mock control (I) and CHIKV-infected (II) 
immunoblots, whereby an increase in spot intensity was observed in the CHIKV-
infected blot as compared to the mock control blot. 
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4.5 Transcript expression analysis 
 Quantification of mRNA expression was performed with real-time qPCR. Prior 
to quantification, the purity and integrity of extracted RNA and the efficiency of each 
primer pair was determined to ensure data accuracy.  The following three sections 
describe the results obtained from this study. 
 
4.5.1 Determination of RNA purity and integrity 
 All RNA samples used in this study were determined to have A260:A280 and 
A260:A230 ratios that fall within the purity ranges of 1.8-2.0 and >2.0, respectively, as 
shown in Appendix B. Meanwhile, RNA integrity for all samples was confirmed by the 
presence of two intact bands corresponding to the 28S and 18S ribosomal RNA (rRNA) 
and a 28S:18S rRNA band intensity ratio of approximately 2:1 (as shown in the 
example in Figure 4.18).   
 
4.5.2 Primer efficiency test 
Primer efficiency test was performed to evaluate the amplification efficiency and 
specificity of each primer pair to the gene of interest.  A total of 52 primers were 
designed for 51 targeted genes (36 genes for whole cell proteins and 15 genes for 
secretome) and the endogenous control, ACTB.  The amplification efficiency for all 
primer sets was determined to be within the acceptable range of 90% to 110% (Slope 
value between -3.1 and -3.6) (Refer to appendix C for the primer sequences and 
efficiency test data).  The specificity of each primer set was also confirmed by the 
presence of a single peak in the dissociation curve (data not shown). 
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Figure 4.18: Representative gel profile of intact total RNA samples extracted from 
mock control and CHIKV-infected cells for whole cell proteome study 
RNA integrity of mock control and CHIKV-infected RNA samples was visualised on 
1.0% agarose gel.  Two discrete bands were observed in both samples, with the 28S 
rRNA band having approximately twice the intensity of the 18S rRNA band, 
confirming sample integrity.  
Lane 1: Mock control  
Lane 2: CHIKV-infected (MOI 5.0) 
 
Lane 1  Lane 2 
28S rRNA band 
 
18S rRNA band 
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4.5.3 Real-time qPCR analysis of differential mRNA expression 
 The mRNA expression levels of 36whole cell proteins and 15 secreted proteins, 
representing all functional classes, were evaluated to investigate the mechanisms 
leading to the altered protein expression.  The transcript expression for all targeted 
proteins were normalised against ACTB.  Of the 36 whole cell proteins analysed, 18 
showed significant changes at the mRNA level (p< 0.05), 15 of which were in 
concordance in the direction of fold difference as the protein, while the other three 
showed the opposite direction of expression change (Table 4.4).  The mRNA expression 
levels for the remaining 18 proteins showed no significant differences (p> 0.05).  
Conversely, only one of the 15 selected proteins from the secretome sample, which is 
kexin type 9 precursor (PCSK9), showed significant changes at the mRNA expression 
level, and is in concordance in the direction of fold difference as the protein expression 
(Table 4.5).   
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Table 4.4: Comparison of real-time qPCR and proteomics results for 36 selected 
proteins from the whole cell proteome sample 
* Bold indicates RNA expression changes which are in concordance with protein 
expression changes in terms of directionality, and are determined to be statistically 
significant (p< 0.05); NSD indicates no significant differences in the RNA expression.  
** More than one protein spot was identified. 
Gene name mRNA fold-change (p-value) Protein fold-change 
ADSS -1.36 (0.0126) -2.25 
APRT 1.33 (0.0087) -1.52 
ARPC2 1.24 (0.0030) -1.41 
CBX3 NSD 1.39 
CDK1 -1.38 (0.00003) -1.77 
CPNE1 NSD -1.75 
EEF2 -1.12 (0.0008) -1.63, -1.35** 
eIF2B1 -1.25 (0.0295) -1.54 
eIF3H NSD -1.58 
ENO1  -1.32 (0.0005) -1.32 
ETFA 1.34 (0.0009) -1.42 
GDI2 NSD -2.34, -1.51** 
GNB2L1 NSD -2.58, -1.88, -1.40** 
HMGCS1 NSD -1.62 
HNRNPC NSD 3.1 
IDH1 -1.14 (0.0100) -1.57 
IDI1 -1.48 (0.0057) -1.63 
ITPA NSD -1.32 
KRT7 NSD 1.4 
MTAP -1.26 (0.0298) -1.44 
NAMPT NSD -1.44 
NPM1 NSD 1.38 
PCBP1 -1.82 (0.00008) -1.42 
PDHA1 1.30 (0.0047) 1.96 
PGAM1 NSD -1.37 
PIR -1.25 (0.0142) -1.57 
PPIA NSD -1.36 
PRPS1 -1.27 (0.0042) -1.33 
PSAT1 -1.62 (0.00002) -1.73 
PSMA6 NSD -1.52 
RCN1 NSD 1.41 
SET 1.41 (0.0057) 1.43 
SSB NSD -1.67 
TPI1 NSD -1.81, -1.47** 
TXNDC17 NSD -1.37 
UBE2N -1.33 (0.0100) -1.45 
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Table 4.5: Comparison of real-time qPCR and proteomics results for 15 selected 
proteins from the secretome sample 
* Bold indicates RNA expression changes which are in concordance with protein 
expression changes in terms of directionality, and are determined to be statistically 
significant (p< 0.05); NSD indicates no significant differences in the RNA expression.  
** More than one protein spot was identified. 
 
Gene name mRNA fold-change (p-value) Protein fold-change 
ATP6AP2 NSD -4.42 
B2M NSD -1.68  
C3 NSD -3.21  
CDH2 NSD -2.97 
CST3 NSD -2.72  
CTSD NSD -2.72  
CSTL1 NSD -2.53, -1.78** 
COL5A1 NSD -3.14 
PCMT1 NSD -2.29 
PCSK9 -1.43 (0.0002) -4.30, -3.50, -2.40** 
RAN NSD 3.68 
RANBP NSD 1.80 
SERPINE1 NSD -2.46 
TIMP1 NSD -3.45 
TIMP2 NSD -2.11, -1.86** 
143 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
144 
 
 CHIK is an arthropod-borne disease that has caused multiple recurring outbreaks 
over the past five decades in the Asian, African, and more recently, the European 
continent.  Despite being less deadly and prevalent than dengue (DEN) fever, which 
reports an approximate 50 to 100 million cases annually (Schmidt-Chanasit et al., 
2012), this arboviral infection should not be taken lightly  given the observed increase 
in the number of documented cases and outbreaks with each successive year.  
Moreover, the similarities between DEN and CHIK symptoms, as well as co-circulation 
of both CHIKV and dengue virus (DENV) in the same regions often lead to 
misdiagnosis of CHIK as DEN cases.  This causes an underestimation of the actual 
number of CHIK cases worldwide (Powers et al., 2000).  In addition, the rapid mutation 
of CHIKV has led to evolution of a deadlier strain of the virus, evidenced by the 
emergence of atypical complications and higher death rates in recent outbreaks (Powers 
& Logue, 2007).  Therefore, there is no question that CHIK is a potential threat to the 
global community.  
 
Studies on host-interaction and the pathways exploited by CHIKV for successful 
invasion, propagation and dissemination in the human body are highly pursued research 
areas in recent years.  Regardless, the knowledge obtained so far, albeit progressing, is 
still limited.  Proteomics is fast becoming a popular tool to study host-virus interaction 
by looking at changes implicated by viruses on the host proteome.  Incorporation of 
pathway studies to interpret protein expression data has proven to be valuable in 
predicting the potential interacting protein partners and to elucidate the pathways that 
may be involved during viral infection (Lietzen et al., 2011).  The current study 
integrated the aforementioned approaches to investigate changes in the host whole cell 
proteome and secretome during early CHIKV infection in WRL-68 cells.  Findings of 
this study are being discussed at length in the paragraphs that follow.  Prior to 2-DGE 
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analysis, optimisation of the MOI and time-point was performed to determine the 
suitable condition that defines early infection, that is, the stage before cell death.  This is 
to ensure that changes in the whole cell proteome and secretome are caused solely by 
CHIKV infection, and not due to cell death factors, such as apoptotic factors 
(Pattanakitsakul et al., 2007).  Furthermore, cell death needs to be minimised to prevent 
contamination of the secretome with cellular debris and intracellular proteins released 
due to cell lysis, which renders the 2-DGE results inaccurate.  Hence, the MOI and 
time-point selected for infection should induce minimal cell death as compared to the 
mock control, while simultaneously maintaining a significant percentage of infection.  
Combination of morphological analysis, IIFA and flow cytometric quantification was 
performed to thoroughly investigate the best condition for early infection, which 
resulted in the selection of the MOI of 5.0 and 24 hours post-infection incubation.  
Infection under this condition resulted in a high percentage of infection at 74.77% 
without causing any observable CPE.  Meanwhile, percentage of cell death (25.90%) 
was comparable to that of cells infected at lower MOI (at the same time-point), albeit 
slightly higher than mock control cells (14.33%).  Hence, this MOI and time-point was 
used for the subsequent proteomics study. 
 
Secretome is defined as the complex set of molecules secreted by living cells 
(Makridakis & Vlahou, 2010).  In cell culture, these proteins are secreted into the 
culture media, which are typically rich in a variety of proteins in the serum as nutrients 
for cell growth.  These proteins are in abundance in comparison to secreted proteins.  
When resolved using 2-DGE technique, these highly abundant proteins will mask the 
actual target proteins.  To eliminate interfering proteins from the serum, serum-free 
DMEM medium was used during incubation period following infection.  However, 
serum starvation may have negative effects on cell growth and proliferation, as 
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previously reported (Mattanovich et al., 2009).  Therefore, the viability and integrity of 
cells cultured in serum-free medium must be evaluated.  In addition, flow cytometer 
analysis revealed a slightly higher percentage of cell death in CHIKV-infected cells than 
in mock control cells at the selected condition for infection.  Thus, it is also pertinent to 
determine that membrane integrity of CHIKV-infected cells is not greatly compromised 
to avoid severe contamination of the secretome with intracellular proteins.   
 
The viability and integrity of WRL-68 cells under serum starvation and CHIKV-
infection was evaluated by MTS cell proliferation and dead-cell protease assays.  MTS 
assay measures cell viability through the activity of enzymes involved in the 
cytochrome system of viable cells, which reduces the MTS (a tetrazolium salt) to water-
soluble formazans (Barltrop & Owen, 1991).  On the other hand, cell-death protease 
assay is a luminescent assay which evaluates membrane integrity by measuring the 
activity of proteases that have been released from dead cells.  The luminogenic peptide 
substrate or AAF-Glo™ substrate (alanyl-alanyl-phenylalanyl aminoluciferin) is not 
permeable to viable cells with intact membranes, and therefore can only detect proteases 
that have been leaked out from damaged membranes (Niles et al., 2007).   
 
MTS assay results showed that serum starvation did not affect the viability of 
WRL-68 cells at 24 hours incubation.  However, cell lysis was found to be inevitable, as 
proteases were detected in the supernatant of control cells cultured with serum-
supplemented medium.  Nevertheless, the degree of cellular disruption between cells 
grown in serum-supplemented medium, serum-free medium and CHIKV-infected cells 
(MOI 5.0) incubated in serum-free medium were comparable.  Taken together, it can be 
deduced that serum-starvation and infection at the selected MOI and time-point did not 
result in significant loss of cell viability and integrity.  
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 Proteomics analysis was subsequently performed to compare the whole cell 
proteome and secretome gel profiles between mock control and CHIKV-infected WRL-
68 cells.  Immobiline™ drystrip of a wide pH range of 3 to 10 was used for a broad 
overview of the total protein distribution.  The proteins were further separated on 12.5% 
polyacrylamide gel which gave well resolved gel profiles, with minimal overlapping 
spots.  For analysis, five biological replicates (n=5) were used for each group to 
minimise biological variations.  The gel images were analysed using ImageMaster™ 2D 
Platinum v7.0 software with stringent selection of spot detection parameters (minimal 
area: 5.0; smooth factor: 3.0; and saliency: 200.0) to minimise detection of staining 
artifacts.  Manual re-matching of incorrectly matched spots was performed following 
automatic matching.  More than 1000 spots were detected for both gel profiles, of which 
34 and 53 spots from the whole cell proteome and secretome samples, respectively, 
were significantly regulated by at least 1.3 fold.   
 
 Mass spectrometric identification of these 87 spots resulted in successful 
identification of 50 and 25 spots from the whole cell proteome and secretome samples, 
respectively.  The remaining 12 spots failed to be identified due to low MOWSE scores 
(below the significant threshold), or multiple significant protein hits with no 
overlapping peptide sequence match, indicating the presence of more than one protein.  
Furthermore, several spots were identified as the same protein, such as that of GNB2L1 
and TIMP2 proteins.  These spots were found to have either similar Mr, but slightly 
different pI, or vice versa, and hence, could probably be isoforms of that protein.   
 
 Three of the identified proteins were further validated by Western blot.  ACTB 
and GAPDH were used as endogenous controls for CDK1 and PHDA1, respectively.  
GAPDH was selected as the loading control for PDHA1 because PDHA1 and ACTB 
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have similar molecular mass of ~43 kDa, and thus, cannot be stained together on the 
same blot.  On the contrary, 2-D Western blot was used for secretome protein validation 
due to the lack of a universal loading control for secretome to normalise loading 
quantities, which is a requirement for 1-D Western blot analysis.  Nevertheless, both 
methods were successful in validating the expressions of CDK1 and PHDA1, and 
confirming the identity of RAN protein spot. 
 
Transcript analysis of 51 selected proteins showed a moderate degree of 
correlation between the mRNA and whole cell protein expression (15 positive 
correlations).  Only PCSK9 showed positive correlation with its mRNA expression in 
terms of directionality.  This is not surprising, given that post-transcriptional 
modifications such as mRNA splicing or editing and post-translational modifications 
often determine the final translation rate of a protein (Brockmann et al., 2007).  Also, 
the poor correlation between the transcript and secretome expression levels suggests 
that other mechanisms may be involved in determining the protein secretion rate, such 
as protein folding rate and cell cycle position (Frykman & Srienc, 2001; Thor et al., 
2009). 
 
Early CHIKV infection was found to cause widespread alterations of the whole 
cell proteome and secretome.  Proteins of diverse functions and sub-cellular locations 
were differentially expressed, majority of which were down-regulated.  Only half of the 
proteins identified in the secretome fraction were secretory proteins.  Other intracellular 
proteins identified in the culture supernatant could have been secreted through the non-
classical pathway, such as that of cathepsins (Lietzen, et al., 2011).  However, several 
cytosolic proteins, including moesin (MSN) and protein-L-isoaspartate O-
methyltransferase (PCMT1), are not known to be secreted.  Hence, their release into the 
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culture medium could be due to cell lysis.  In terms of functional classification, a large 
subset of the proteins were found to be involved in metabolism, DNA/RNA/protein 
biogenesis, immune response and transport, suggesting that these functions may be 
important during CHIKV infection in host cells.  
 
STRING network analysis was used to predict the functional interactions 
between proteins based on existing information from public text collections and 
experimental data.  All metabolic proteins, except glucosamine-6-phosphate isomerase 
(GNPDA1), nicotinamide phosphoribosyltransferase (NAMPT) and phosphoserine 
aminotransferase (PSAT1) showed functional linkages in the whole cell proteome 
network (Figure 4.16A).  The proteasome complex, comprising of the alpha and beta 
subunits, formed a large cluster in the interaction map.  One of the subunits, proteasome 
subunit alpha 6 (PSMA6), was down-regulated in this study.  In addition, seven of the 
identified proteins, namely SET protein, hnRNP C1/C2, NPM1, CDK1, electron 
transfer flavoprotein (ETFA), alpha enolase (ENO1) and eukaryotic elongation factor 
(EEF2), were functionally linked to one or more of these subunits.  
 
Meanwhile, three immune and defence response proteins; cystatin 3 (CST3), 
cathepsin D (CTSD) and cathepsin L1 (CTSL1), showed strong linkages in the 
secretome network, as shown in Figure 4.16B.  Beta-2 microglobulin (B2M), on the 
other hand, was linked to the major histocompatibility (MHC) class I complex through 
human leukocyte antigen A (HLA-A).  Tubulointerstitial nephritis antigen-like 
precursor (TINAGL1), conversely, was linked to complement proteins, complement C3 
(C3) and complement factor H (CFH) in a separate cluster.  Tissue inhibitor of 
metalloproteinase 1 and 2 (TIMP1 and TIMP2), and collagen alpha-I (V) chain 
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precursor (COL5A1) were indirectly connected through matrix metalloproteinase 2 
(MMP2) protein. 
 
The functional linkages were then used to determine the significant biological 
processes involved in each network.  The FDR-filtered (p < 0.05) list of biological 
processes showed that gene expression, mRNA processing, energy and precursor 
metabolite biogenesis, cell cycle regulation and ubiquitin-related processes were 
involved in the whole cell proteome network, whereas immune response, as well as 
ECM and cellular compartment organisation were identified in the secretome network.  
Identification of these processes confirms the aforementioned functional roles that were 
postulated to play a role during CHIKV infection.  The functions these proteins are 
being discussed in the following sections to elucidate the key events that take place 
during early CHIKV infection. 
 
i) Functional disorder of the host gene expression machinery 
Expression of a gene for subsequent synthesis of its functional product involves 
transcription of the gene to mRNA, which is then processed and translated to produce 
the protein it encodes.  Virus hijacking of the gene expression machineries is well 
documented in many virus-host interaction studies (Scheller & Diez, 2009; Toribio & 
Ventoso, 2010).  Viruses with positive sense RNA in particular, have been shown to 
recruit components of the host cellular mRNA processing and translational machineries 
for viral RNA and protein synthesis (Li et al., 1999).  In this study, five proteins 
involved in mRNA processing and translation were found to be deregulated, namely 
hnRNP C1/C2, poly(rC)-binding protein 1 (PCBP1) or hnRNP E1, EEF-2, translation 
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initiation factor EIF-2B subunit alpha (eIF2B1) and eukaryotic translation initiation 
factor 3 subunit H (eIF3H).  
 
Heterogeneous ribonucleoprotein C1/C2 (hnRNP C1/C2) protein expression 
showed up-regulation by 3.10 fold whereas hnRNP E1 was down-regulated by 1.42 
fold.  The transcript expression level of hnRNP E1 showed higher fold difference (-1.82 
fold-change) than the protein expression, but of the same directionality.  Meanwhile, the 
transcript level of hnRNP C1/C2 did not alter significantly.  Both hnRNPs belong to the 
hnRNP complexes of RNA and proteins involved in multiple cellular functions such as 
transcription, pre-mRNA processing and cytoplasmic mRNA translation (Krecic & 
Swanson, 1999).  Previous studies have demonstrated the yin and yang of hnRNPs in 
viral pathogenesis.  During DEN infection, hnRNP C1/C2 was shown to interact with 
DENV NS1 protein, promoting virus survival in host cells (Noisakran et al., 2008).  
Conversely, during vesicular somatitis virus (VSV) infection, hnRNP E1 showed 
antagonistic relationship with the virus as virus replication is inhibited in its presence 
(Dinh et al., 2011).  Thus, the up-regulation of hnRNP C1/C2 in this study possibly 
signifies its recruitment by CHIKV whereas hnRNP E1 may potentially have adverse 
effects towards CHIKV replication which is counteracted by its inhibition. 
 
Translation factors play crucial roles in viral protein synthesis and different 
viruses exert different mechanisms to modulate host translational proteins to their 
benefit (Kushner et al., 2003).  Eukaryotic translation is a three-step process which 
begins with initiation of translation, a process mediated by 11 initiation factors (eIF1 
through eIF6), followed by elongation of the growing amino acid chain by elongation 
factors (EEF-1α, EEF-1βγ, EEF-2 and EEF-3), and ends with termination by the release 
factor upon reaching the stop codon (Merrick, 1992).  Alphaviruses have been shown to 
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induce global shutoff of protein synthesis by inhibiting or modifying host translational 
factors.  Semliki Forest virus, for example, induces shutoff by phosphorylating eIF2α 
and subsequently inhibiting eIF2B (McInerney et al., 2005).  CHIKV, conversely, 
induces protein synthesis shutoff through an unknown protein kinase R (PKR)-
independent mechanism, as the absence of PKR-induced phosphorylation of eIF2α did 
not prevent host translational shutoff (White et al., 2011).  Down-regulation of EEF-2, 
eIF2B1 and eIF3SH protein expression was observed in this study, although only EEF-2 
and eIF2B1 was down-regulated at the transcript level.  The roles of these proteins in 
host translational shutoff cannot be ascertained at this point. Nevertheless, down-
regulation of these proteins would disrupt the host translational machinery, possibly 
contributing to the down-regulation of most differentially expressed proteins. 
 
ii) Perturbation of cellular energy production and host cell metabolism 
In this study, we found severe disruption of the host cell metabolism upon 
CHIKV infection.  Two (10%) and 19 (42.22%) identified proteins from the secretome 
and whole cell proteome fractions, respectively, were involved in cellular metabolism.  
This finding is not surprising given that liver is the central site for metabolism.  Our 
proteomics data showed that 18 of the 19 metabolic proteins identified in the whole cell 
proteome fraction were down-regulated.  Only PDHA1, a key enzyme in transforming 
pyruvate to acetyl-Coenzyme A in the tricarboxylic acid (TCA) cycle (Dahl et al., 
1987), was up-regulated by 1.96 fold, as confirmed by immunoblot analysis (Figures 
4.17A and 4.17C).  Transcript expression levels for eight (PHDA1, ENO1, PSAT1, 
isocitrate dehydrogenase (IDH1), adenylosuccinate synthetase isozyme 2 (ADSS), 
ribose-phosphate pyrophosphokinase 1 (PRPS1), isopentyl-diphosphate Delta-
isomerase 1 (IDI1), and S-methyl-5-thioadenosine phosphorylase (MTAP)) of the 14 
selected proteins were similar in the direction of expression changes as the protein 
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expression (Table 4.4).  Conversely, aldose reductase (AKR1B1), a catalyst involved in 
reduction of glucose to sorbitol for glucose metabolism, was found to be up-regulated 
by 1.84 in the secretome study while PCSK9 was found to be down-regulated at both 
the protein and transcript levels.  
 
Overall, energy production in CHIKV-infected WRL-68 cells was disrupted 
through reduced expression of glycolytic enzymes including ENO1, phosphoglycerate 
mutase 2 (PGM2) and triosephosphate isomerase (TPI1), as well as down-regulation of 
IDH1 which catalyses the conversion of isocitrate to α-ketoglutarate in the TCA cycle 
(Christensen et al., 2011).  CHIKV was also found to disrupt the adenine salvage 
pathway.  Four enzymes involved in this pathway were down-regulated, including 
PRPS1 which catalyzes the synthesis of phosphoribosylpyrophosphate (PRPP) for 
purine and pyrimidine synthesis (Becker et al., 1982); ADSS, a catalyst for the 
synthesis of adenosine monophosphate (AMP) from inosine monophosphate (IMP) for 
adenine production (Guicherit et al., 1994); MTAP, an enzyme involved in adenine and 
methionine salvage (Appleby et al., 1999); and adenine phosphoribosyl transferase 
(APRT), the enzyme involved in adenine salvage for AMP recovery (Itai et al., 2000).  
 
Mevalonate pathway is an essential pathway for the production of metabolically 
and physiologically important molecules and end-products such as cholesterol, 
conenzyme Q, dolichyl-P for protein glycosylation and isoprenylated proteins for signal 
transduction and protein localization.  In this study, two important enzymes in this 
pathway, namely hydroxymethylglutaryl-CoA synthase (HMGCS1) of cytoplasmic 
origin, which is involved 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) 
synthesis for the production of mevalonate (Hegardt, 1999); and IDI1, a catalyst for the 
conversion of isopentenyl pyrophosphate (IPP) to dimethylallyl pyrophosphate 
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(DMAPP) (Ramos-Valdivia et al., 1997), were down-regulated.  Mevalonate serves as 
the precursor in this pathway for production of IPP, the basis for all terpenoids.  
Terpenoids, in turn, are intermediates for steroids and sterols (such as cholesterol) 
production.  More importantly, down-regulation of both the protein and mRNA 
expression of IDI1 suggests that CHIKV disrupts the cholesterol producing route in the 
pathway as DMAPP is required for production of lanosterol, the key intermediate for 
production of cholesterol and other steroids (Schroepfer, 1982).  In addition, the 
secretion of PCSK9, which is involved in regulating cholesterol homeostasis by 
enhancing degradation of low-density lipoprotein (LDL) receptor protein (Duan et al., 
2012), was also down-regulated.  
 
The results obtained here is in contrary to several findings in which metabolic 
enzymes and metabolites involved in various metabolic processes were found to be 
significantly up-regulated (Diamond et al., 2010; Munger et al., 2006).  Most viruses 
are known to utilise the host metabolic machinery to acquire energy and 
macromolecular precursors for replication (Munger, et al., 2006).  However, production 
of energy and biosynthetic precursors through metabolic processes are also required for 
heat shock response activity as a defence mechanism against these pathogens (El-Bacha 
et al., 2004; Widnell et al., 1990).  Therefore, one plausible explanation for the 
observed down-regulation of most metabolic enzymes is that CHIKV possibly 
suppresses these metabolic processes to inhibit the activation of heat shock responses.   
 
iii) Inhibition of proteins involved in ubiquitin proteasome pathway (UPP) 
UPP is an intracellular system involved in the ubiquitination of proteins targeted 
for degradation by proteasomes.  UPP plays vital roles in host cellular functions such as 
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DNA repair, apoptosis, regulation of cell cycle and transcription, and signal 
transduction (Glickman & Ciechanover, 2002).  Hence, this pathway is often targeted 
by viruses during host cell infection.  Many viruses have been reported to evolve 
different strategies to manipulate this pathway; either to avoid the host immune 
surveillance or to facilitate viral transcriptional regulation, maturation and progeny 
release (Gao & Luo, 2006). For instance, enterovirus 71 was shown to inhibit the 
expression of proteasome subunit alpha type-2 and ubiquitin carboxyl-terminal esterase 
L3 (Leong & Chow, 2006), while the EA6P ubiquitin ligase is required for 
ubiquitination and degradation of hepatitis C virus (HCV) core protein (Shirakura et al., 
2007).  
 
In this study, two UPP associated proteins, ubiquitin-conjugating enzyme E2 N 
(UBE2N) and PSMA6 were down-regulated by 1.45 and 1.52 fold, respectively.  At the 
transcript level, only UBE2N showed down-regulation by 1.33 fold, whereas the mRNA 
level for PSMA6 remained unchanged.  UBE2N is a ubiquitin-carrier enzyme that 
carries and binds ubiquitin to the ubiquitin-ligase enzyme, which then ubiquitinates 
targeted proteins.  PSMA6, on the other hand, is a subunit of the 20S proteasome 
subcomplex, which forms the multicatalytic 26S proteasome that degrades the 
polyubiquitinated proteins into smaller peptides (Glickman & Ciechanover, 2002).  
Changes in the expression levels of both proteins suggest perturbation of the cellular 
UPP by CHIKV during early infection via a different strategy than that of other viruses.  
In addition, disruption of this pathway may affect other proteins, such as those linked to 
the proteasome subunits in the whole cell proteome network postulated by STRING 
analysis.  Regardless, the exact interaction between the proteasome and these proteins 
can only be determined through functional studies.  
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iv) Potential involvement of CDK1 in CHIKV-induced cell death 
In this study, we found evidence suggesting disruption at the G2/M-phase 
transition, an important phase for DNA replication and cell division, through alteration 
of CDK1 and SET protein expressions.  CDK1, also known as p34
cdc2
 protein kinase, 
was found to be down-regulated whereas the SET protein was up-regulated at both the 
protein and transcript levels.  STRING network analysis also showed a functional 
linkage between CDK1 and the SET protein.  CDK1 is a member of the serine/threonine 
kinases family that is activated by cyclin B.  This kinase regulates the cell cycle by 
allowing entry into mitosis from the G2 phase (Schang, 2004).  In general, regulation of 
cyclin dependent kinases (CDKs) is typically associated with replication of DNA 
viruses in the nucleus, although several studies have illustrated the potential role of 
CDKs in the replication of RNA viruses, such as that of reoviruses (Poggioli et al., 
2002).   
 
The SET protein is a ubiquitously expressed phosphoprotein that has been 
shown to inhibit cyclin B-CDK1 activity, causing cell cycle arrest at the G2 phase 
(Canela et al., 2003).  Hence, up-regulation of the SET protein would further inhibit the 
activity of CDK1.  Moreover, the disruption of cholesterol synthesis via down-
regulation of HMGCS1 and IDI1 would have further inhibited CDK1 activity, as a 
previous study showed that restriction of cholesterol provision decreased CDK1 activity 
(Martinez-Botas et al., 1999).  Taken together, these findings suggest that CHIKV 
targets CDK1 during early infection through multiple mechanisms.  While the 
progression of these events would lead to cell death, there is also a possibility that 
deregulation of CDK1 facilitates CHIKV replication through a yet unknown 
mechanism. 
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v) Disruption of host cell immune response 
 Results from our proteomics data show down-regulation of several immune 
response-related proteins, including cyclophilin A (PPIA) which was detected in the 
cytosolic fractions, as well as C3, CTSD, CTSL1 and B2M, all of which were detected 
in the culture supernatant.  PPIA, a ubiquitously expressed protein of the immunophilin 
family, is a multifunctional protein involved in immune response, cell death, 
transcription and mitochondrial function (Watashi & Shimotohno, 2007).  A recent in 
vivo study showed the importance of PPIA in regulating the immune response by acting 
as a suppressor towards the development of CD4
+
 T cell responses (Brazin et al., 2002).  
Despite being an intracellular protein, PPIA can be secreted in response to inflammatory 
stimuli such as reactive oxygen species (ROS) (Jin et al., 2000).  In this study, we only 
found PPIA to be down-regulated in the cytosolic fraction, but no changes in its 
secretion was detected.  This could possibly be due to the lack of ROS generation in this 
study as no stress-related proteins were found to be differentially expressed.  Other than 
that, PPIA may have antagonistic impact on CHIKV replication, as was seen with               
influenza A virus replication (Liu et al., 2012), which could have potentially contributed 
to its down-regulation in the cytoplasm. 
 
CHIKV-infection was also found to decrease the expression of C3 protein, an 
integral component of the innate immune system in the clearance and inactivation of 
viral pathogens (Boere et al., 1986).  Complement C3 protein plays a protective role 
during virus infection, in particular for alphaviruses.  Studies on alphaviruses such as 
Semliki Forest virus (Boere, et al., 1986), Ross River virus (Aaskov et al., 1985), and 
Sindbis virus (Hirsch et al., 1978) have demonstrated that C3 deficient mice were 
highly susceptible towards virus infection and replication, as evidenced by enhanced 
virus titer in the main target organs.  Conversely, C3 competent mice were protected 
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against the virus infection.  Therefore, it is hypothesised that CHIKV modulated this 
protein to disrupt the host immune regulation, thereby weakening the host defence 
system and allowing the virus to invade and replicate in the liver cells. 
 
 Cathepsins are proteases contained within the lysosomes that play multiple roles 
in the cell including lysosomal protein recycling, antigen processing, maturation of 
MHC class II components, wound healing and apoptosis (Conus & Simon, 2010).  
CSTD and CSTL1 secretion was found to be down-regulated in CHIKV-infected cells 
at the protein level, despite no changes in expression at the transcript level.  Cathepsins 
have been shown to play an important role in innate immunity.  Lietzén and colleagues 
recently demonstrated the role of secreted cathepsin D in the induction of 
inflammasome response by influenza A (Lietzen, et al., 2011).  In a different study, 
cathepsin L was shown to enhance the activity of interleukin-8 (IL-8), a chemokine 
which induces chemotaxis in its target cells, including neutrophil granulocytes (Ohashi 
et al., 2003).  Thus, down-regulation of these proteins could impair the host innate 
immune response towards CHIKV infection.  Although these two proteins were 
strongly linked to CST3 in the STRING network, CST3 is known to inhibit cathepsin L 
only (Hall et al., 1995).  Hence, the exact role of CST3 in this network cannot be 
determined at this point of study. 
 
 B2M is a component of the MHC class I molecule, which is involved in the 
MHC class I antigen presentation pathway.  This pathway plays a vital role in detecting 
virus-infected cells and activating the cytotoxic T lymphocytes (CTL) to detect and 
eliminate infected cells (Hewitt, 2003).  Thus, many viruses such as adenoviruses and 
retroviruses have devised strategies to evade or interfere with this pathway (Tortorella et 
al., 2000).  For instance, cytomegalovirus (CMV) was shown to decrease the expression 
159 
 
of B2M and HLA class I in human fibroblast cells to the point where HLA class I was 
undetectable at the late stage of infection, possibly to avoid T cell recognition of 
infected cells (Barnes & Grundy, 1992).  Therefore, a similar mechanism may also be 
employed by CHIKV during early infection. 
 
 Collectively, down-regulation of different immune-related proteins of different 
immune functions during early CHIKV infection suggests the different immune 
impairment or evasive mechanisms undertaken by the virus to subvert or escape 
immune detection, thereby allowing successful replication and dissemination in the host 
cells.  Nonetheless, further functional studies would need to be carried out to provide a 
better elucidation of how these proteins work in favour of CHIKV propagation. 
 
vi) Impairment of proteins involved in ECM organisation 
 Three ECM-regulating proteins; COL5A1, TIMP1 and TIMP2, which are 
secreted proteins, were found to be down-regulated in the early stage of CHIKV 
infection, although transcript analysis showed no significant changes in expression. 
These three proteins were also linked together in the STRING network through MMP2.  
COL5A1 functions to maintain extracellular matrix integrity by acting as an anchor for 
proteoglycans in the extracellular matrix (LeBaron et al., 1989).  TIMPs are 
multifunctional proteins exhibiting various biochemical and physiological functions 
such as matrix binding, cell growth promotion and the induction of apoptosis (Higa et 
al., 2008).  TIMP2 is a known inhibitor to most activated matrix metalloproteinases 
(MMPs), particularly MMP2 and MMP14 (Tetu et al., 2006), whereas TIMP1 inhibits 
all MMPs except MMP14, MMP16 and MMP19 (Meissburger et al., 2011).  MMPs 
function in remodelling ECM by degrading its component proteins, including collagen 
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and fibronectin (O'Farrell & Pourmotabbed, 2000).  Down-regulation of TIMP1 and 
TIMP2 will lead to increase activation of MMPs, particularly MMP2, and this 
occurrence together with down-regulation of COL5A1 have been correlated with 
increased replication of Hepatitis C virus in human liver stellate cells (Watanabe et al., 
2011).  Hence, it is postulated CHIKV may also manipulate these proteins in a similar 
manner for successful replication in our in vitro study. 
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CHAPTER 6 
CONCLUSION 
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This study aimed to investigate the early host response towards CHIKV 
infection, using WRL-68 cells as the in vitro study model.  By using flow cytometry and 
IIFA, the optimal infection condition for early host response study was determined to be 
24 hours post-infection incubation at the MOI of 5.0.  Comparison between the MOCK 
control and CHIKV-infected whole cell proteome and secretome profiles revealed 53 
and 34 differentially expressed protein spots, respectively.  MS/MS analysis resulted in 
the identification of 45 proteins from the whole cell proteome sample, while 20 proteins 
from the secretome sample were successfully identified.  The expression for CDK1, 
PDHA1 and RAN proteins were validated by Western blot.   
 
Functional classification and STRING network analysis of these proteins 
showed a widespread alteration of the whole cell proteome and secretome during early 
CHIKV infection.  The most notable outcome of the infection is the disruption of 
metabolic processes, with 20 down-regulated proteins involved mainly in the 
carbohydrate, nucleotide and lipid metabolism.  Only PDHA1 was up-regulated upon 
infection.  This suggests that the host metabolic machinery is important for CHIKV 
infection.   
 
CHIKV infection was also found to hijack the host transcription and translation 
processes through down-regulation of PCBP1, EEF-2, eIF2B1 and eIF3H, and up-
regulation of hnRNP C1/C2, a protein of importance in promoting DENV survival in 
host cells.  Down-regulation of UPP-related proteins, UBE2N and PSMA6, as well as 
cell cycle protein, CDK1, was also observed.  Meanwhile, the SET protein, an inhibitor 
of cyclin B-CDK1 activity was up-regulated.  Impairment of the host immune-related 
proteins, a typical event during virus infection, was evident in this study.  CHIKV 
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infection caused a decrease in the protein levels of PPIA, C3, CTSD, CTSL1 and B2M, 
possibly to evade the host immune system.   
 
Proteins involved in other functions such as protein transport, ECM regulation, 
signalling and chaperoning were also deregulated although the exact significance of 
these changes remain unclear.  Finally, transcript expression of 16 selected proteins 
showed positive correlation with the protein expression, while most of the other genes 
evaluated did not show any significant differences at the gene level.  This suggests that 
the observed protein expression changes are not exclusively caused by alterations at 
gene levels, and that other host factors are at play.   
 
In conclusion, this study provides new insights into the plausible mechanisms 
involved during early CHIKV infection, which complements previous study on the late 
host response in neonate mice.  Nonetheless, further studies that look into the functional 
characterisation of these proteins either through reverse genetics and/or knock-out 
studies are warranted to explore the effects and consequences of alterations of these 
proteins on CHIKV replication success and the eventual host cell demise.  
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Appendix A1: Protein names and gene symbols used in the whole cell proteome network 
Protein name Gene Name
 
Protein SET SET 
Nucleophosmin (B23) NPM1 
Reticulocalbin-1   RCN1 
Heterogeneous nuclear ribonucleoproteins C1/C2 HNRNPC 
Keratin, type I cytoskeletal 17  KRT17 
Keratin, type II cytoskeletal 7  KRT7 
Chromobox protein homolog 3 CBX3 
Pyruvate dehydrogenase E1 component subunit alpha, mitochondrial PDHA1 
Spartin SPG20 
Phosphoglucomutase-2 PGM2 
Elongation factor-2 EEF2 
Gamma-enolase ENO2 
Hydroxymethylglutaryl-CoA synthase, cytoplasmic HMGCS1 
Copine-1 CPNE1 
Spermidine synthase SRM 
Ubiquitin-conjugating enzyme E2 N UBE2N 
Inosine triphosphate pyrophosphatase ITPA 
Adenine phosphoribosyltransferase APRT 
Nicotinamide phosphoribosyltransferase NAMPT 
Rab GDP dissociation inhibitor beta GDI2 
La ribonucleoprotein  SSB 
Alpha-enolase ENO1 
Adenylosuccinate synthetase isozyme 2 ADSS 
Isocitrate dehydrogenase [NADP] cytoplasmic IDH1 
Eukaryotic translation initiation factor 3 subunit H EIF3H 
Poly(rC)-binding protein1 (hnRNP E1)            PCBP1 
Phosphoserine aminotransferase PSAT1 
Aldo-keto reductase family 1 member C2 AKR1C2 
Pirin PIR 
Ribose-phosphate pyrophosphokinase1 PRPS1 
Glucosamine-6-phosphate isomerase 1 GNPDA1 
S-formylglutathione hydrolase              ESD 
Actin-related protein 2/3 complex subunit 2 (p34-ARC) ARPC2 
Electron transfer flavoprotein subunit alpha, mitochondrial ETFA 
Guanine nucleotide-binding protein subunit beta-2-like 1  GNB2L1 
Cyclin-dependent kinase 1 CDK1 
Translation initiation factor eIF-2B subunit alpha EIF2B1 
Phosphoglycerate mutase 1 PGAM1 
Proteasome subunit alpha type-6 PSMA6 
Isopentyl-diphosphate Delta-isomerase 1  IDI1 
Triosephosphate isomerase TPI1 
S-methyl-5-thioadenosine phosphorylase MTAP 
Thioredoxin-like protein 5 TXNDC17 
Fatty-acid binding protein, epidermal FABP5 
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Appendix A1: Continued 
Peptidyl-prolyl cis-trans isomerase A (Cyclophilin A) PPIA 
Proteasome subunit alpha type-1 PSMA1 
Proteasome subunit alpha type-2 PSMA2 
Proteasome subunit alpha type-3 PSMA3 
Proteasome subunit alpha type-4 PSMA4 
Proteasome subunit beta type-1 PSMB1 
Proteasome subunit beta type-2 PSMB2 
Proteasome subunit beta type-3 PSMB3 
Proteasome subunit beta type-4 PSMB4 
Proteasome subunit beta type-5 PSMB5 
Cyclin-dependent kinase 2 CDK2 
Cyclin-dependent kinase inhibitor 1B CDKN1B 
Cyclin A1 CCNA1 
Cyclin A2 CCNA2 
Cyclin B1 CCNB1 
Cyclin B2 CCNB2 
Actin related protein 2/3 complex subunit 3 APRC3 
Actin related protein 2/3 complex subunit 4 (20 kDa) ARPC20 
Ubiquitin-conjugating enzyme E2 variant 2 UBE2V2 
Electron transfer flavoprotein, beta polypeptide ETFB 
Pyruvate dehydrogenase beta PDHB 
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Appendix A2: Protein names and gene symbols used in the secretome network 
Protein ID Gene Name 
Cathepsin D CTSD 
Cathepsin L1 CTSL1 
Complement C3 precursor C3 
β-2 microglobulin B2M 
Cystatin-3 CST3 
Glutamate receptor subunit 3A precursor GRIN3A 
Ran-specific GTPase-activating protein RANBP1 
GTP-binding nuclear protein Ran RAN 
Vesicular integral-membrane protein VIP36 precursor LMAN2 
Tubulointerstitial nephritis antigen-like precursor TINAGL1 
Collagen alpha-1(V) chain precursor COL5A1 
Cadherin-2 precursor CDH2 
Tissue inhibitor of metalloproteinases 2 (TIMP-2) TIMP2 
Tissue inhibitor of metalloproteinases 1 (TIMP-1) TIMP1 
Aldose reductase AKR1B1 
Proprotein convertase subtilisin/kexin type 9 precursor PCSK9 
Protein-L-isoaspartate O-methyltransferase PCMT1 
Renin receptor precursor (ATPase H(+)-transporting lysosomal 
accessory protein 2) 
ATP6AP2 
Moesin MSN 
Plasminogen activator inhibitor 1 precursor SERPINE1 
Karyopherin (Importin) beta 1 KPNB1 
Regulator of chromosome condensation 1 RCC1 
Exportin 1 XPO1 
Ran binding protein 2 RANBP2 
Ran GTPase activating protein 1 RANGAP1 
SUMO1 pseudogene 3 SUMO 
Ubiquitin-conjugating enzyme E2I UBE2I 
Axin 1 AXIN1 
Glycogen synthase kinase 3 beta GSK3B 
Beta transducin repeat containing BTRC 
Transcription factor 7-like 2 TCF7L2 
Catenin alpha 1 CTNNA1 
Catenin beta 1 CTNNB1 
Presenilin 1 PSEN1 
Cadherin 1 CDH1 
Lymphoid enhancer-binding factor 1 LEF1 
CD8a molecule CD8A 
Matrix metalloproteinase 2 MMP2 
Major histocompatibility complex , class I, A HLA-A 
Complement factor H CFH 
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Appendix B: Concentration and purity of total RNA extracted from mock control and 
CHIKV-infected WRL-68 cell pellets for cell lysate and secretome qPCR analysis 
Sample 
RNA 
concentration 
(µg/ml) 
A260:A280 
ratio 
A260:A230 
ratio 
Whole cell proteome    
Mock control #1 757 2.013 2.048 
Mock control #2 797 1.841 2.278 
Mock control #3 824 2.130 2.221 
CHIKV-infected #1 546 1.881 2.065 
CHIKV-infected #2 558 1.941 1.958 
CHIKV-infected #3 301 1.802 2.198 
Secretome    
Mock control #1 389 1.813 2.250 
Mock control #2 354 1.811 2.351 
Mock control #3 275 1.830 1.977 
CHIKV-infected #1 274 1.850 3.054 
CHIKV-infected #2 219 1.903 1.938 
CHIKV-infected #3 285 1.801 1.835 
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Appendix C: Primer sequences and efficiency test results 
Gene name
 
Primer sequences 
Primer efficiency 
Slope 
Efficiency 
(%) 
Endogenous control   
ACTB_F781 5’-CTCTTCCAGCCTTCCTTCCT-3’ 
-3.48 93.82 
ACTB_R896 5’-AGCACTGTGTTGGCGTACAG-3’ 
Primer pairs for selected whole cell proteome    
UBE2N_F258 5’- CGTCACAGGGGCTATTTGTT -3’ 
-3.38 97.81 
UBE2N_R379 5’- CCTGTGGATCATCTGGCTCT -3’ 
PSMA6_F100 5’- CAGGGTGGCCTTACATCAGT -3’ 
-3.40 97.00 
PSMA6_R249 5’- CATTCCGGTCATCACACAAC -3’ 
SET_F576 5’- GAAGAGGCAGCATGAGGAAC -3’ 
-3.27 102.24 
SET_R720 5’- ATCATCCATATCGGGAACCA -3’ 
GNB2L1_F509 5’- GGGACAAGCTGGTCAAGGTA -3’ 
-3.32 99.99 
GNB2L1_R616 5’- GGGATCCATCTGGAGAGACA -3’ 
CDK1_F123 5’- GGAAGGGGTTCCTAGTACTGC -3’ 
-3.39 97.32 
CDK1_R223 5’- TGGAATCCTGCATAAGCACA -3’ 
PDHA1_F473 5’- AGAACTTCTACGGGGGCAAT -3’ 
-3.34 99.38 
PDHA1_R616 5’- CGAATATCTGGCCCTGGTTA -3’ 
ENO1_F765 5’- CTCCGTGACCGAGTCTCTTC -3’ 
-3.47 94.05 
ENO1_R908 5’- CCAGTCTTGATCTGCCCAGT -3’ 
IDH1_F888 5’- TTGTCCAGATGGCAAGACAG -3’ 
-3.43 95.71 
IDH1_R1036 5’- GCTTTGCTCTGTGGGCTAAC -3’ 
PGAM1_F585 5’- GGCTATCATGGAGCTGAACC -3’ 
-3.33 99.84 
PGAM1_R710 5’- TCTTCATCCCCCAGAAACTG -3’ 
TPI1_F573 5’- ATGGCTGAAGTCCAACGTCT -3’ 
-3.51 92.69 
TPI1_R695 5’- ACAAGGAAGCCATCCACATC -3’ 
HMGCS1_F1290 5’- AGAGGACACCCATCATTTGG -3’ 
-3.35 98.94 
HMGCS1_R1405 5’- GCCGAGCGTAAGTTCTTCTG -3’ 
IDI1_F601 5’- TGGGGTGAACATGAAATTGA -3’ 
-3.40 96.68 
IDI1_R744 5’- AATTTCACCACTGGCTGCTT -3’ 
NAMPT_F1305 5’- GCCAGCAGGGAATTTTGTTA -3’ 
-3.41 96.51 
NAMPT_R1404 5’- TGTCACCTTGCCATTCTTGA -3’ 
ITPA_F166 5’- AAATGTCAGGAGGCAGTTCG -3’ 
-3.41 96.52 
ITPA_R309 5’- GAGCTGGTGGAGACCTTCAG -3’ 
APRT_F190 5’- CTAGACTCCCGAGGCTTCCT -3’ 
-3.56 91.00 
APRT_R336 5’- AATCTCCAGCTCAGCCTTCC -3’ 
ADSS_F722 5’- CCCTACATGGACCACCAAAG -3’ 
-3.36 98.55 
ADSS_R868 5’- CATTTTGAGGTGGCATACCC -3’ 
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Appendix C: Continued 
MTAP_F590 5’- CCACAGTTCCAGAGGTGGTT -3’ 
-3.42 95.99 
MTAP_R695 5’- GAAACTGCTTCCTCGTGCTC -3’ 
PRPS1_F49 5’- GACATGGCTGACACTTGTGG -3’ -3.45 94.87 
PRPS1_R154 5’- GACCGGAGAAGATTCCATGA -3’ 
PSAT1_F282 5’- AGCAGGAAGGTGTGCTGACT -3’ 
-3.49 93.38 
PSAT1_R387 5’- CCCAAGTTTAGGGTGAACGA -3’ 
CBX3_F244 5’-GCTGGCAAAGAAAAAGATGG -3’ 
-3.24 103.38 
CBX_R346 5’-CTCTTGGTTTGTCAGCAGCA -3’ 
PIR_F482 5’- CCAAGGTTTACACTCGCACA -3’ 
-3.49 93.62 
PIR_R621 5’- ATCATCGGGCCCAATATACA -3’ 
EEF2_F612 5’- CCTCTATGCCAGTGTGCTGA -3’ 
-3.35 98.91 
EEF2_R796 5’- TCCTGTTCAAAACCCCGTAG -3’ 
eIF3H_F104 5’- CCGTGAAGCAAGTGCAGATA -3’ 
-3.43 95.89 
eIF3H_R215 5’-ACAACCAGACCCAAAAGCAC -3’ 
eI2B1_F117 5’- GGAGACAATCCAGGGTCTGA -3’ 
-3.38 97.81 
eI2B1_R232 5’- GACTGATGAAGCGGAGGAAG -3’ 
HNRNPC_F95 5’- ATGTGGAGGCAATCTTTTCG -3’ 
-3.53 92.14 
HNRNPC_R218 5’- CTGCCATCCTCTCCTGCTAC -3’ 
PCBP1_F96 5’- AGGGGAGTCGGTTAAGAGGA -3’ 
-3.54 91.77 
PCBP1_R218 5’- TCTTCCTCCAGCTTGTCGAT -3’ 
SSB_F90 5’- GCCACGGGACAAGTTTCTAA -3’ 
-3.38 97.68 
SSB_R235 5’- GTTCTGCCTTGGATTTGCTC -3’ 
KRT7_F508 5’- CAGGATGTGGTGGAGGACTT -3’ 
-3.39 97.32 
KRT7_R623 5’- TTGCTCATGTAGGCAGCATC -3’ 
ARPC2_F108 5’- AGATTTCGATGGGGTCCTCT -3’ 
-3.32 100.07 
ARPC2_R212 5’- CCATGTGCCTGAAGTTCCTT -3’ 
NPM1_F435 5’- TGGAGGTGGTAGCAAGGTTC-3’ 
-3.38 97.58 
NPM1_R582 5’- TTTCTTCACTGGCGCTTTTT -3’ 
CPNE1_F1394 5’- GACCCCTGCATACACGTTCT -3’ 
-3.35 98.91 
CPNE1_R1542 5’- GGCCCTGAAGTATGAGACCA -3’ 
GDI2_F965 5’- GACCAGCTTTGGAGCTCTTG -3’ 
-3.24 103.68 
GDI2_R1072 5’- TGCGGGAAATAAAGATCTGG -3’ 
ETFA_F224 5’- AAGTTCTGGTGGCTCAGCAT -3’ 
-3.33 99.88 
EFTA_R373 5’- CTGCTACTCTGGGCAAAAGG -3’ 
PPIA_F380 5’- TGGTGTTTGGCAAAGTGAAA -3’ 
-3.42 96.11 
PPIA_R494 5’- TCGAGTTGTCCACAGTCAGC -3’ 
RCN1_F202 5’- GACTCCAAGACCTTCGACCA -3’ 
-3.34 99.45 
RCN1_R321 5’- CCAGGTTTTCAGCTCCTCAG -3’ 
TXNDC17_F71 5’- GCAAGACCATTTTCGCCTAC -3’ 
-3.56 90.94 
TXNDC17_R181 5’- TAATGTGCTTCAGCCCCTCT -3’ 
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Primer pairs for selected secretome    
B2M_F25 5’- AGGCTATCCAGCGTACTCCA -3’ 
-3.44 95.37 
B2M_R167 5’- TCAATGTCGGATGGATGAAA -3’ 
CTSL1_F35 5’- TGGGAATTGCCTCAGCTACT -3’ 
-3.54 91.51 
CTSL1_R161 5’- TTCTCCCACACTGCTCTCCT -3’ 
CTSD_F883 5’- GACACAGGCACTTCCCTCAT -3’ 
-3.46 94.69 
CSTD_R1031 5’- CCTCCCAGCTTCAGTGTGAT -3’ 
C3_F2645 5’- ACCAGCAGACCGTAACCATC -3’ 
-3.53 92.11 
C3_R2744 5’- GCAGCCTTGACTTCCACTTC -3’ 
PCSK9_F143 5’- GACGATGCCTGCCTCTACTC -3’ 
-3.49 93.46 
PCSK9_R250 5’- AAAGTTGGTCCCCAAAGTCC -3’ 
COL5A1_F1258 5’- TACTACGACCCCACCAGCTC -3’ 
-3.42 96.03 
COL5A1_R1372 5’- GTTCTCCCTTTTGGCCTTTC -3’ 
TIMP1_F237 5’- TGACATCCGGTTCGTCTACA -3’ 
-3.58 90.14 
TIMP1_R338 5’- TGCAGTTTTCCAGCAATGAG -3’ 
TIMP2_F143 5’- AAGCGGTCAGTGAGAAGGAA -3’ 
-3.45 94.98 
TIMP2_R250 5’- TCTCAGGCCCTTTGAACATC -3’ 
CDH2_F1223 5’- AGGATCAACCCCATACACCA -3’ 
-3.49 93.33 
CDH2_R1347 5’- TGGTTTGACCACGGTGACTA -3’ 
CST3_F174 5’- CGAGTACAACAAAGCCAGCA -3’ 
-3.55 91.29 
CST3_R307 5’- GGGTCTTGGTACACGTGGTT -3’ 
PCMT1_F691 5’- TTAAAGCCCGGAGGAAGATT -3’ 
-3.58 90.44 
PCMT1_R817 5’- GCACGTATATCACCCCCATC -3’ 
RAN_F356 5’- TGTGTGGCAACAAAGTGGAT -3’ 
-3.40 96.72 
RAN_R500 5’- TTCCTAGCAAGCCAGAGGAA -3’ 
RANBP1_F183 5’- GAACGATCTCCCAGAATGGA -3’ 
-3.42 95.94 
RANBP1_R305 5’- TGGTTGGCACAGATCTTCAG -3’ 
SERPINE1_F733 5’- GACATCCTGGAACTGCCCTA -3’ 
-3.41 96.64 
SERPINE1_R870 5’- GGTCATGTTGCCTTTCCAGT -3’ 
ATP6AP2_F283 5’- TCGTACCCTTTGGAGAATGC -3’ 
-3.26 102.81 
ATP6AP2_R385 5’- GAGCCAACTGCAAAACAACA -3’ 
Differential Proteome Analysis of Chikungunya Virus
Infection on Host Cells
Christina Li-Ping Thio1,4*, Rohana Yusof2,4, Puteri Shafinaz Akmar Abdul-Rahman2,3, Saiful
Anuar Karsani1,3,4*
1 Institute of Biological Sciences, Faculty of Science, University of Malaya, Kuala Lumpur, Malaysia, 2Department of Molecular Medicine, Faculty of Medicine, University of
Malaya, Kuala Lumpur, Malaysia, 3Medical Biotechnology Laboratory, Faculty of Medicine, University of Malaya Centre for Proteomics Research (UMCPR), University of
Malaya, Kuala Lumpur, Malaysia, 4Drug Design and Development Research Group (DDDRG), University of Malaya, Kuala Lumpur, Malaysia
Abstract
Background: Chikungunya virus (CHIKV) is an emerging mosquito-borne alphavirus that has caused multiple
unprecedented and re-emerging outbreaks in both tropical and temperate countries. Despite ongoing research efforts,
the underlying factors involved in facilitating CHIKV replication during early infection remains ill-characterized. The present
study serves to identify host proteins modulated in response to early CHIKV infection using a proteomics approach.
Methodology and Principal Findings: The whole cell proteome profiles of CHIKV-infected and mock control WRL-68 cells
were compared and analyzed using two-dimensional gel electrophoresis (2-DGE). Fifty-three spots were found to be
differentially modulated and 50 were successfully identified by MALDI-TOF/TOF. Eight were significantly up-regulated and
42 were down-regulated. The mRNA expressions of 15 genes were also found to correlate with the corresponding protein
expression. STRING network analysis identified several biological processes to be affected, including mRNA processing,
translation, energy production and cellular metabolism, ubiquitin-proteasome pathway (UPP) and cell cycle regulation.
Conclusion/Significance: This study constitutes a first attempt to investigate alteration of the host cellular proteome during
early CHIKV infection. Our proteomics data showed that during early infection, CHIKV affected the expression of proteins
that are involved in mRNA processing, host metabolic machinery, UPP, and cyclin-dependent kinase 1 (CDK1) regulation (in
favour of virus survival, replication and transmission). While results from this study complement the proteomics results
obtained from previous late host response studies, functional characterization of these proteins is warranted to reinforce
our understanding of their roles during early CHIKV infection in humans.
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Introduction
Chikungunya (CHIK) is a long-neglected disease that only
recently began to garner attention from the scientific community
following devastating outbreaks that struck India and the Indian
Ocean Islands from 2004 to 2007. This disease causes substantial
morbidity and an estimated death rate of 1:1,000 [1]. Despite
being perceived as a tropical disease, recent CHIK cases and
sporadic outbreaks were documented in temperate regions,
suggesting that this infectious disease is no longer geographically
restricted to tropical countries [2]. In Malaysia, three separate
outbreaks have been reported over the past 15 years [3,4,5].
The causative agent for CHIK infection is the chikungunya
virus (CHIKV), an alphavirus belonging to the family Togaviridae
[6]. CHIKV is transmitted by the mosquito Aedes aegypti and Aedes
albopictus. CHIKV can be genotypically classified into the East
Central South African, West African and Asian genotypes [7].
Upon infection, CHIKV causes an acute illness characterized by
the classical triad of symptoms of fever, rash and debilitating
arthralgia which can persist for years. However, cases from recent
outbreaks saw an increasing occurrence of atypical clinical
manifestations such as neurological and cardiovascular complica-
tions [8]. As there is currently no effective vaccine or antiviral
regimen to combat this disease, treatment is solely palliative. All
things considered, it is not surprising that CHIK is now regarded
as a potential health problem in need of a solution.
Recent research efforts have focused on understanding the viral
tropism and mechanisms associated with the pathogenesis of
CHIK infection. In vitro studies using a panel of mammalian cell
lines showed rapid induction of cytopathic effects and cell death
via apoptosis in most adherent cell lines with the exception of
blood-derived cell lines [9]. Autophagic process and apoptosis
were also recently shown to facilitate CHIKV dissemination
[10,11]. At the molecular level, proteomics studies on CHIKV
interaction with vector and mammalian host proteins have
unravelled new clues in elucidating the mechanisms involved in
viral replication and transmission from vector to host as well as
disease progression in host cells [12,13,14]. Despite the extensive
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research, much remains to be discovered to fully comprehend the
pathogenesis of CHIKV.
Contrary to the aforementioned proteomics research which
investigated the late host response to CHIKV infection [13], our
present study aims to identify proteins altered during early
infection in the host cells by means of 2-dimensional gel
electrophoresis (2-DGE). The global proteome profile of
CHIKV-infected WRL-68 cells was compared with uninfected
mock control cells to single out differentially expressed spots for
mass spectrometric (MS) identification with subsequent Western
blot validation, as well as transcript expression analysis. Results
showed widespread alteration of proteins involved in several
biological processes known to play essential roles in virus
replication. While this study provides new insights into CHIKV
pathogenesis, functional characterization of these proteins will be
required to better understand their roles during early infection.
Results
Cytopathogenicity of CHIKV
The cytopathic nature of CHIKV infection in mammalian cell
lines, which was reported in several studies [9,15,16], was
observed in WRL-68 cells infected with the virus at varying
MOI (MOI of 0.5, 1.0, 5.0 and 10.0) and time-points (24 and
48 h). This isolate was found to induce cytopathic effects (CPE),
characterized by cell shrinkage and detachment, within 48 h of
infection, as depicted in Figure 1A. CPE induction was also
determined to be MOI-dependent, as cells infected at higher MOI
(MOI of 5.0 and 10.0) showed more profound CPE than that of
cells infected at low MOI (MOI of 0.5 and 1.0), at 48 h post-
infection (p.i.). On the contrary, no significant changes in
morphology were observed at 24 h p.i. at the MOI of 0.5, 1.0
and 5.0, while mild CPE was observed at the MOI of 10.0. Mock
control cells were cultured in parallel and served as negative
control.
Optimization of the infection conditions for early
infection study
As the aim of this study was to investigate alterations in the host
cellular proteome during early CHIKV infection (i.e., the stages
preceding cell death), the infection conditions (MOI and
incubation time-point) were meticulously optimized to maximize
infection while maintaining cell death at a minimum level.
Relative quantification of percentages of infection and cell death
of WRL-68 cells infected at various MOI (MOI of 0.5, 1.0, 5.0 and
10.0) for 24 and 48 h was determined by flow cytometric analysis.
The results showed that WRL-68 cells infected at the MOI of
5.0 for 24 h recorded significantly high percentage of infection at
74.77% (Figure 1B). Percentage of cell death (25.90%), albeit
higher than mock control cells (14.33%), showed no significant
differences when compared with cells infected at lower MOI (MOI
of 0.1 and 0.5) at 24 h p.i. (Figure 1C). Furthermore, prolonging
the incubation period significantly increased the percentage of cell
death to more than 50%, irrespective of the MOI used.
Immunostaining with anti-CHIK E2 mAb 3E4 revealed intense
cytoplasmic staining in infected cells at the selected conditions,
confirming infection, whereas no staining was apparent with the
mock control cells (Figure 1D). Taken together, the MOI of 5.0
and 24 h incubation time-point were determined to be the optimal
conditions for early CHIKV infection study.
2-DGE profiles of CHIKV infected WRL-68 cells
Comparative proteomics analysis between mock control and
CHIKV-infected WRL-68 whole cell proteome was carried out
using 2-DGE. Five biological replicates (n = 5) were analysed for
each group. A typical gel profile for WRL-68 whole cell proteome
is shown in Figure 2 (The representative proteome maps for mock
control and CHIKV-infected WRL-68 cells are shown in
Supplementary Figure S1). Image analysis using the ImageMas-
terTM 2D Platinum v7.0 software detected more than 1300 spots
in each gel. Comparison of the normalized percentage spot
volume between both groups revealed 53 differentially expressed
spots (Fold-change.1.3, p,0.05). Of these, 44 demonstrated
reduced spot intensity whereas nine exhibited increased spot
intensity. All 53 protein spots were manually excised for
subsequent tryptic digestion and tandem MS identification.
Mass spectrometric identification of differentially
expressed proteins
Of the 53 protein spots subjected to MALDI-TOF/TOF
identification, 50 were successfully identified, corresponding to 45
proteins (Table 1). Unique peptides identified for each protein are
listed in Supplementary Table S1. Three protein spots were not
identified most likely due to low abundance, resulting in low
confidence score. More than one spot was identified for four
proteins; guanine nucleotide-binding protein subunit beta-2-like 1
(GNB2L1), Rab GDP dissociation inhibitor beta (GDI2), eukary-
otic elongation factor-2 (EEF2) and triosephosphate isomerase
(TPI1)). These spots are most likely different isoforms of the
protein. Functional classification based on existing information
from Swiss-Prot/TrEMBL database identified proteins involved in
metabolism (42.22%) and transcription/translation (17.78%) to be
mainly affected by CHIKV infection (Figure 3A), whereas
classification based on sub-cellular localization showed that most
altered proteins to be of cytoplasmic (56.90%) and nuclear origin
(17.24%) (Figure 3B).
Protein network analysis
STRING network analysis of protein-protein interactions was
performed to identify functionally linked proteins and determine
the potential biological processes affected [17]. The network is
presented under confidence view, whereby stronger associations
are represented by thicker lines or edges and vice versa, whereas
proteins are represented as nodes. Twenty additional interacting
proteins were added to provide a more comprehensive view of the
interactions. The protein names and gene symbols used in this
network are listed in Supplementary Table S2. All gene symbols
were derived from the HUGO Gene Nomenclature Committee
(HGNC) (http://www.genenames.org). Figure 4 shows the
interaction between 45 identified proteins and the additional
interactors. Thirty seven proteins were found to be linked either
directly or indirectly through one or more interacting proteins,
suggesting the existence of reported functional linkages. Eight
biological processes were determined to be significantly involved
(p,0.05 based on false discovery rate (FDR) correction) in this
network, including energy production, cell cycle regulation, gene
expression, mRNA metabolism, protein metabolism and modifi-
cation, DNA replication and ubiquitin-protein ligase activity
(Table 2).
Immunoblot validation of proteomics data
Two proteins, CDK1 and PDHA1, representing the down- and
up-regulated groups respectively, were randomly selected for
Western blot validation. GAPDH was used as the loading control
for PDHA1 as both PDHA1 and ACTB have similar molecular
mass of ,43 kDa, and thus, cannot be stained together on the
same blot. Immunoblots confirmed their down- and up-regulation,
Proteome of Chikungunya Virus-Infected Host Cells
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as shown in Figures 5A and 5B. Densitometric analysis revealed
fold differences of 21.42 and 1.72 CDK1 and PDHA1
respectively (Figures 5C and 5D), which was comparable to the
observed 21.77 and 1.96 fold-changes in 2-DGE analysis.
Transcript expression analysis of selected altered
proteins
The transcript expression of 36 selected proteins was evaluated
using real-time qPCR (The gene names and primer sequences are
listed in Supplementary Table S3). All primers had amplification
efficiencies within the acceptable range of 90 to 110% (Slope
values between 23.1 to 23.6). It is a known fact that mRNA
expression do not always correlate with protein expression [18]. In
our study however, the direction of mRNA and protein expression
changes of 15 proteins including CDK1 and PDHA1 were the
same (Table 3). On the other hand, the transcript expression of
four other proteins; adenine phosphoribosyltransferase (APRT),
electron transport flavoprotein subunit alpha (ETFA), actin-related
protein 2/3 complex subunit 2 (ARPC2) and cyclophilin A (PPIA),
showed the opposite direction of expression change despite being
statistically significant. Meanwhile, the mRNA expression levels of
17 other proteins showed no statistically significant differences.
Discussion
It is well-established that CHIKV induces rapid and profound
CPE in human host cells which culminate in cell death via
apoptosis. The events preceding the inevitable cell demise,
however, remain ill-characterized. A previous proteomic study
on new-born mice focused on investigating the dynamic overview
of altered protein expression during late stages of CHIKV
infection, whereby alterations of stress, inflammation, urea cycle,
energy metabolism and apoptotic-related proteins were implicated
in the observed disease pathogenesis [13]. In this study, we shifted
the focus to examining global changes of the host cell proteome
during early CHIKV infection, with aims of identifying key
proteins that are potentially involved in facilitating CHIKV
replication. It has been reported that during early infection, viral
replication and dissemination occurs rapidly through manipula-
Figure 1. Optimization of the MOI and incubation time-point for early CHIKV infection study. (A) Morphological examination of WRL-68
cells infected at the MOI of 0.5, 1.0, 5.0 and 10.0 at 24 and 48 h incubation revealed a MOI and time-dependent induction of CPE by CHIKV. All images
were captured at 100X magnification. (B) Flow cytometric quantification of percentage of cell death by AV/PI double staining of cells. Error bars
indicate standard deviation of three biological replicates. (C) Flow cytometric quantification of percentage of infection by immunostaining of cells
with anti-CHIK E2 mAB 3E4 (1:100 dilution). Error bars indicate standard deviation of three biological replicates. (D) Confirmation of infection via
indirect immunofluorescence assay at the optimized MOI of 5.0 at 24 h p.i. Mock cells served as negative control. All images were captured at100X
magnification.
doi:10.1371/journal.pone.0061444.g001
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tion of the host cell machinery owing to the simplicity of the viral
makeup [19]. By collating data from proteomics and bioinfor-
matics analyses, we inferred the potential manipulation or
subversion of various important cellular processes including
mRNA and protein metabolism, energy production, ubiquitin-
proteasome pathway (UPP) and cell cycle regulation by CHIKV.
Alteration of proteins involved in mRNA processing and
translation machinery
Virus hijacking of the host mRNA processing and translational
machinery is an essential process for virus replication. Viruses with
positive sense RNA in particular, have been shown to recruit
components of the host protein biosynthesis machineries for viral
RNA and protein synthesis [20]. In the current study, we
identified several deregulated proteins involved in mRNA
processing and translation, including heterogeneous nuclear
ribonucleoproteins C1/C2 (hnRNP C1/C2), poly(rC)-binding
protein 1 (hnRNP E1), elongation factor- 2 (EEF-2), translation
initiation factor EIF-2B subunit alpha (eIF2B1) and eukaryotic
translation initiation factor 3 subunit H (eIF3H).
Heterogeneous ribonucleoproteins (hnRNPs) are complexes of
RNA and proteins involved in an array of cellular functions such
as transcription, pre-mRNA processing and cytoplasmic mRNA
translation and turnover [21]. In our study, hnRNP C1/C2 was
found to be up-regulated by 3.10 fold while hnRNP E1 was down-
regulated by 1.42 fold. Transcript level of hnRNP E1 mRNA
showed similar down-regulation while the mRNA expression of
hnRNP C1/C2 was not significantly altered, suggesting that post-
transcriptional and post-translational modification may play a role
in modulating the expression of the latter protein. In a previous
study, hnRNP C1/C2 was shown to promote dengue virus
survival in host cells [22] while hnRNP E1 inhibits vesicular
somatitis virus replication [23]. Ergo, the up-regulation of hnRNP
C1/C2 in the present study may signify its recruitment by CHIKV
whereas hnRNP E1 may possibly exert negative effects towards
CHIKV propagation which is counteracted by its inhibition.
Translation factors are known to play crucial roles in viral RNA
and protein synthesis and different viruses exert different
mechanisms to modulate host translational proteins to their
benefit, as shown in several studies [24,25,26]. Alphaviruses have
been shown to induce global shutoff of protein synthesis by
inhibiting or modifying host translational factors [27]. CHIKV-
induced host translational shutoff was recently shown to occur,
through an unidentified protein kinase R (PKR)-independent
mechanism [28]. In this study, down-regulation of proteins
involved in initiation of translation (eIF2B1 and eIF3SH) and
elongation of the newly synthesised polypeptide chain (EEF-2) was
observed, although at the transcript level, only EEF-2 and eIF2B1
genes were down-regulated. The exact roles of these proteins in
host translational shutoff, however, cannot be ascertained at this
Figure 2. Reference map of the whole cell proteome of WRL-68 cells. Forty mg of protein sample were focused on 13 cm, pH 3–10 linear IPG
drystrips, followed by second dimension SDS-PAGE separation on 12.5% polyacrylamide gel which was silver stained. Five biological replicates (n = 5)
for each group (Mock control and CHIKV-infected) were analyzed using ImageMasterTM 2D Platinum v7.0 software. Fifty-three spots were determined
to be differentially expressed (Fold-change .1.3, p,0.05). The position of each spot is indicated by circles on the proteome map. The uppercase ‘U’
and ‘D’ denote up-regulated and down-regulated spots, respectively.
doi:10.1371/journal.pone.0061444.g002
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point. Nonetheless, down-regulation of these proteins may inhibit
the host translational machinery to a certain extent, possibly
contributing to the observed down-regulation of most altered
proteins in this study.
Differential expression of proteins involved in cellular
energy production and metabolism
Of the 19 regulated proteins identified to be involved in cellular
metabolism, 18 were down-regulated. Only PDHA1, a subunit of
the pyruvate dehydrogenase complex involved in transforming
pyruvate to acetyl-CoA in the tricarboxylic acid (TCA) cycle [29],
was up-regulated by 1.96 fold. Up-regulation of this protein was
further confirmed by immunoblot (Figures 5B and 5D). Transcript
expression study on 14 selected genes revealed that 8 genes;
PHDA1, alpha-enolase (ENO1), isocitrate dehydrogenase (IDH1),
isopentyl-diphosphate Delta-isomerase 1 (IDI1), adenylosuccinate
synthetase isozyme 2 (ADSS), ribose-phosphate pyrophosphoki-
nase 1 (PRPS1), S-methyl-5-thioadenosine phosphorylase (MTAP)
and phosphoserine aminotransferase (PSAT1), had expression
changes of the same directionality as the protein expression
(Table 1).
Based on the proteomics analysis, energy production in WRL-
68 cells was expected to be significantly affected through reduced
expression of glycolytic enzymes including ENO1, TPI1 and
phosphoglycerate mutase 1 (PGAM1), as well as down-regulation
of IDH1 which catalyzes the oxidative decarboxylation of
isocitrate to alpha-ketoglutarate in the TCA cycle [30]. Four
proteins associated with the adenine salvage pathway, namely
PRPS1, ADSS, MTAP and adenine phosphoribosyltransferase
(APRT), were also down-regulated. Similar dysregulation was
observed with IDI1 and hydroxymethylglutaryl-CoA synthase
(HMGCS1), two key enzymes involved in the biosynthesis of
cholesterol, coenzyme Q and isoprenylated proteins through the
mevalonate pathway [31].
Effects on proteins involved in the UPP
UPP is an essential intracellular system for protein degradation,
with multiple cellular functions including cell cycle regulation,
apoptosis, DNA repair, signal transduction and transcriptional
Figure 3. Functional classification and sub-cellular distribution of differentially expressed whole cell proteins during early CHIKV
infection. (A) Functional categorization and (B) Sub-cellular localization of differentially modulated proteins were determined based on Swiss-Prot/
TrEMBL database search.
doi:10.1371/journal.pone.0061444.g003
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regulation [32]. Many viruses have been reported to evolve
different strategies to utilize the UPP for various purposes,
including avoidance of host immune surveillance, viral matura-
tion, viral progeny release and transcriptional regulation
[33,34,35]. Our proteomics data showed down-regulation of two
UPP associated proteins; ubiquitin-conjugating enzyme E2 N
(UBE2N) and proteasome subunit alpha type-6 (PSMA6). At the
transcript level however, only UBE2N showed the same direction
of expression change as the protein expression. UBE2N is a
ubiquitin-carrier enzyme which carries and binds ubiquitin to the
ubiquitin-ligase enzyme for subsequent ubiquitination of targeted
proteins. PSMA6 is the subunit of the 20S proteasome subcomplex
which forms the multicatalytic 26S proteasome that degrades
polyubiquitinated proteins into smaller peptides [32].
Down-regulation of proteins involved in cell cycle
regulation
Cyclin-dependent kinases (CDKs) are a family of cyclin-
activated serine/threonine kinases involved in various cellular
processes including regulation of cell cycle (CDK1, 2, 3, 4, 6 and
7), neuronal functions (CDK5) and transcription (CDK7, 8 and 9)
[36]. While CDKs are commonly associated with nuclear
replication of DNA and RNA viruses, several studies have
expanded the role of CDKs to cytoplasmic replication of RNA
Figure 4. STRING interaction network showing association between differentially expressed proteins. Interaction map was generated
using default settings (Medium confidence of 0.4 and 7 criteria for linkage: neighbourhood, gene fusion, co-occurrence, co-expression, experimental
evidences, existing databases and text mining). Twenty additional interplay proteins were also added to each network. The protein names and gene
symbols used in this network are listed in Supplementary Table S2.
doi:10.1371/journal.pone.0061444.g004
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viruses as well [37,38]. In this study, CDK1 was found to be down-
regulated, both at the protein and gene expression level. CDK1 is
activated by cyclin B and functions in allowing entry into mitosis
from the G2 phase [39]. Inhibition of this protein would cause cell
cycle arrest at G2 phase. Meanwhile, SET protein is a
phosphoprotein found to regulate the cell cycle by inhibiting
cyclin B-CDK1 activity [40]. In our study, SET protein was found
to be up-regulated at both the protein and transcript levels, which
favours the inhibition of cyclin B-CDK1 activity.
In conclusion, our proteomics data suggested that during early
infection, CHIKV affects the expression of proteins involved in
mRNA processing, host metabolic machinery, UPP, and cyclin-
dependent kinase 1 (CDK1) regulation (in favour of virus survival,
replication and transmission). While results from this study
complement the proteomics results obtained from previous late
host response studies, functional characterization of these proteins
is warranted to reinforce our understanding of their roles during
early CHIKV infection in humans.
Materials and Methods
Cell lines
WRL-68 human hepatic cells, a HeLa derivative cell line that is
highly susceptible to CHIKV infection (ATCC Cat No. CL-48),
Vero cells (ATCC Cat. No. CCL-81), and C6/36 Aedes albopictus
cells (ATCC Cat. No. CRL-1660) were used in this study. WRL-
68 and Vero cells were cultured in DMEM medium (GIBCO,
Grand Island, NY) supplemented with 10% heat-inactivated fetal
bovine serum (FBS) (GIBCO, Grand Island, NY) at 37 uC. C6/36
cells were grown in L-15 medium (Sigma Aldrich, St Louis, MO)
Table 2. GO enrichment analysis of the biological processes
involved in the STRING protein network.
GO Biological process p-valuea
Regulation of ubiquitin-protein ligase activity 4.34610214
Gene expression 1.1461026
mRNA metabolic process 8.0661026
Protein modification 1.7561025
Regulation of cell cycle 1.6361025
Protein metabolic process 1.0261025
Generation of energy and precursor metabolite 1.3561022
DNA replication 5.0561022
aThe significance of the GO biological process derived from the cytosolic
protein network was determined by FDR correction (p,0.05).
doi:10.1371/journal.pone.0061444.t002
Figure 5. Western blot validation and densitometric analysis of CDK1 and PDHA1 proteins. Confirmation of the expression profiles for
CDK1 (A) and PDHA1 (B) was performed via immunoblot analysis. Densitometric analysis of the mean relative intensity (n = 3) for each target protein
showed down-regulation of CDK1 by 1.42 fold (C) and up-regulation of PDHA1 by 1.72 fold (D). The intensity for CDK1 and PDHA1 was normalized
against ACTB and GAPDH, respectively. Error bars indicate standard deviation of three biological replicates. * indicates significant difference in
expression (p,0.05).
doi:10.1371/journal.pone.0061444.g005
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supplemented with 10% tryptose phosphate broth (TPB) (Sigma
Aldrich, St Louis, MO) and 10% FBS at 28 uC.
Antibodies
The antibodies used for indirect immunofluorescence assay
(IIFA) and immunostaining by flow cytometry were anti-CHIK E2
monoclonal antibody (mAb) 3E4 (a kind gift from Dr. Philippe
Despre`s from the Pasteur Institute of France) and FITC-
conjugated goat anti-mouse IgG secondary antibody (Novus
Biologicals, Littleton, CO). The primary antibodies used for
Western blot validation were mouse mAb to beta-actin (ACTB),
cyclin-dependent kinase 1 (CDK1), glyceraldehyde 3-phosphate
dehydrogenase (GAPDH) or pyruvate dehydrogenase (PDHA1).
Horseradish peroxidise (HRP)-conjugated goat anti-mouse IgG
was used as the secondary antibody. All antibodies used for
validation were purchased from Santa Cruz Biotechnology, Santa
Cruz, CA.
Virus stock propagation and titration
CHIK/06/08 clinical isolate of the ECSA genotype was
propagated twice in C6/36 cell line and virus stock was harvested
from the culture supernatant and stored at 280 uC. Mock control
cells were cultured in parallel but without virus infection and
processed in the same manner. Virus titer was determined by
standard plaque assay procedure on Vero cells. Titers were
expressed as plaque-forming units (PFU)/ml.
Infection of WRL-68 cells with CHIKV
WRL-68 cells were infected with CHIKV at the MOI of 0.5,
1.0, 5.0 and 10.0 for 2 h at 37 uC. Mock control cells were
incubated in parallel with culture supernatant of mock control
C6/36 cells. Viral inoculum was subsequently removed and the
cells were further incubated in DMEM maintenance medium
containing 2% FBS for 24 and 48 h. The optimal MOI and time-
point for early infection study were selected based on flow
cytometric quantitative analysis of percentage of cell infection and
cell death [24].
IIFA
Prior to flow cytometric quantification, CHIKV infection in
WRL-68 cells was confirmed by IIFA, as previously described [41]
with modifications. WRL-68 cells were seeded overnight at a
density of 1.56105 cells/well in a 24-well culture dish, and
subsequently infected at various MOI. Mock control cells were
cultured in parallel. After 24 and 48 h incubation, the cells were
fixed with 3.7% formaldehyde in phosphate buffered saline (PBS)
for 20 min, washed with PBS and permeabilized with 0.15 M
glycine for 10 min. Permeabilized cells were washed extensively
and further incubated with anti-CHIK E2 mAb 3E4 (1:100
dilution) for 30 min at 37 uC. Thereafter, the cells were washed
with PBS and incubated in FITC-conjugated secondary antibody
(1:1000 dilution) for 30 min at 37 uC. The cells were observed
under an inverted microscope (Nikon Eclipse Ti-5, Japan) and
fluorescent pictures were acquired using NIS-Elements imaging
software (Nikon, Japan).
Flow cytometric quantification of percentage CHIKV
infection and cell death
Quantification of percentage infection was carried out as
previously described [24] with modifications. Mock control and
CHIKV-infected cells were harvested at appropriate time-points
and fixed with 3.7% formaldehyde for 30 min. The cells were
washed with staining buffer (0.1% (w/v) sodium azide in 1% FBS,
pH 7.5), and incubated with anti-CHIK E2 mAb 3E4 (1:100
dilution) for 90 min at 37 uC. Thereafter, the cells were washed
and further incubated in FITC-conjugated goat anti-mouse IgG
secondary antibody (1:1000 dilution) for 60 min at 37 uC. After
extensive washing, the cells were resuspended in PBS and analyzed
with BD FACSCanto II flow cytometer (BD Biosciences, San Jose,
CA) using FACSDiva v6.1 software.
Percentage cell death was determined using FITC Annexin V
Apoptosis Detection Kit I (BD Biosciences, San Jose, CA)
Table 3. Comparison of real-time qPCR and proteomics
results for selected genes.
Gene symbol mRNA fold-change Protein fold-change
UBE2N 21.33 21.45
PSMA6 NSD 21.52
SET 1.41 1.43
GNB2L1 NSD 22.58, 21.88, 21.40**
CDK1 21.38 21.77
PDHA1 1.30 1.96
ENO1 21.32 21.32
IDH1 21.14 21.57
PGAM1 NSD 21.37
TPI1 NSD 21.81, 21.47**
HMGCS1 NSD 21.62
IDI1 21.48 21.63
NAMPT NSD 21.44
ITPA NSD 21.32
APRT 1.33 21.52
ADSS 21.36 22.25
PRPS1 21.27 21.33
MTAP 21.26 21.44
PSAT1 21.62 21.73
CBX3 NSD 1.39
PIR 21.25 21.57
EEF2 21.12 21.63, 21.35**
EIF3H NSD 21.58
EIF2B1 21.25 21.54
HNRNPC NSD 3.1
PCBP1 21.82 21.42
SSB NSD 21.67
KRT7 NSD 1.4
ARPC2 1.24 21.41
NPM1 NSD 1.38
CPNE1 NSD 21.75
GDI2 NSD 22.34, 21.51**
ETFA 1.34 21.42
PPIA 1.14 21.36
RCN1 NSD 1.41
TXNDC17 NSD 21.37
*Bold indicates RNA expression changes which are in concordance with
protein expression changes in terms of directionality, and are determined to be
statistically significant (p,0.05); NSD indicates no significant differences in the
RNA expression.
**More than one protein spot was identified.
doi:10.1371/journal.pone.0061444.t003
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according to the manufacturer’s protocol. Annexin V/propidium
iodide stained cells were analyzed by flow cytometry.
Protein sample processing
Whole cell proteome were extracted on ice with lysis buffer
(7 M Urea, 2 M Thiourea, 4% CHAPS, 2% IPG Buffer, 40 mM
DTT). Cellular debris was pelleted at 17,0006g and protein
supernatant was cleaned using 2-D Clean-Up Kit (GE Heathcare,
Uppsala, Sweden) as described by the manufacturer. Protein
estimation was performed using Bradford Protein assay (Bio-Rad
Laboratories, Richmond, CA).
2-DGE
Forty mg (for analytical gel) and 160 mg (for preparative gel) of
protein was mixed with rehydration buffer (7 M Urea, 2 M
Thiourea, 2% CHAPS, 0.5% IPG Buffer, 1% Bromophenol blue)
to a final volume of 250 ml and left overnight to rehydrate into
13 cm pH 3–10 linear immobilized pH gradient DryStrips (GE
Healthcare, Uppsala, Sweden). First dimension isoelectric focusing
was performed at 20 uC according to the following protocol: (i)
500 Vh, 500 V (Step-and-hold), (ii) 1,000 Vh, 1,000 V (Gradient),
(iii) 16,000 Vh, 8,000 V (Gradient) and (iv) 12,000 Vh, 8,000 V
(Step-and-hold). The strips were subsequently equilibrated with
equilibration buffer (6 M Urea, 75 mM Tris-HCl pH 8.8, 29.3%
Glycerol, 2% SDS, 0.002% Bromophenol Blue) containing 1%
DTT for 15 min, followed by equilibration with equilibration buffer
containing 2.5% iodoacetamide for another 15 min. Proteins were
resolved on 12.5% SDS-PAGE homogenous gels at 50 V for
30 min, and 500 V for 2 h. Gels were silver stained according to a
modified, MS-compatible silver staining protocol [42].
Differential gel analysis
Gels were scanned with ImageScannerTM III (GE Healthcare,
Uppsala, Sweden) and analyzed using ImageMasterTM 2D Plati-
num v7.0 software (Amersham Biosciences, Sweden). Ten gels were
used for analysis (five biological replicates per group). The volume of
each spot was normalized against the total volume of all spots in the
gel, and the normalized values were expressed as percentage spot
volume. Spots having a fold-change of at least 1.3 and p,0.05 (as
determined by one-way ANOVA and Student’s t-test) were excised
from multiple preparative gels for in-gel digestion.
In-gel tryptic digestion
In-gel digestion was performed using Trypsin Gold (Promega,
Madison, WI) as previously described [43,44]. Briefly, excised
spots were destained with destaining solution (15 mM potassium
ferricyanide/50 mM sodium thiosulphate), followed by reduction
with 10 mM DTT/100 mM ammonium bicarbonate for 30 min
at 60 uC and alkylation with 55 mM iodoacetamide/100 mM
ammonium bicarbonate for 20 min in the dark. The gel plugs
were washed trice with 50% acetonitrile (ACN)/100 mM ammo-
nium bicarbonate, 20 min each wash, and dehydrated with 100%
ACN for 20 min. The gel plugs were subsequently dried using a
vacuum centrifuge (HetoVac VR-1 vacuum concentrator, Bir-
kercd, Denmark), and digested overnight in 25 ml of 10 ng/ml
trypsin at 37 uC. Tryptic peptides were then extracted twice, first
with 50% ACN for 15 min, followed by 100% ACN for another
15 min. The extracted solutions were pooled together into a clean
tube and dried using a vacuum centrifuge.
MALDI-TOF/TOF analysis
Dried peptides were reconstituted in 0.1% formic acid (FA) and
desalted using ZipTip C18 (Millipore, Billerica, USA), according
to the manufacturer’s protocol. Following ZipTip cleanup, the
peptides were eluted out in 2 ml elution solution (50% ACN/0.1%
FA) and mixed with saturated a-cyano-4-hydroxycinnamic acid
(CHCA) matrix prepared in 50% ACN/0.1% trifluoroacetic acid
(TFA), at a 1:1 ratio. Peptides were spotted on stainless-steel
sample target plate in 0.7 ml aliquots in duplicates. Mass spectra
for each peptide were obtained on a MALDI-TOF/TOF (ABI
4800 Plus, Applied BiosystemsTM, Foster City, CA) mass
spectrometer using a previously established setting [43]. The
spectra were analyzed with the Global Protein Server (GPS)
explorer 3.6 software (Applied BiosystemsTM, Foster City, CA),
which uses an internal MASCOT program (Matrix Science,
London, UK) to match the MS and MS/MS data against existing
database information. The data obtained were searched against
human databases downloaded from the Swiss-Prot/TrEMBL
homepage (http://www.expasy.ch/sprot).
Bioinformatics
Categorization of functional and sub-cellular distribution of
proteins was performed based on Swiss-Prot/TrEMBL database
search. Protein-protein interactions were predicted using Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING)
database v9.0 (http://www.string-db.org/). The Swiss-Prot iden-
tifier for the genes (eg. ENOA_HUMAN for alpha-enolase), in
‘Protein mode’, was used to search against the STRING database.
Network analysis was set at medium stringency (STRING
score = 0.4). Proteins were linked based on seven criteria;
neighbourhood, gene fusion, co-occurrence, co-expression, exper-
imental evidences, existing databases and textmining.
Western blot
Samples of CHIKV-infected and mock control cells from three
independent biological replicates (not used for 2-DGE analysis)
were lysed with RIPA buffer (25 mM Tris pH 7.6, 150 mM NaCl,
1.0% Triton-X, 1.0% Sodium deoxycholate, 0.1% SDS) and
quantified using BCA Protein Assay Kit (Pierce, Rockford, IL).
Denatured proteins (20 mg) from each sample were loaded into
each lane and resolved on 12.5% polyacrylamide gels at a constant
voltage of 100 V. The resolved proteins were electroblotted onto
PVDF-membranes at a constant current of 80 mA for 1 h 30 min.
Non-specific bindings were blocked overnight at 4 uC with 5% w/
v non-fat powdered milk in Tris-buffered saline with Tween-20
(TBST) solution (50 mM Tris pH 7.4, 150 mM NaCl, 0.05%
Tween-20). After extensive washing, the membranes were
incubated with either mouse mAb to ACTB, CDK1, GAPDH
or PDHA1 (1:500 dilution) for 1 h 30 min at room temperature.
Subsequently, the membranes were incubated with HRP-conju-
gated goat anti-mouse IgG (1:2,500 dilution) for 1 h at room
temperature. Target proteins were detected with TMB Stabilized
Substrate for HRP (Promega, Madison, WI). The blots were
scanned using ImageScannerTM III in reflective mode and
densitometric quantification was performed using ImageJ v1.45
freeware (http://rsbweb.nih.gov/ij). The mean relative density for
each target band was normalized against ACTB or GAPDH.
Real-time quantitative PCR (qPCR)
Total RNA of CHIKV-infected and mock control cells from
three biological replicates was extracted using Qiagen RNeasy
Mini Kit (Qiagen, Valencia, CA) as described by the manufac-
turer. Purity of extracted RNA was determined by measuring the
A260/A280 and A230/A260 absorbance ratio using Gene-
QuantTM 1300 spectrophotometer (GE Healthcare, Uppsala,
Sweden). RNA integrity was confirmed by visualization of distinct
18S and 28S ribosomal RNA bands resolved on 1% agarose gel
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electrophoresis. One mg of high quality RNA was converted to
cDNA using High Capacity RNA-to-cDNA Kit (Applied Biosys-
temsTM, Foster City, CA), following the manufacturer’s protocol.
Primers specific for the gene of interest were designed with
Primer3 Input v4.0 (http://frodo.wi.mit.edu/primer3/) and
primer efficiency test was performed for each primer pair to
confirm specificity towards the gene of interest. RNA sample
(10 ng) was mixed with the respective primer pair and Fast
SYBRHGreen Master Mix (Applied BiosystemsTM, Foster City,
CA). Real-time qPCR was performed using StepOnePlusTM Real-
Time PCR System (Applied BiosystemsTM, Foster City, CA). The
expression level of each target gene was normalized against
ACTB. Statistical significance of altered gene expression was
determined using Student’s t-test, where the significance was
defined at p,0.05.
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